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Changes that occur in malignant cells can take a variety of forms and include changes 
in cellular glycosylation. Aberrant glycosylation is considered to be a universal 
feature of malignant transformation and tumour progression. Mucins are major 
carriers of altered glycans in most carcinomas, and mainly belong to the MUC 
family, with MUC1 considered one of its most prestigious affiliates, as it is 
upregulated and aberrantly glycosylated in the majority of breast and many other 
adenocarcinomas. The large domain of the extracellular region of MUC1 is made up 
of tandemly repeated amino acids that form a scaffold for the attachment of the O-
linked glycans. The aberrant glycosylation of MUC1 observed in breast cancer results 
in the expression of simple, unbranched sugars that are often sialylated and this is 
partly due to the upregulation of the sialyltransferase, ST3Gal-I. These consistent and 
conserved changes suggest that aberrant glycosylation is advantageous for the 
tumour, and data generated by this thesis suggest that indeed this is the case.  
Attention has been focused on MUC1 as a target molecule for the immunotherapy of 
cancer. To investigate specific MUC1 tumour-associated glycans, recombinant 
MUC1 glycoproteins carrying specific and defined O-linked glycans were purified 
from engineered CHO cells. The immune responses to these MUC1 glycoforms were 
analysed using wild-type and MUC1 transgenic mice. Different tumour-associated 
glycoforms elicited different immune responses, with MUC1 carrying the 
disaccharide known as T inducing a cellular response in MUC1 Tg mice, while the 
MUC1-ST glycoform was incapable of inducing an immune response in MUC1 Tg 
mice or even wild-type mice. 
To determine whether the changes in glycosylation, observed in breast carcinomas, 
confer an advantage to cancer cells, we generated transgenic mice over-expressing 
ST3Gal-I in the mammary gland and other epithelial tissues, and crossed these with 
mice that develop spontaneous mammary tumours. The tumours that developed from 
the ST3Gal-I mice appeared significantly earlier than the controls. Thus over-
expression of ST3Gal-I in the mammary gland promotes tumorigenesis in this model, 
and the MUC1-ST glycoform formed by the action of ST3Gal-I on the T antigen is 
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1.1  General Introduction 
 
Glycobiology, the study of structure, biosynthesis and biology of saccharides (sugar 
chains or glycans) is one of the most rapidly growing fields in biomedical sciences, 
with relevance in basic research, biomedicine and biotechnology. Cells carry a dense 
and complex array of sugar chains, and since most of the glycans are on the outer 
surface of cells, they are in a position to modulate or mediate many cell interactions 
crucial to the development and function of complex multicellular organisms, but also 
interactions between organisms such as host to pathogens. 
  
The glycosylation found in eukaryotic cells is primarily defined according to the 
nature of the linkage to the protein or lipid. Two of the most common types of 
protein glycosylation are N-linked glycans (N-(Asn)-linked glycans) and mucin type 
O-linked glycans (O-(Ser/Thr)-linked glycans). N-linked glycans are covalently 
linked to an asparagine residue of a polypeptide chain, while mucin type O-linked 
glycans are linked via N-acetylgalactosamine (GalNAc) to a serine or threonine 
residue and can be extended into a variety of different core structures (Varki A. et al. 
2009). Unlike N-linked glycans, which are initially added en bloc, O-linked glycans 
are added individually and sequentially, with each linkage being catalysed by a 
specific glycosyltransferase.   
  
In cancer, tumour cells undergo activation and division, adhere to a variety of other 
cell types and cell matrices and invade tissues. To some extent this parallels patterns 
and processes observed during embryogenesis. More than 90% of cancer cases are 
attributed to environmental factors such as environmental pollutants, diet and 
radiation, and 5-10% of cases are due to inherited genetic mutation (Anand P. et al. 
2008). Genes in cancer cells can be modified by mutations, which can inhibit 
expression or alter the function of the protein they encode, or through epigenetic 
modifications to chromatin, which alter the gene-expression pattern. 
 
The changes that occur in malignant cells can take a variety of forms, for example 
loss of expression or increased expression of certain proteins. However, changes in 
cellular glycosylation are a universal feature of malignant transformation and tumour 
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progression (Ono M. and Hakomori S. 2004). For example, cancer cells are generally 
found to have an increase in β1-6 branching N-linked glycans (Varki A. et al. 2009), 
and the composition and number of O-glycans added to cell surface mucins is also 




This thesis focuses on breast cancer and the associated changes that occur in mucin 
O-linked glycosylation, with relevance to the immune system. Some of the most 
striking glycosylation changes in cancer occur to the O-glycans carried by mucins, so 
the focus has been on these changes, and in particular those on human mucin 1 
(MUC1), one of the major and most abundant mucins aberrantly glycosylated in 
breast cancer. The relevance of O-linked glycosylation to changes in tumour growth 
and the effects on interactions with the immune system has been examined. The 
exploitation of MUC1 glycosylation changes as a target for immunotherapeutic 
approaches has also been investigated.  
 
The aims of this project were to analyse the immune response to various glycoforms 
of MUC1 and investigate the mechanism involved in that response. MUC1 carrying 
specific and defined O-linked glycans has been expressed in CHO cells and CHO 
cell derivatives and purified. The immune response to these glycoforms was 
analysed, in vitro and in vivo using wild-type and MUC1 transgenic mice. Also, in 
order to determine if changes in glycosylation observed in breast carcinomas confer 
an advantage to cancer cells, transgenic mice over-expressing a breast cancer 
associated glycosyltransferase were generated, and crossed with mice that develop 
spontaneous mammary tumours. The growth rate of these tumours was observed and 







1.2  Breast cancer 
 
With over 40,000 new cases every year in the UK, breast cancer is the most common 
of all malignancies to affect women. The incidence has risen over the past 50 years 
and globally the incidence is approximately 1 million new cases per year, making it 
the 3rd most common cancer in the world, with approximately 400,000 deaths each 
year (Tobias J. and Hochhauser D. 2010). It is estimated that 1100 people die of 
breast cancer per day across the world (Parkin D. M. 2001) and that in the UK about 
1 in every 9 women will develop breast cancer at some point during their lives. 
 
The vast majority of breast cancers are adenocarcinomas, arising from glandular 
epithelial cells in the breast ducts or lobules. On presentation, most cancers have 
invaded the stroma and are therefore locally invasive. However, some women 
present with tumours that have not invaded the basement membrane and are termed 
CIS (carcinoma in situ), with the most common form being ductal carcinoma in situ 
(DCIS). Early breast cancer is often asymptomatic, and patients may find it difficult 
to identify, as breast tissue is naturally lobular and changeable. However, in recent 
years, with the introduction of mammography screening, the number of DCIS cases 
detected has increased and around 20% of breast cancer patients now present with 
DCIS (Ernster V. L. et al. 2002).  
Recent advances in genetic and proteomic profiling have contributed to a better 
understanding of breast cancer. Gene expression analysis has shown that it is 
possible to identify specific patterns, or signatures, which relate not only to 
phenotype but also to prognosis.  
In 2001 Sorlie and colleagues proposed a classification system based on expression 
analysis, which identified sub-groups of breast cancer, which correlated with 
histological markers (fig 1.1) (Sorlie T. et al. 2001). When this classification was 
applied to survival, diversity of outcomes became apparent. The luminal A subgroup 
(representing 45% of all breast cancers), have a remarkably good prognosis (about 
90% survival after 8 years), whereas the basal group, which represent 15% of breast 
cancers patients, have a poor prognosis, with the vast majority (about 70%) of 
patients assessed deceased within 4 years. This diversity of outcome highlighted the 
 18 




Figure 1.1  Gene expression patterns of 85 breast cancers. 
 
Tumour specimens were divided into five subtypes based on differences in gene expression. The 
diagram show five subtypes of tumours coloured as: luminal subtype A, dark blue; luminal subtype B, 




More recently, a multicentre team of investigators, which included members of our 
department, investigated the genomic and transcriptomic architecture of about 2000 
breast cancer tumours (Curtis C. et al. 2012). This revealed novel subgroups with 
distinct clinical outcomes. The tumours were analysed by joint clustering of copy 
number and gene expression data, dominated by cis-acting copy number aberrations 
(CNAs). Ten clusters of breast cancer were identified (fig 1.2). Importantly, this 
analysis revealed a subgroup of oestrogen receptor positive tumours (ER+) that, in 
contrast to the majority of ER+ tumours, had a very poor prognosis (cluster 2, green 
line in fig 1.2), suggesting that additional therapy may be required for these patients.  
 
 19 
                     
 
Figure 1.2  Copy number aberration grouping relation to clinical outcome of 
breast cancer patients. 
 
Kaplan-Maier plot of disease-specific survival, truncated at 15 years, generated by grouping well 
define copy number aberrations (Taken from Curtis C. et al. 2012). 
 
 
Breast cancer can spread and disseminate quickly within the mammary glands and 
other organs, being so closely situated to the well-connected lymphatic system. The 
growth of the vascular and lymphatic network “angiogenesis” is very important for 
the growth of tumours and the metastatic spread of cancer tissue (Gelao L. et al. 
2013). Lymph-borne secondaries mainly occur in the supraclavicular and axillary 
nodes, but can spread to other regional nodes, as well as the chest wall and its 
structures. Metastases can also localise to the bone, liver, lung, skin and CNS as 
secondary or tertiary sites. However, in some cases the disseminated cells may 
remain dormant for many years before metastases occur. It is this secondary disease 
that invariably causes the death of the patient, and there is a strong inverse 
relationship between the number of metastatic lymph node lesions and survival 





Evidence is now accumulating that glycans play a role in dissemination and 
determining the destination of metastatic cells (Barthel S. R. et al. 2009; Julien S. et 
al. 2011). In a recent study from our group, in which I collaborated, oestrogen 
receptor alpha-negative (ER-) tumours expressed increased levels of sialyl-Lewis x 
(sLex) as compared to ER positive.  SLex expression per se had no influence on the 
survival however high expression was significantly associated with bone metastasis. 
Interestingly, this was seen only in oestrogen receptor (ER) positive cancer, 
suggesting that the backbone on which the glycan is carried is important for its 
involvement in the extravasation process required for metastatic spread (Julien S. et 
al. 2011).  
 
1.2.1 Current treatment of breast cancer 
 
Breast cancer is usually treated according to the stage of the disease at presentation 
(TNM; tumour, node, metastases), the grade (measure of differentiation), the cancer 
type (luminal invasive, basal invasive, DCIS), histological markers (ER, PR and 
HER2) and the patient’s menopausal status and general health (Tobias J. and 
Hochhauser D. 2010). Generally, healthy, late stage, high grade, triple negative 
patients receive the most aggressive treatments. 
 
Standard treatments include surgery, radiotherapy, hormone therapy, chemotherapy, 
immunotherapy and targeted therapy. Surgery is usually the first treatment, with a 
fine balance being drawn between removing the lesion with a good margin, and the 
cosmetic and psychological impact on the patient. Preoperative chemotherapy is 
increasingly becoming common practice as neo-adjuvant therapy where a large 
tumour is shrunk before surgery to allow for more breast tissue conservation. 
Following surgery the vast majority of patients (90-95%) go on to receive some sort 
of adjuvant therapy, in the form of radiotherapy, hormone therapy, chemotherapy, 
immunotherapy or targeted therapy to inhibit growth of disseminated tumour cells 
(Turner N. C. and Jones A. L. 2008). Furthermore, when physicians make 
judgements as to which extra or adjuvant therapies to include, age, menopausal 
status, tumour grade, tumour burden, lymph node involvement, and expression of 




Classically radiotherapy will follow surgery as it is a localised treatment, most 
effective on smaller lesions or post-surgical ‘clean-up’, and, in some cases it is used 
as neo-adjuvant therapy. The use of neo-adjuvant radiotherapy can influence the 
amount of tissue removed, with many women choosing minimal surgery with 
maximum radiotherapy. Radiotherapy is a targeted high-energy beam that causes the 
cells to undergo apoptosis and die. Advances in radiotherapy machines and targeting, 
such as its use in combination with CT scanning, mean that the risk of more severe 
side effects such as excessive skin burning and damage to the heart and lungs can be 
greatly reduced (Edlund T. and Gannett D. 1999). Breaking the dose into fractions 
can also reduce side effects, which can still be substantial. Tiredness, followed by 
skin redness and burn are the most common side effects, along with lymphoedema, 
and some minor effects that are more cosmetic than troublesome, such as skin 
darkening. However, the major drawback of radiotherapy is that it is limited to use 
around the area of the primary tumour and is not a systemic treatment. For patients 
with no lymph node involvement, i.e. no evidence of metastasis, this is not a 
problem, but where tumour cells have moved elsewhere in the body, a more 
widespread treatment, such as chemotherapy is usually needed. 
 
Chemotherapy 
Chemotherapy is also designed to cause apoptosis in cells, but acts by disrupting the 
cell’s basic functions for example the generation and repair of the actin tubules and 
other internal structures involved in cell stability and division. Because tumour cells 
divide more rapidly than many normal cells they are preferentially affected. In 
addition, it has recently been shown that some chemotherapeutic agents have 
immune-stimulatory and anti-angiogenic properties (Liu W. M. et al. 2010, and 
2012). In some cases chemotherapy is used as neo-adjuvant therapy to shrink the 
tumour thereby allowing more breast-conserving surgery. Whether or not they have 
received neo-adjuvant chemotherapy, the vast majority of patients will receive the 
treatment postoperatively to kill any cancer cells that may not have been removed 
through surgery. Side effects include nausea, vomiting and hair loss, as well as 
increased risk of infection and anaemia, and are brought about by damaging normal 
cells that have a high proliferative rate such as hair follicles, bone marrow and 
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haemopoietic cells. In the longer term, gonads may become damaged enough to 
cause infertility and early menopause. 
 
Endocrine therapy 
Hormone therapy may also be given as adjuvant treatment to women whose tumours 
are ER-positive, although sometimes hormone therapy can also be used in a neo-
adjuvant setting. The oestrogen receptors, when engaged, can enhance the growth of 
the tumour, and hormone therapy is designed to prevent the supply of oestrogen to 
tumour cells. Drugs such as Tamoxifen block the binding of oestrogen to the 
oestrogen receptor, preventing any engagement of any oestrogen present in the 
system resulting in tumour growth inhibition. The oestrogen receptor/Tamoxifen 
complex can bind to different co-factors, including co-repressors that inhibit ERα 
mediated transcription (Green K. A. and Carroll J. S. 2007). However, with time 
many patients become resistant to Tamoxifen (Thrane S. et al. 2013). Recent studies 
have established that Tamoxifen is extensively metabolized by the enzyme CYP2D6. 
Patients who carry a particular polymorphism in the gene encoding the CYP2D6 
enzyme have a lower response to Tamoxifen. This is because certain polymorphisms 
result in a lack of enzyme activity, and therefore these patients lack the ability to 
produce endoxifen, which is necessary for successful treatment (Irvin W. J. et al. 
2011, Binkhorst L. et al. 2012). Aromatase inhibitors may also be used in 
postmenopausal women, which act by preventing the conversion of androgen to 
oestrogen by aromatases in the fatty tissue, thus limiting the supply of oestrogen in 
the circulation.  
 
Side effects of endocrine therapy vary. Endocrine therapy can cause weight gain, loss 
of bone density, joint problems (Bjarnason N. H. et al. 2008, Santen R. J. 2011) and 
increase the risk of thrombosis and developing cancer of the womb. Some patients 
may experience menopausal symptoms with Tamoxifen, such as hot flushes and 
vaginal dryness (Smith L. L. and White I. N. 1998, Singh M. N. et al. 2007).  
 
Targeted therapy 
Targeted therapy in breast cancer is, as the term suggests, the targeting of specific 
molecular abnormalities that are responsible for malignant progression. For many 
years endocrine therapy has been a successful targeted therapy with Tamoxifen 
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perhaps being the best example. In recent years the targeting of growth-promoting 
proteins such as HER2, which is over-expressed on the surface of about 15-20% of 
breast cancers, led to the approval for therapy with agents such as Trastuzumab 
(Herceptin). Herceptin, a humanized monoclonal antibody that binds the 
extracellular domain of the HER2 receptor, has been shown to significantly improve 
the clinical outcome of metastatic breast cancer patients in combination with 
cytotoxic therapy in the adjuvant setting (Slamon D. J. et al. 2001). Although 
Herceptin is widely used for the treatment of HER2 overexpressing breast cancer, its 
mechanism of action is not fully understood. The proposed mechanisms of action for 
Herceptin include: G1 growth arrest, inhibition of angiogenesis, induction of HER2 
down regulation and activation of antibody-dependent cellular cytotoxicity (ADCC) 
(Valabrega G. et al. 2007). Other novel targeted treatments are in clinical evaluation 
and include anti-angiogenic compounds like Bevacizumab, Sunitinib and Vatalanib, 
and bi-functional drugs such as Lapatinib (small molecule inhibitor of HER2 and 
EGFR) (Longo R. et al. 2012). 
 
Immunotherapy  
With the exception of humanized monoclonal antibodies to HER2, at present no 
other immunotherapeutic agents have been approved for routine use in breast cancer 
treatment. The notion of cancer immunotherapy has a long history, with associations 
between tumour regression and infections dating back to the 1890s (Coley W. B. 
1894). Subsequent trials included chemoimmunotherapy trials and in the 1980s, 
bacterial injections were combined with chemotherapy (Hortobagyi G. N. et al. 
1983). At present, various vaccine strategies are in different stages of development 
(Dalgleish A. G. 2008, Kim S. H. et al. 2009, Wiedermann U. et al. 2010) and, in 
general, these strategies are composed of a method to deliver target antigens or 
epitopes to the immune system, together with an immune-stimulating adjuvant to 
trigger an immune response. However, as the tumour microenvironment often 
renders the infiltrating T cells inert (Gajewski T. F. 2006, Mellor A. L. and Munn D. 
H. 2008), developing strategies to overcome those immunosuppressive mechanisms 
and combining these with vaccines appears to be necessary. Because of the relevance 
to the current work, breast cancer immunotherapy will be discussed in further detail 
in a later section of this chapter. 
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In conclusion, breast cancer is a progressive disease, with a number of different 
subtypes that have different prognoses, but nonetheless for the majority of breast 
cancer patients if treatment is started quickly after an early presentation, the overall 
prognosis is good.  
 
1.3  Glycosylation  
 
The term glycosylation refers to the enzymatic process that attaches glycans to 
proteins, lipids, or other organic molecules, and is a form of co-translational and 
post-translational modification. These glycans serve a variety of structural and 
functional roles in intracellular, membrane and secreted proteins (Varki A. et al. 
2009). Virtually all membrane and secreted proteins are glycosylated and with the 
discovery of O-GlcNAc it was found that many intracellular and nuclear proteins 
could also carry glycans (Reason A. J. et al. 1992). Glycosylation increases diversity 
in the proteome, because almost every aspect of glycans can be modified, including 
the glycosidic bond, glycan composition, structure and length. 
 
Glycosylation can be divided into a number of different types: 
1) Glycosylation of glycolipids 
2) Glycosylation of proteoglycans 
3) N-linked glycans on proteins  
4) O-linked glycans on proteins 
 
1.3.1 Glycosylation of glycolipids 
 
Glycolipids are monosaccharide residues covalently linked to a hydrophobic moiety, 
such as acylglycerol, sphingoid or phenyl phosphate. In mammals, the majority of 
glycolipids are glycosphingolipids (GSLs) and are present in cellular membranes, 
typically the plasma membrane where they play a role in cell-cell recognition, cell-
matrix interaction and cell surface receptor signalling (Varki A. et al. 2009).  
 
Glycosphingolipid synthesis starts on the cytosolic face of the endoplasmic reticulum 
membrane. Ceramide is synthesized first where D-erythro-spinganine  (sphingosine-
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2-amino-4-octadecene-1,3-diol- and a fatty acid) is acetylated and desaturated, prior 
to glucosylation by a specific ceramide glucosyltransferase to form glucosylceramide 
(GlcCer) or galactosylated by a specific galactosyltransferase to form 
galactosylceramide (GalCer) (Varki A. et al. 2009, Merrill A. H. 2002). GalCer 
extension is limited and undergoes few reactions, and α-galactosylceramide and 
analogues have been found to be important immunomodulators (Parekh V. V. et al. 
2013). Unlike GalCer derivatives, GlcCer can give rise to hundreds of structures and 
beginning with the addition of a β-linked galactose residue. Following galactose 
addition the molecules can be elongated in a stepwise fashions. A typical example is 
the biosynthesis of gangliosides, in which, after the action of the enzyme GalNAc 
transferase, several extensions can take place involving several glycosyltransferases 
and sialyltransferases (fig 1.3). 
                 
 
Figure 1.3  Ganglio glycosphingolipid synthesis pathway. 
 
 
Alterations of these ganglioside structures have been found in different diseases, 
including cancers. For example it has been shown that induction of the cell surface 
expression of GM3 is associated with malignancy through an integrin and CD9-
dependent mechanism (Mitsozuka K. et al. 2005). 
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1.3.2 Glycosylation of proteoglycans 
 
Proteoglycans (PGs) are heavily glycosylated proteins, consisting of a protein moiety 
and one or more covalently attached, long and unbranched polysaccharides 
(glycosaminoglycans or GAGs). They are a major component of the extracellular 
matrix of multicellular organisms, where they form large complexes with 
hyaluronan, and fibrous matrix proteins such as collagen. PGs are involved in 
regulating the movement of molecules through the matrix, attract cations, bind water, 
and can affect the activity and stability of other proteins and signalling molecules 
within the matrix. Moreover, the attached GAG chains can serve as lubricants and 
hydrated gels enabling joints and tissues to absorb large pressure changes (Prydz K. 
and Dalen K. T. 2000, Simons K. and Ikonen E. 1997). 
 
Glycosylation of the PGs occurs in the Golgi apparatus and starts by the sequential 
addition of xylose, galactose, galactose and glucuronic acid to a serine, where the 
serine residue is generally in the sequence -Ser-Gly-X-Gly- (X can be any amino 
acid residue). From the tetrasaccharide linker the sugar chains are extended by the 
addition of two alternating monosaccharides, an amino sugar and uronic acid (GlcA) 
(fig 1.4). 
           
 
Figure 1.4  Structure of the GAG linkage to protein in proteoglycans 
 
 
Proteoglycans and GAGs perform numerous vital functions within the body, for 
example the well-defined function of the GAG, heparin, in preventing coagulation of 
the blood. Because of the multitude of key roles in the normal physiology of cells 
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and tissue, disturbances in their metabolism can produce a variety of pathological 
changes, and can include symptoms such as organomegaly, heart disease, dwarfism, 
mental retardation and early mortality (King M. W. et al. 2013).    
 
1.3.3 N-linked glycosylation 
 
The most common type of protein glycosidic bond is N-linked, and is important for 
the folding of some eukaryotic proteins and for cell-cell and cell-extracellular matrix 
attachment. As briefly mentioned in the general introduction, N-linked glycans are 
covalently linked to an asparagine residue of a polypeptide with their core glycans 
initially added en bloc to proteins. Studies using peptides modified by N-
glycosylation showed that the consensus sequence containing the acceptor aspargine 
is Asn-X-Thr/Ser, where X is any amino acid except proline (Mellquist J. L. et al. 
1998). In general about 30% of potential N-glycosylated sites appear to be 
glycosylated, although this percentage varies substantially among different 
glycoproteins. 
 
N-linked glycans are formed when the N-glycan lipid-linked oligosaccharide 
precursor structure is transferred to the nascent protein in the endoplasmic reticulum 
by a family of transferases. These transferases are encoded by the aspargine-linked 
glycosylation gene family, with this step as well as several subsequent processing 
reactions being conserved in all eukaryotic cells. In the cytosol the biosynthesis of 
the N-glycan precursor begins with the transfer of GlcNAc-P from UDP-GlcNAc by 
the enzyme GlcNAc-1-phosphotransferase to the dolichol phosphate (Dol-P) to 
generate dolichol pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc). 
Following this addition, a second N-acetylglucosamine is added by the enzyme 
ALG14, followed by nine mannoses and three glucoses, with each step catalysed by 
a different transferase. The 14-sugar precursor migrates to the lumen of the ER 
where it is transferred to the protein by an oligosaccharyltransferase, and trimmed by 
endoplasmic reticulum glucosidase and mannosidase to Man5GlcNAc2. The Mgat 
family of GlcNAc-transferases can then add up to four branches, and its core can be 
modified during its passage through the Golgi (Varki A. et al. 2009). N-linked 
glycans can be further classified in three classes that share the main core sugar 
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sequence but differ in the chain elongation (fig 1.5): 1) high-mannose, in which only 
mannose residues are attached to the core; 2) complex, in which GlcNAcs are added 
to the mannoses by N-acetylglucosaminyltransferases; 3) hybrid, in which on one 
side, mannose residues are attached to Manα1-6 of the core and, on the other side, 
GlcNAcs are attached to the Manα1-3. Different portion of proteins can have 
different types of N-glycans, and this is thought to depend on the accessibility to 




Figure 1.5  Comparative overview of major types of N-glycans in vertebrate. 
 
 
Mouse models with N-glycan biosynthetic deficiency, including deficiency in the 
GlcNAc-1-phosphotransferase (required for building the N-glycan dolichol 
oligosaccharide precursor without which N-glycosylation cannot occur) resulted in 
embryonic lethality (Ioffe E. and Stanley P. 1994). In humans carbohydrate-deficient 
glycoprotein syndromes (CDGS) are relatively severe genetic diseases, caused by 
incomplete or failed N-glycan biosynthesis. All of these syndromes present as 
childhood diseases and are typically quite devastating, resulting in a failure to thrive 
(Jaeken J. et al. 1994).     
 
1.3.4 O-linked glycosylation 
 
O-linked glycosylation is the attachment of sugar molecules to an oxygen atom in an 
amino acid residue within a protein (Van den Steen P. et al. 1998). In eukaryotes, 
with the exception of O-GlcNAc and O-Mannosylation, O-linked glycosylation is 
initiated in the Golgi apparatus (Varki A. et al. 2009), and therefore occurs at a later 
stage of protein processing. Functions of O-linked glycoproteins are many and 
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varied, and include forming the architecture of the extracellular matrix, plus cell-cell 
and ligand-receptor interactions.  
O-linked glycosylation can be divided into various types, which are listed in table 1.1  
 
 
Table 1.1. List of O-glycan and example of O-glycosylated protein. 
 
O-Glycan Type Glycoprotein Type 
O-linked GlcNAc Nuclear and cytoplasmic 
O-linked mannose α-dystroglycan 
O-linked fucose 
EGF domains; this particular O-fucosylation is critical in 
the function of the receptor protein Notch 
O-linked glucose EGF domains 
O-linked galactose Collagens 
Mucin-type-O-
glycosylation 





This type consists of a single β-N-acetylglucosamine linked to the hydroxyl group of 
a serine or threonine residue, and is found on numerous cytoplasmic and nuclear 
proteins. At the present time, only one enzyme has been found to be involved with 
O-GlcNAc glycosylation, O-GlcNAc transferase (OGT), and only one enzyme is 
involved with its removal, D-N-acetylglucosaminidase (O-GlcNAcase). O-GlcNAc 
glycosylation (also called O-GlcNAcylation), is dynamic, with a very short half-life, 
and often competes with phosphates for the same sites. It plays an essential role in 
transcription with virtually every RNA polymerase II transcription factor O-
GlcNAcylated (Hart G. W. et al. 1996, Wells L. et al. 2001).  
 
An increase or decrease of GlcNAcylation due to elevated or diminished UDP-
GlcNAc levels has been linked to diseases such as diabetes and cancer. In diabetes 
many proteins involved in PI3K/AKT signalling are modified with O-GlcNAc, and 
modification induces insulin resistance (Issad T. et al. 2010). In this way O-GlcNAc 
can be thought as a metabolic sensor. In cancer, tumour associated proteins like c-
Myc and p53 are O-GlcNAcylated, which can inhibit phosphorylation and stabilize 
the protein (Chou T. Y. et al. 1995, Slawson C. et al. 2010). 
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O-linked mannose 
O-mannosylation was first identified in 1968 by Sentandreu and Northcote who 
isolated glycosylated proteins from the yeast cell wall (Sentandreu R. and Northcote 
D. H. 1968). O-linked terminal mannose is α1,2-linked to Ser or Thr and in yeast and 
fungi, the first mannose can be further extended to form mannotriose (Manα1,2 
Manα1,2 Manα1-Ser/Thr), with this core structure having further mannose moiety 
extensions depending on the yeast/fungi species (fig 1.6A) (Lommel M. and Strahl S. 
2009). In mammals, O-mannosyl residues are composed of variations of the 
tetrasaccharide Neu5Ac-Gal-GlcNAc-Manα1-Ser/Thr (fig 1.6B), can be sulphated, 
and are found on proteins like α-dystroglycan (α-DG) in nerves and muscles (Chiba 
A. et al. 1997, Sasaki T. et al. 1998).  




























Figure 1.6 Schematic representation of O-mannosyl glycans. 
 A: in yeast B: in mammals  
 
Initiation of O-mannosylation occurs in the endoplasmic reticulum, where protein O-
mannosyltransferases 1 (POMT1) and 2 (POMT2) catalyse the transfer of mannose 
B 
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from Dol-P-Man to Ser/Thr residues on certain proteins. Further residue extension 
takes place in the Golgi apparatus. In mammals elongation of O-mannosyl glycans 
includes transfer of GlcNAc to mannose in a 2-OH position catalized by O-mannose 
N-acetylglucosaminyltransferase 1, and followed by the addition of galactose and 
sialic acid (Lommel M. and Strahl S. 2009).   
To date, the best-studied O-mannosylated protein is α-DG, which is an important 
component of the dystrophin-glycoprotein complex (DGC) in skeletal muscles. 
Glycosylation deficiency within the DGC results in muscular dystrophy, Walker 
Worburg syndrome (WWS), and muscle-eye-brain disease (MEB). These diseases 
are associated with mutation of glycosyltransferases genes such as POMT2 
(Biancheri R. et al. 2007).    
 
O-linked Fucose 
O-fucosylation involves the addition of a fucose to a protein through the hydroxyl 
group of a serine or threonine residue. The consensus sequence for O-linked fucose 
is C-X-X-G-G-(Ser or Thr)-C, where X is any amino acid (Harris R. J. et al. 1993). 
Although only a small number of proteins have been identified with the O-linked 
fucose, in humans numerous secreted and cell-surface proteins contain the consensus 
sequence for its addition (Moloney D. J. and Haltiwanger R. S. 1999). 
 
O-fucosylated proteins identified so far contain epidermal growth factor (EGF) like 
domains and thrombospondin-1 (TSP-1) repeats. These glycans have been found in 
proteins involved in clotting and fibrinolysis, such as urokinases, tissue plasminogen 
activator (t-PA), clotting factor VII, and also on Notch-1 (Varki A. et al. 1999). An 
O-fucosyltransferase (O-fut1) is responsible for the initiation of this modification, 
utilizing GDP-fucose, and, because this modification has been found mainly on 
secreted proteins, it is presumed to occur within the secretory pathway. Moreover, as 
GDP-fucose transporters have been found in the Golgi compartments, O-linked 
fucose addition to proteins is expected to occur within the Golgi (Moloney D. J. and 
Haltiwanger R. S. 1999). Initial reports described O-linked fucose modification as a 
simple monosaccharide, perhaps because fucose on other oligosaccharides in 
mammalian systems had always been seen as a terminal sugar, however subsequent 
research has shown that fucose can be further extended. For example, human clotting 
factor IX contains the tetrasaccharide fucose structure Neu5Acα2–6Galβ1–
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4GlcNAcβ1–3Fucα-, and on proteins derived from Chinese hamster ovary (CHO) 
cells, fucose was found to be elongated with a β1,3 linked glucose residue (Harris R. 
J. et al. 1993, Moloney D. J. et al. 1997). 
 
O-fucosylation is particularly important for the protein receptor Notch, which plays 
essential roles in many phases of development. Mutation of Notch or its downstream 
signalling pathway has been implicated in a multitude of diseases, including 
Leukemia, Multiple Sclerosis, and Breast Cancer (Rana N. A. and Haltiwanger R. S. 
2011, Rampal R. et al. 2007). O-fucose addition by POFUT1 is absolutely necessary 
for Notch function, and POFUT1 mutations results in loss of Notch signalling (Yao 
D. et al. 2011, Okajima T. and Irvine K. D. 2002). GlcNAc elongation at the O-
fucose by the β1-3N-acetylglucosaminyl transferase, Fringe, has been shown to 
modulate Notch activity in a number of tissues (Moloney D. J. et al. 2000, Bruckner 
K. et al. 2000), and alter Notch-ligand binding (Stanley P. and Okajima T. 2010).  
 
O-linked glucose 
Similarly to O-fucosylation, O-glucosylation has been found on TSP-1 repeats and 
EGF-like domains, although these two types of glycosylation have been found to 
occur together only on EGF-like domains. Proteins such as Notch, factor VII, factor 
IX, δ-like protein 1, and protein Z contain O-linked glucose on their EGF-like 
repeats, and in δ-like protein 1 and factor VII the presence on a single EGF-like 
domain of both O-fucose and O-glucose has been shown (Bjoern S. et al. 1991, 
Krogh T. N. et al. 1997).  
 
Proteins are O-glucosylated at a specific serine of the EGF-like repeats, and the O-
glucosylated consensus motif is C1-X-S-X-P-C2, where C1 and C2 are the first and 
second cysteine of the EGF domain. Furthermore, the importance of O-glucosylation 
was demonstrated in recent years after the discovery of the O-glucosyltransferase, 
Rumi, as in its absence, Notch signalling is abolished (Acar M. et al. 2008). All the 
O-glucosylated sites, not just a single one, contribute to a robust Notch signalling 






O-galactosylation is defined by the building of an O-linked galactose on 
hydroxylysine residue, with the O-galactosylated consensus motif being Gly-Xaa-
Hyl-Gly (Michaelsson E. et al. 1994). Currently, only a few proteins have been 
found to be O-galactosylated, including collagen and sulfactant (Varki A. et al. 
2009). O-galactosylation occurs in the endoplasmic reticulum, and is catalysed by 
two galactosyltransferases GLT25D1 and GLT25D2. The GLT25D1 gene is 
constitutively expressed in all human tissue, while GLT25D2 gene is found to be 
expressed at a low level in the human nervous system (Schegg B. et al. 2009).  
 
Mucin-type O-linked glycoproteins  
Mucins are the most common group of O-glycosylated proteins in humans 
(Brockhausen I. 1999, Wopereis S. et al. 2006), and their glycosylation is termed 
mucin-type-O-glycosylation. The synthesis of mucin-type-O-glycosylation is 
initiated by a family of enzymes called peptidyl N-acetylgalactosaminyltransferases 
(ppGalNAcTs) which transfer an N-acetylgalactosamine (GalNAc) moiety from 
UDP-GalNAc to a serine or threonine residue. The first ppGalNAc gene to be cloned 
and characterised from bovine tissue was a type II transmembrane protein, and the 
amino acid sequence showed little homology with other glycosyltransferases cloned 
at the time (Hagen F. K. et al. 1993). When the ppGalNAc gene was knocked out in 
a mouse model, the mouse showed no phenotypic differences, suggesting complexity 
in O-glycan biosynthesis that must involve multiple enzymes with overlapping 
specificities (Hennet T. et al. 1995). Since then, many more ppGalNAcT genes have 
been cloned with distinct but overlapping specificities (Sorensen T et al. 1995, 
Clausen H. and Bennett E. P. 1996, Wandall H. H. et al. 1997). Comparison of 
amino acid sequences of ppGalNAcTs from mammalian homologues were found to 
be between 97 to 100% (Hagen F. K. et al. 1995), and analysis of enzyme kinetics by 
capillary electrophoresis and mass spectrometry showed that various ppGalNAcTs 
react at different rates with individual sites in the tandem repeats of mucins (Wandall 
H. H. et al. 1997). Following GalNAc addition, this sugar is used as a substrate for 
the addition of different glycans to form various core structures which are listed in 
table 1.2, and the glycosyltransferases involved in the early steps of mucin-O-linked 
glycosylation are listed in table 1.3.  
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GalNAc to serine or threonine in 
alpha linkage to form Tn 
Large family of enzymes, designated 
GalNAcT1, T2, T3 etc. 
CMP-Neu5Ac:GalNAc-R 
α2,6-sialyltranferase-I 
ST6GalNAc-1 Sialic acid to GalNAc-Ser/Thr in an 
α2,6 linkage to form STn 
At present this is the only enzyme 
shown to synthesize STn 
Core 1 β3-Gal-transferase β1,3GalT Gal to GalNAc in β1,3 linkage to 
form core1 (T). 
Require expression of a molecular 




ST3Gal-I Sialic acid to Gal of core 1 in α2,3 
linkage to form sialyl core 1 (ST) 
Compete with C2GnT1 for the same 
substrate in the mammary glands. 
ST3Gal-II has the same specificity but is 
not expressed by the mammary gland. 
CMP-Neu5Ac: GalNAc-R 
α2,6-sialyltranferase-II 
ST6GalNAc-II Sialic acid in α2,6 linkage to the 
GalNAc of core 1 or sialyl  core 1 
to form disialyl core 1 (disialyl T) 
Mouse ST6GalNAc-II can also make 
STn. This has not been demonstrated for 
the human enzyme.  
Core 2 β1,6-N-
acetylglucosamyl transferase 1 
C2GnT1 GlcNAc to the GalNAc of core 1 in 
β1,6 linkage to form core 2. 
The C2GnT1 expressed by the 
mammary gland compete with ST3Gal-
1 for the same substrate. 
Core 2/4 β1,6-N-
acetylglucosamyl transferase  
C2GnT2 or 
C2/4GnT 
GlcNAc to GalNAc of core 1 or 
core 3 in β1,6 linkage to form core 
2or core 4 respectively. 
Does not appear to be expressed by the 
mammary gland. 
Core 2 β1,6-N-
acetylglucosamyl transferase 3 
C2GnT3 GlcNAc to GalNAc of core 1 in 
β1,6 linkage to form core 2. 
Only occasionally expressed by the 
mammary gland 
Core 3 β1,6-N-
acetylglucosamyl transferase  
C3β3GnT GlcNAc to GalNAc  in β1,3 linkage 
to form core 3. 




Further elongation of core structures by specific transferases is highly regulated, for 
example the core 2 structure is usually extended with a further Gal residue on C4 of 
the GlcNAc. This is followed by a variable number of lactosamine chains that can be 
terminally fucosylated by α3-Fuc-transferase (α3-FucT) followed by sialylation of an 
α3-sialic acid to Gal by an α3-sialyltransferase (ST3Gal), to form the Lex or sLex 
structures (fig 1.7). Extension of core 2 structures can also occur from the galactose, 
which can be terminally fucosylated by α4-Fuc-Transferase (α4-FucT) followed by 
sialylation of an α3-sialic acid to Gal by an α3-sialyltransferase (ST3Gal) to form the 
structures Lea or SLea. Branching of the polylactosamine backbone can occur.    
 
 
Figure 1.7  Example of O-glycosylation extension  (SLex) 
 
In cancer many changes in O-linked glycosylation occurs, and those changes will be 
discussed further later in this chapter. 
  
1.4  Mucins 
 
Mucins are proteins with a high content of O-linked carbohydrates where GalNAc is 
linked to serine and threonine. The carbohydrate content typically makes up between 
50 to 90% of the mucin’s total molecular weight. There are currently 20 members in 
the mucin family (table 1.4). Physiologically, mucins are important in protection 
from pathogens, lubrication, prevention of water loss and cell-cell interactions, 
which is reflected by their expression patterns (table 1.4). Broadly, mucins can be 
split into two groups: secreted mucins (gel-forming) and membrane bound (non gel-
forming). A feature common to all the mucins is the presence of tandemly repeated 
 36 
amino acid sequences, which contain a high level of serine and threonine residues 
potential sites of O-glycosylation. These tandem repeats are used as a scaffold for 
large numbers of O-linked carbohydrate chains. In many mucins the number of 




Table 1.4 Currently identified mucins.  
The chromosomal localisation, tissue expression, number of amino acids in the tandem repeat and the 















Mucin 1 m,s 1q21-q24 20 Most simple epithelial 
cells, some leukocytes 
(Gendler S. J. et al. 
1987) 
Mucin 2 S 11p15 23 GI tract, respiratory tract (Gum J. R. et al. 1994) 
Mucin 3A m,s 7q22 17 GI tract (Van Klinken B. J. et al. 
1997) 
Mucin 3B m,s 7q22 17 GI tract (Kyo K. et al. 2001) 
Mucin 4 m,s 3q29 16 Trachea, colon, bronchus, 
breast 
(Nollet S. et al. 1998) 
Mucin 5AC S 11p15 8 Respiratory, rectum, eye, 
stomach 
(Guyonnet Duperat V. 
et al. 1995) 
Mucin 5B S 11p15 87 Respiratory, Stomach (Meezaman D. et al. 
1994) 
Mucin 6 S 11p15.5-15.4 169 Bile duct, stomach, colon, 
endocervix 
(Toribara N. W. et al. 
1993) 
Mucin 7 S 4q13-q21 22 Salivary gland (Bobek L. A. et al. 
1993) 
Mucin 8 S 12q24.3 ? Trachea, nasopharynx (Shankar V. et al. 1994) 
Mucin 9 M 1p13 15 Trachea, oviduct (Lapensee L. et al. 
1997) 
Mucin 11 M 7q22 28 GI tract (Williams S. J. et al. 
1999) 
Mucin 12 m,s 7q22 28 GI tract, uro-genital tract (Williams S. J. et al. 
1999) 
Mucin 13 M 3q13.3 ? GI tract, urogenital tract (Williams S. J. et al. 
2001) 
Mucin 15 M 11p14.3 ? GI tract (Pallesen L. T. et al. 
2002) 
Mucin 16 M 19p13.3 156 Eyes, Ovaries (Davies J. R. et al 2007) 
Mucin 17 M 7q22 ? Ovaries (Gum J. R. et al. 2002) 
Mucin 19 S 12q12 ? Trachea, salivary gland (Chen Y. et al. 2004) 
Mucin 20 M 3q29 ? Kidneys, placenta, lungs, 
prostate, liver 
(Higuchi T. et al. 2004) 
Mucin 21 M 11p15 15 Bronchi, bronchioli, large 
intestine, thymus, testis. 






1.4.1  Secreted mucins  
 
The MUC2, MUC5AC, MUC5B and MUC6 secreted mucins are thought to share a 
common ancestor and are encoded by a cluster of genes at the chromosomal locus 
11p15 (Desseyn J. L. et al. 2000). Many of these secreted mucins contain cysteine 
rich domains that are responsible for dimerization in the endoplasmic reticulum and 
oligomerization in the Golgi, which results in the formation of a viscous gel. This 
provides lubrication, prevents dehydration and inhibits the access of bacteria to the 
cell surface. 
 
The functions of secreted mucins are dependent on their ability to form viscous 
solutions or gels. The highly glycosylated domains are devoid of secondary 
structures and secreted mucins are long extended structures that are much less 
flexible than unglycosylated random coils. The oligosaccharides contribute to this 
stiffness in two ways, by limiting the rotation around peptide bonds and by charge 
repulsion among the neighbouring negatively charged oligosaccharide groups 
(Jentoft N. 1990). Such long, extended molecules have a much greater solution 
volume than native or denatured proteins with little or no carbohydrate, resulting in 
highly viscous aqueous mucin solutions.  
 
MUC2 has been found to be the main mucin of the intestinal mucus, organized in a 
sophisticated two-layer system. The outer layer has been found to provide a good 
symbiotic environment in which bacteria can thrive, while the inner mucus is well-
structured and virtually impermeable to bacteria (Johansson M. E. and Hansson G. C. 
2011). Mucins protect against infection by microorganisms that bind to 
carbohydrates, and mucin genes appear to be up-regulated by substances derived 
from bacteria, e.g. lipopolysaccharides (Lieleg O. et al. 2012, Radziejewska I. 2012, 
Dohrman A. et al. 1998).  
 
1.4.2  Membrane bound mucins 
 
Membrane bound mucins, or transmembrane mucins, such as MUC1, MUC3A and 
B, MUC4 and MUC16 are membrane bound due to the presence of a hydrophobic 
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membrane-spanning domain that favours retention in the plasma membrane. The 
extracellular domains of membrane bound mucins protrude far into the extracellular 
space, for example MUC1 extends between 200 to 500nm from the cell surface and 
so far beyond the 30nm glycocalyx. It is the relatively rigid structure, which is the 
result of high number of proline residues and clustered glycans, which allows the 
membrane mucins to extend far above the cell surface (Godula K. et al. 2009). 
Generally all mucins have a protective role, but membrane bound mucins 
additionally interact with many different proteins inside and/or outside the cell, and 
are involved in modulation of cell-cell and protein-protein interactions and in the 




Human mucin-1 (MUC1) was first identified as a major component of milk fat 
globule membranes by Shimizu and Yamauchi in 1982, and during the early years of 
its discovery was also known by other names including epithelial membrane antigen 
(EMA) (Ormerod M. J. et al. 1983), polymorphic urinary mucin (PUM) (Swallow D. 
M. et al. 1987) and episialin (Ligtenberg M. J. et al. 1990). Several antibodies to 
MUC1 were developed using epithelial cells or membrane extracts derived from 
them. These antibodies were used in expression cloning to clone the partial cDNA of 
MUC1 (Gendler S. J. et al. 1987) followed by cloning of the full-length sequence 
(Gendler S. J. et al. 1991) and this allowed the prediction of its amino acid sequence.  
 
The MUC1 gene is localized on chromosome 1q21 (Swallow D. M. et al. 1987), and 
is translated as a single protein before being cleaved in the ER into two subunits (N-
terminal and C-terminal subunit), that are held together on the cell surface in a 
heterodynamic complex by strong non-covalent sodium dodecyl sulphate (SDS)-
labile bonds (Hattrup C. L. and Gendler S. J. 2008, Levitin F. et al. 2005). Like many 
mucins MUC1 has a variable number of tandem repeats, which is allele dependent, 
varying from 20 to 125 (Gendler S. J. et al. 1987; Burchell J. M. et al. 2001). Like all 
the mucins, MUC1 has a high percentage of carbohydrates (more than 50% by mass) 
predominantly O-linked to serine or threonine residues (Taylor-Papadimitriou J. et 
al. 2002). The dense glycosylation is crucial for its protective functional role, giving 
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a bottlebrush-like structure, allowing it to extend 200-500nm from the cell surface 
(fig 1.8), far more than the glycocalyx (30nm) and surface receptors (Singh P. K. and 
Hollingsworth M. A. 2006) and contributing to its binding, water-holding, protease 
insensitivity and pathogen binding properties (McAuley J. L. et al. 2007, Linden S. 
K. et al. 2009, Patton S. et al.1995). 
 
In response to environmental signals, the large MUC1 N-terminal subunit can be 
shed from the cell surface (Abe M. and Oshima R. G. 1990), and the MUC1 C-
terminal subunit is associated with intracellular signalling. These intracellular 
activities are found to play important roles in the physiology of both malignant and 
non-malignant cells (Carson D. D. 2008), including functioning as a substrate for 
epidermal growth factor receptor (EGFR) mediated signalling (Li Y. et al. 2001), 
and other tyrosine kinase receptors. 
 
Figure 1.8  Schematic diagram of MUC1 and sites of expression  
     (Figure adapted from Brayman, M. et al. 2004).    
 
MUC1 Protein structure  
MUC1 is a type I membrane bound glycoprotein. At the C-terminal its cytoplasmic 
tail is composed of 72 amino acids (aa) and the transmembrane domain has 31aa. 
The cytoplasmic domain shows a high degree of homology between mouse and 
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human indicating conserved functions. The MUC1 precursor is proteolytically 
cleaved in the ER, separating the cytoplasmic domain, the transmembrane domain 
and the first 65aa of the extracellular domain from the rest of the precursor 
(Ligtenberg M. J. et al. 1992, Levitin F. et al. 2005, Macao B. et al. 2006). The two 
subunits of MUC1 then form a stable non-covalent complex, which is expressed on 
the apical surface of normal simple epithelial cells. The major region of the 
extracellular domain is made up of VNTRs of 20-conserved amino acids, rich in the 
serine and threonine residues that are sites of potential O-glycosylation (Tandem 
repeat amino acids sequence HGVTSAPDTRPAPGSTAPPA). Flanking the 
conserved tandem repeats, there are degenerate tandem repeats differing only by few 
amino acids (Gendler S. J. et al. 1990). 
 
The polymorphic nature of MUC1 can be seen at the RNA, DNA and protein level, 
and has been shown to be due to the variable number of VNTRs, with the number 
differing depending on the allele (Swallow D. M. et al. 1987, Gendler S. J. et al. 
1990). In heterozygote individuals, two bands can be observed at the DNA level 
(Southern blots), RNA level (Northern blot) and protein level on SDS gels, due to the 
co-dominant expression of alleles (Karlsson S. et al. 1983). The mass of the core 
protein without glycosylation has been found to be between 120-225 kDa (Gendler 
S. J. et al. 1990). In breast cancer, with the attachment of carbohydrates the size of 
MUC1 can range between 250-500 kDa, and much more in normal epithelial 
expression due to the extended glycosylation. 
 
Both N-and O-linked glycosylation occurs on MUC1, with O-glycans being the most 
abundant. MUC1 glycosylation starts during translation, with the addition of N-
glycans in the endoplasmic reticulum which are modified in the Golgi, while the O-
linked glycosylation, as described in the O-linked glycosylation section of this 
introduction, occurs in the Golgi apparatus (Rose M. C. and Voynow J. A. 2006). In 
polarized epithelial cells MUC1 is translocated to the luminal surface, and the first 
three residues (CQC) of the cytoplasmic domain are involved in retention at the 
plasma membrane (Pemberton L. F. et al. 1996). MUC1 ectodomain glycosylation is 
found to affect MUC1 cell surface expression by slowing down delivery through the 
biosynthetic pathway and by increasing its internalization (Altschuler Y. et al. 2000). 
MUC1 tandemly repeated core glycosylation is found to be an apical target for 
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signals delivered upon binding to lectins such as the tomato lectin (Lycopersicon 
esculentum; LEA) and wheat germ agglutinin (Triticum vulgare; WGA) (Kinlough C. 
L. et al. 2011). 
 
In addition to the high levels of serine and threonine residues, MUC1 is also rich in 
proline (about 25% of the total aa), which contributes to its extended structure and 
enables the formation of β-sheets. Proline inhibits the formation of α-helix structures 
and therefore promotes an extended conformation allowing the access of 
glycosyltransferases. In addition, the tandem repeat domain of MUC1 does not 
contain any hydrophobic residues such as Trp, Ile and Phe, further promoting a rigid 
and extended protein structure. 
 
Expression 
MUC1 is mainly expressed on the apical surface of the epithelial cells lining glands 
or ducts in normal tissues, including the mammary gland (Patton S. et al. 1995). A 
very low level of expression has been observed in resting (Chang J. F. et al. 2000) 
and activated T cells (Agrawal B. et al. 1998, Correa I. et al. 2003). However, 
contrary to the findings by Chang and colleagues, the study by Correa and colleagues 
showed that resting T cells were negative for MUC1 expression at both the protein 
and mRNA level. MUC1 expression was shown to be induced on activated T cells, 
but found to be 50 times lower than that expressed by autologous breast cancer. With 
regard to the present work, MUC1 expression on T cells is of substantial importance, 
when considering MUC1 based immunogen for immunotherapy, because it could 
theoretically lead to immune tolerance. This is based on the assumption that if T cells 
express MUC1, those cells may deplete each other if primed to MUC1. Recently, 
MUC1 has been associated with the development of different regions of the terminal 
respiratory tract and on a population of stem cells (Engelmann K. et al. 2008, Hikita 
S. T. et al. 2008), suggesting a developmental role. However, in the mammary 
glands, MUC1 is a marker of differentiation. 
 
MUC1 is highly expressed by the majority of carcinomas, including breast, pancreas, 
ovary, lung and colon (Girling A. et al. 1989), and is also present in some non-
epithelial malignancies such as about 30% of sarcomas and brain tumours and 20% 
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of lymphomas (Zotter S. et al. 1988). In a human breast cancer cell line, the levels of 
MUC1 protein correlate with mRNA levels (Abe M. and Kufe D. 1990), indicating 
that the overexpression of MUC1 observed in cancer is controlled at the level of 
transcription. In adenocarcinomas, when the cancer cell loses its polarity, MUC1’s 
apical distribution is lost and its expression is found all over the cell and in the 
cytoplasm (Rahn J. J. et al. 2001). In addition to its high expression in the majority 
of carcinomas, MUC1 has also been detected on some T cell lymphomas and 
myelomas associated with the development of CD8 memory T cells specific for 
MUC1 (Takahashi T. et al. 1994, Choi C. et al. 2005), and a small percentage of 
plasma cells (Hilkens J. et al. 1995).  
 
1.4.4 Signalling function of MUC1 and other membrane mucins 
 
In normal polarized epithelial cells transmembrane mucins are found on the luminal 
surface and are therefore spatially separated from many of the growth factor 
receptors. However, in malignancy when polarity is lost, mucins can come into 
contact with these receptors. Some membrane mucins such as MUC1 and MUC4, 
have been found to interact with other receptor families, such as the receptor tyrosine 
kinases ErbB1 (EGFR) and ErbB2, to enhance cancer cell proliferation. As 
diagrammatically described in figure 1.9 (taken from Bafna S. et al. 2010), MUC1 
interacts through its cytoplasmic tail (CT) with EGFR increasing cell proliferation 
via activation of extracellular signal-regulated kinases (Erks) (Pochampalli M. R. et 
al. 2007). MUC1 has also been found to be involved in the nuclear localisation and 
function of EGFR (Bitler B. G. et al. 2010). The cytoplasmic tail of MUC1 (MUC1-
CT) can also interact with β-catenin, which inhibits β-catenin interacting with 
GSK3β-mediated degradation (Ren J. et al. 2006). The MUC1-CT/β-catenin 
complex has also been found to influence transcription by binding to chromatin 
within the nucleus where the complex influences cell proliferation (Ren J. et al. 
2006).  
 
Figure 1.9 (Bafna S. et al. 2010) describes diagrammatically how MUC4 has been 
shown to contribute to increased cell proliferation through ErbB2 and subsequent 
activation of Erk and Akt signalling pathways (Chaturvedi P. et al. 2008, Ramsauer 
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V. P. et al. 2006). Moreover, MUC4 has been proposed as an activation ligand for 
ErbB2, due to the fact that its expression in some cell lines elevates ErbB2 tyrosine 
phosphorylation (Albrecht H. and Carraway K. L. 2011). 
 
            
Figure 1.9 Examples of transmembrane mucin-mediated cellular functions (1) 
 
Proposed MUC1 and MUC4 mechanisms for enhanced cell proliferation (Figure taken from Bafna S. 
et al. 2010).  
 
In addition to increasing cell proliferation, MUC1 and MUC4 have also been shown 
to repress apoptosis by distinct mechanisms. As shown in figure 1.10, MUC1-CT 
suppresses the induction of apoptosis by activating p53 through direct binding, which 
in turn selectively decreases transcription of apoptotic genes as a survival response to 
stress and thereby decreases cell death (Wei X. et al. 2005). Also, MUC1 activates 
the FOXA3a survival-related transcription factor in response to oxidative stress by 
inhibiting its phosphorylation (Yin L. et al. 2004). Direct interaction of the MUC1 
cytoplasmic tail with Inhibitor Kappa B (IkB) kinase complex can cause degradation 
of this complex. Thus nuclear factor-kB (NF-kB) is released from IkB and is free to 
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act as a transcription factor blocking apoptosis and inducing transformation (Ahmad 
R. et al. 2007). In addition, MUC1 has been shown to block nuclear targeting of c-
Abl, which blocks apoptosis (Raina D. et al. 2006). Furthermore, MUC1-CT is also 
thought to attenuate the mitochondrial apoptotic pathway through binding of HSP90 
(Ren J. et al. 2006), and by interacting with the death domain of FADD (Agata N. et 
al. 2008). MUC4 has been proposed to repress apoptosis by up-regulation of Kip 
(Chaturvedi P. et al. 2007). 
 
                
 
Figure 1.10 Examples of transmembrane mucin-mediated cellular functions (2) 
 
Proposed MUC1 and MUC4 mechanisms for the repression/activation of apoptosis (Figure taken 
from Bafna S. et al. 2010).  
 
Additional proposed regulation of various downstream signalling events, 
investigated in murine models, includes the direct binding of Muc1 to effector 
proteins like c-Src, tyrosine kinases and β-catenin. Indeed in a spontaneous 
mammary tumour mouse model (PyMT) Muc1 was found to interact with c-Src. 
Importantly c-Src is essential for the induction of mammary tumours in this model 
and in Muc1 null mice the development of PyMT induced tumours is significantly 
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delayed. These interactions have been shown to induce the activation of a variety of 
effector proteins including phosphatidylinositol 3-kinase, Shc, and STAT3 (fig 1.11), 
and induce the transcription of a variety of genes involved in mitogenesis, 
differentiation, apoptosis and quiescence (Senapati S. et al. 2010, Al Masri M. and 




























Figure 1.11 Schematic representation of Muc1 cytoplasmic tail interactions  
(Al Masri M. and Gendler S. J. 2005) 
 
 
1.5 Aberrant glycosylation in cancer 
 
Change in cellular glycosylation is a universal feature of malignant transformation 
and tumour progression, and is considered as an essential mechanism in defining 
stage, direction, and fate of tumour progression (Ono M. and Hakomori S. 2004). 
Many studies have shown a clear correlation between aberrant glycosylation status 
and invasive/metastatic potential of cancers (Hakomori S. 1996). Moreover, the 
changes that occur in cancer can take a variety of forms. Cancer cells can lose or 
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increase expression of certain structures, can express incomplete or truncated 
structures can have an accumulation of precursor structures and the appearance of 
novel structures can be observed.  Every type of glycosylation (see section 1.3) can 
be altered in tumorigenesis, and perhaps some of the most common and highly 
investigated changes include: increased β1,6GlcNAc branching in N-linked 
structures, resulting from enhanced or induced expression of GlcNAc transferase-V 
(Dennis J. W. 1988); alteration of ganglioside glycosylation resulting in an increase 
in GD3 expression in brain tumours and melanoma (Walker P. R. et al. 2002, 
Ohkawa Y. et al. 2010); and with particular importance to the work described in this 
thesis, changes in O-linked glycans attached to mucins. 
 
Early events in the evolution of neoplasia involve alterations in oncogenes and other 
genes, and subsequent tumour growth, invasion, and metastasis can perhaps be 
regarded as ‘survival of the fittest’ on a cellular level. It is likely that changes in 
tumour cell glycosylation can have the greatest functional consequence during 
subsequent tumour growth, rather than during early events, although this appears not 
always to be the case. Indeed, evidence of this comes from the significant 
correlations between certain types of altered glycosylation and the prognosis of 
tumour-bearing animals or patients. Although, at present time the mechanism by 
which these glycosylation changes alter tumour behaviour is currently not fully 
understood, data are emerging and will be further introduced in this chapter and 
chapter 5 of this thesis describes how overexpression of the glycosyltranferase 
ST3Gal-I in the mammary gland leads to increased mammary tumours.  
 
1.5.1 Aberrant glycosylation of MUC1 in breast cancer 
 
In normal breast epithelial cells the O-linked glycans attached to MUC1 are core 2 
based (see 1.3.4 O-linked glycosylation). However, MUC1 expressed by breast 
carcinomas has an increased proportion of shorter, non-branched O-glycans with a 
higher sialic acid content, often being core 1 based (Brockhausen I. et al. 1995, 
Hanisch F. G. et al. 1996, Lloyd K. O. et al. 1996, Muller S. and Hanisch F. G. 
2002). In breast carcinomas the glycan chain on MUC1 can stop after the addition of 
the first glycan to give Tn (Sorensen A. L. et al. 2006), or the formation of the core 1 
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structure to give T (sometimes called TF). However, as the majority of MUC1 has a 
higher sialic acid content, glycan chains can be terminated through the action of the 
ST6GalNAc-I or ST3Gal-I sialyltransferases, which add sialic acid to the GalNAc or 
to the core 1 structure respectively. ST6GalNAc I, II and IV can further sialylate on a 
C6 of the GalNAc of the sialylated core 1 structure and ST8Sia VI can add sialic acid 
to C8 of the Neu5Ac sialylated core 1 structure, however these events appear to be 
uncommon. Thus, the major glycosylation abnormality of MUC1 in cancer results in 
the exposure of normally cryptic core Tn (GalNAc), and T (Gal β 1-3 GalNAc) 
glycans, and the formation of the sialyl T (Neu5Acα2,3Galβ1,3GalNAc), and sialyl 
Tn (Neu5Acα2-6 GalNAc) glycans (Brockhausen I. et al. 1995, Lloyds K. et al. 
1996, Burchell J. M. et al. 1999, Sewell R. et al. 2006) (fig 1.12).  
 
               
 
Figure 1.12 Pathways of O-glycosylation of MUC1 in mammary carcinomas 
      
 
Sialylation of the core 2 tetrasaccharide can also occur preventing further extension 
of the O-glycans, and fucosylation of shortened sialylated core 2 can give rise to sLex 
which is the minimal recognition motif of many selectins (Ley K. 2003). Although 
this form of glycosylation has not yet been proven to be present on MUC1, it is 
found in breast cancer (Julien S. et al. 2011).  
 
The frequency of aberrant glycosylation of MUC1 in breast carcinomas appears to be 
a common event, as more than 90% of tumours stain strongly when using the 
monoclonal antibody SM3, which recognises the polypeptide PDTRP motif within 
the core protein of MUC1. However, SM3 does not react with MUC1 in normal 
resting breast due to the core 2 branch masking the polypeptide PDTRP motif 
































Figure 1.13 MUC1 associated O-linked glycan changes in breast cancer.  
 
Schematic illustration of change commonly occurring (>90%) to O-linked glycans attached to MUC1 
in breast cancer. Aberrant changes to the glycostructure of MUC1 mainly result in: GalNAc (Tn), 
Neu5Acα2,6GalNAc (Sialyl Tn), Galβ1,3GalNAc (T) and Neu5Acα2,3Galβ1,3GalNAc (sialyl T). 
 
1.5.2 Impact of aberrant glycosylation on the function of glycan 
carrying molecules 
 
The functional impact that altered glycosylation can deliver to cancer is well 
represented by the change leading to the increase in N-glycan elongation due to 
increased activity of N-acetylglucosaminyltransferase V (Mgat5). Increased Mgat5 
expression is regulated by oncogene expression and is found to lead to β1,6GlcNAc 
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branching and sialylation (Yamashita K. et al. 1984, Hakomori S. 1996, 
Brockhausen I. et al. 1988). Furthermore, studies have shown that Mgat5 is 
associated with enhanced cell and tumour invasiveness (Yamamoto H. et al. 2000, 
Guo H. B. et al. 2007), and interestingly in a PyMT mouse model where the Mgat5 
gene was knocked down, tumour progression and metastasis was diminished 
(Granovsky M. et al. 2000). In other studies, N-glycan elongation was found to 
affect selectin binding in both normal leukocytes and tumour cells, therefore 
highlighting a strong association between altered N-glycan elongation and metastasis 
(Zipin A. et al. 2004, Dennis J. W. 1987). Major carriers of N-glycans structures 
such as the group of surface receptors integrins appear to directly contribute to the 
cancer cell dissemination during metastasis (Rambaruth N. D. S. and Dwek M. V. 
2011). Increases in the β1,6GlcNAc structure on the α5β integrin subunit are found 
to increase adhesion to fibronectin, affecting cell-cell, and cell–matrix interactions 
promoting cell motility and invasiveness (Hakomori S. 1996).  
 
Aberrant glycosylation of sialic acid-bearing glycosphingolipids (Ganglioside) can 
be used as a further example to highlight the variety of glycosylation changes found 
in cancer. In a variety of brain tumours, ganglioside glycosylation is markedly 
altered, influencing tumour growth and progression through modulation of adhesion, 
migration and angiogenesis (Hamasaki H. et al. 1999). The sialyltransferase 
ST6GalNAcV, which sialylates GM3 and GM2α, is reduced in brain tumours, 
contributing to the increased expression of the GM3 and GM2α structures, and 
correlates with increased invasiveness (Kroes R. A. et al. 2010). However, 
expression in breast cancer of ST6GalNAcV, which is normally restricted to the 
brain, is associated with brain metastasis by enhancing the adhesion of breast cancer 
cells to brain endothelium and their passage through the blood-brain barrier (Bos P. 
D. et al. 2009). Interestingly, the GM3 ganglioside structure has also been shown to 
inhibit NK cells responses, possibly mediated by antigen presenting cells (Grayson 
G. and Landisch S. 1992, Park J. E. et al. 2008).     
 
As discussed in the earlier section (1.4), mucins such as MUC1 that are expressed by 
cancer cells including breast, express short O-linked glycans, and the most common 
are Thomsen-nouvelle (Tn), Thomsen-Friedenreich (T), and their sialylated version 
STn and ST. Moreover, Tn, STn and T have long been regarded as tumour-
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associated carbohydrate antigens and ST is not normally found on mucins. 
Glycosylation changes of mucins mostly results from the modification of the 
expression of glycosyltransferase genes, with the level of expression of some 
sialyltransferases being proposed as a prognostic marker for the follow-up of breast 
cancer patients (Hebbar M. et al. 2003, Recchi M. A. et al. 1998). MUC1 carrying 
the tumour-specific glycans Tn and STn has been found to interact with antigen 
presenting cells such as macrophages and DC, through the macrophage galactose-
type C-type lectin (MGL) in a Ca+2 -dependent manner (Napoletano C. et al. 2007, 
and personal communication of unpublished data). C-type lectins have been shown 
to participate in the detection of other tumour associated carbohydrate structures 
(Van Gisberger K. P. et al. 2005). Lectin-like receptors can take up antigen, and their 
cytoplasmic tail contains the C-type lectin signalling or internalization motif for 
antigen processing (Cambi A. et al. 2005), so it seems reasonable to propose that 
tumour-associated Tn and STn glycans carried on MUC1 can influence the balance 
between tolerance and immunity. 
 
One of the most common tumour-associated carbohydrate antigens on MUC1 is 
sialyl T (Burchell J. M et al. 2001, Adamczyk B. et al. 2012). Interestingly, within 
the haemopoietic system the vast majority of cells express variable levels of sialic-
acid-binding Ig-like lectins (Siglecs) (Cao H. and Crocker P. R. 2011). Siglecs are 
transmembrane molecules, and in humans this family of cell surface receptors is 
comprised of at least 16 different members. The vast majority of Siglecs contain 
inhibitory signalling motifs named immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) in their cytoplasmic tails that mostly mediate inhibitory signalling (Avril T. 
et al. 2006, Crocker P. R. et al. 2007). The tumour-associated sialyl T on MUC1, 
contain sialic acids in an α-2,3 linkage to Gal, which is the preferred linkage of 
several Siglecs (see table 1.5). Indeed MUC1 has been shown to bind to Siglec 1 
(Nath D. 2001), and Siglec 4, which is not expressed by haematopoietic cells but by 
neurons (Swanson B. J. et al. 2007). However, Siglec 1 does not contain an ITIM 
motif but it is reasonable to assume that other Siglec may bind MUC1-ST, and 
unpublished data from our lab shows that MUC1 sialyl T can bind Siglec 3 (Dr. 
Beatson personal communication). Thus, it can be hypothesized that MUC1-ST via 
binding of Siglecs may transmit an inhibitory signal to the immune system.  
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Table 1.5  Expression, function and preferred ligands of known human-related 






Known functions Preferred glycan ITIM  
Human Siglec-1 
(CD169) 
Macrophages  α-2,3-linked sialic acid No 
Human Siglec-2 
(CD22) 






Inhibition of Ca2+ flux, cell 
growth and apoptosis. 
Release of cytokines 
α-2,6-linked sialic acid Yes 
Human Siglec-4 Oligodendrocytes 
Schwann cells 
Role in myelin 
maintenance, inhibitor of 
axonal growth Alt. 
α-2,3-linked sialic acid Yes 
Human Siglec-5 Neutrophils, B cells Increased respiratory burst 
in neutrophils and uptake of 
Neisseria meningitidis 
α-2,6- and α-2,3-linked 
sialic acids 
Yes 
Human Siglec-6 Trophoblasts and B 
cells 
 Sialyl Tn structures Yes 
Human Siglec-7 Natural killer cells, 
minor subset of 
CD8 T cells, 
monocytes 
Inhibition of cytotoxicity 
and T-cell receptor 
signaling 
α-2,8-linked sialic acid, 
internal α-2,6-linked sialic 
acid; weaker to α-2,3-and 
α-2,6-linked sialic acids. 
Yes 
Human Siglec-8 Eosinophils, 
basophils 
Induction of apoptosis 6′-sulphated sialyl Lewis 
X 
Yes 




Inhibition of T-cell 
receptor-dependent 
signaling 
α-2,6- and α-2,3-linked 
sialic acids 
Yes 
Human Siglec-10 Natural killer-like 
cells, B cells, 
monocytes and 
eosinophils 
Binds CD24 and proposed 
to reduce inflammation in 
response to tissue damage 
α-2,6- and α-2,3-linked 
sialic acids 
Yes 
Human Siglec-11 Macrophages 
especially microglia 
Suppression of production 
of pro-inflammatory 
mediators and phagocytosis 
by microglia. 
α-2,8-linked sialic acids Yes 
Human Siglec-12 Macrophages    Yes 
Human Siglec-13 Eosinophil    Yes 
Human Siglec-14 Neutrophils and 
monocytes 
 α-2,6- and α-2,3-linked 
sialic acids 
No 
Human Siglec-15 Tumour-associated 
macrophages 
Enhance TGF-β production Sialyl Tn structures No 
Human Siglec-16 Macrophages   No 
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In addition to cancer-associated MUC1 potentially influencing tolerance and 
immunity via its interaction with the Siglecs, cancer-associated MUC1 has been 
found to be a natural ligand for galectin-3. Galectins have been shown to 
preferentially bind exposed galactose residues and the MUC1-galectin-3 interaction 
is via the binding of galectin-3 to the T antigen on MUC1 (Iurisci I. et al. 2000). 
Circulating galectin-3 in cancer patients is found to be elevated (Yu L. G. et al. 
2007) and has been shown to promote the adhesion of breast cancer cells to 
endothelium by interacting with the T antigen carried by MUC1. This has been 
proposed to cause the redistribution of MUC1 on the cell surface and the exposure of 
smaller cell adhesion molecules allowing binding to the endothelium (see figure 











Figure 1.14 Proposed action of galectin-3-MUC1 interaction    
  (Taken from Lu-Gang Y. et al. 2007). 
 
MUC1 has been found to interact with other receptor families such as the erbB 
family, especially EGFR. This enhances cancer cell proliferation through activation 
or inhibition of downstream signalling, and /or by suppressing the induction of 
apoptosis. As MUC1’s expression is dramatically increased in cancer downstream 
signalling may be altered. In addition the aberrant glycosylation of the extracellular 
domain could affect the intracellular signalling by MUC1. For example when 
galectin-3 binds the T glycan on EGFR and/or MUC1 it can promote cellular 
proliferation (Merlin J. et al. 2011). 
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Changes in glycosylation seen in cancer may alter the length of time glycoproteins 
are retained on the cell surface, which will affect their function (Partridge E. A. et al. 
2004, Hernandez J. D. et al. 2006). It is not clear if the aberrant glycosylation affects 
the retention on the cell surface of MUC1, but shorter side chains may aid protease 
cleavage of MUC1 from the cell surface.  
 
The abnormal expression of sLex functioning as a selectin ligand in cancer cells has 
been proposed to contribute to extravasation, mimicking a molecular mechanism 
involved in leukocyte extravasation mainly binding to E-selectin (Barthel S. R. et al. 
2007, Laubli H. and Borsig L. 2010). Indeed in many cancers, but in particular 
colorectal, enhanced expression of sLex and sLeα is seen, and these are closely 
associated with haematogenous metastasis (Ono M. and Hakomori S. 2004, Kannagi 
R. et al. 2004). Although in breast cancer sLex expression has been associated with 
ER-negative status, lymph node involvement, and high grade of breast tumours, its 
correlation with bone metastasis, where E-selectin is constitutively expressed, was 
only seen in ER positive tumours (Julien S. et al. 2011). 
 
1.6 Mechanisms attributed to the altered O-glycan profiles 
 
Changes in expression of glycosyltransferases 
Of the glycosyltransferase enzymes involved in the core 1 to core 2 conversion of O-
glycans added to MUC1, ST3Gal-I and C2GnT1 appear to play an important role by 
competing with each other for the same substrate Galβ1-3GalNAc in the Golgi 
apparatus. C2GnT1 regulates the glycosylation pattern found in normal mammary 
epithelium, and over-expression of ST3Gal-1 leads to the altered glycosylation 
pattern commonly found in breast cancer. The competition between those two 
glycosyltransferases has been demonstrated in cell lines (Mungul A. et al. 2004, 
Dalziel M. et al. 2001). ST3Gal-I has been found to be elevated in breast carcinomas, 
and its increased expression is correlated with tumour grade (Burchell J. et al. 1999). 
Expression of C2GnT1 was found to be low or absent in around 50% of breast 
cancer cell lines and carcinomas (Burchell J. et al. 1999, Whitehouse C. et al. 1997, 
Brockhausen I. et al. 1995), making ST3Gal-1 the more dominant enzyme in cancer.  
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In further support of the competition between ST3Gal-I and C2GnT1, a correlation 
has been observed between the level of mRNA expression encoding ST3Gal-I and 
the intensity of staining seen with the antibody SM3 (Burchell J. et al. 1999, Dalziel 
M. et al. 2001).  
 
Like all glycosyltransferases the ST3Gal-I sialyltransferase has a type II 
transmembrane topology, and ST3Gal-I localizes to the Golgi body, where it 
overlaps to a certain degree with C2GnT1 (Whitehouse C. et al. 1997, Takashima S. 
2008). It is composed of a short N-terminal cytoplasmic tail, a transmembrane 
domain, a stem region and a catalytic domain, with the whole protein being 337 
amino acids in length (Fig 1.15). As with the other known sialyltransferases, 
ST3Gal-I contains highly conserved motifs called sialyl motifs L (Long), S (Short), 
III, and VS (Very Short) (Drickamer K. 1993, Jeanneau C. et al. 2004, Geremia R. 
A. et al. 1997). Sialyl motif L is characterized by a 55 amino acid region in the 
centre of the protein, involved in the binding of a donor substrate, CMP-Sia (Datta 
A. K. and Paulson J. C. 1995). Sialyl motif S is located in the C-terminal region and 
is 28 amino acid long, and has been found to be involved in the binding of both the 
donor and the acceptor substrate (Datta A. K. et al 1998). Sialyl motif VS is located 
to the C-terminal region, and this motif is involved in its catalytic activity (Jeanneau 
C. et al. 2004). 
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Figure 1.15 Structure of ST3Gal-I 
 
CP, Cytoplasmic tail; TM, transmembrane domain; Stem, stem region; L, sialyl motif L; S, sialyl motif 
S; III, sialyl motif III; VS, sialyl motif VS. 
 
Amino acid sequences have revealed that in the mouse and human genome ST3Gal-I 
shares about 50% similarity with ST3Gal-II, but relatively less (about 30%) with the 
other members of the same family, ST3Gal-III, IV, V and VI (Takashima S. 2008). 
In mice, the ST3Gal-I gene is located on chromosome 15 (15D2), and in humans is 
located on chromosome 8 (8q24.2) (Takashima S. et al. 2002). Knockout of the gene 
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in mice showed that this glycosyltransferase plays an important role in the sialylation 
of core 1 O-glycans in T lymphocytes, which is involved in the survival of CD8+ T 
cells by making them more resistant to apoptosis (Priatel J. J. et al. 2000). However, 
a more recent study by Kao and colleagues found that CD8-induced cell death is not 
markedly influenced by ST3Gal-I deficiency, and that this deficiency has no 
detectable impact on CD8 binding to multimeric peptide/MHC class I ligands at any 
stage of thymocyte development (Kao C. et al. 2006). Human ST3Gal-I has been 
found to have five potential N-glycosylation sites, which are not necessary for 
enzyme activity, but which appear to contribute to the proper folding and trafficking 
of the enzyme (Jeanneau C. et al. 2004).    
 
In breast cancer cell lines, Cyclooxygenase-2 (COX-2) was shown to increase 
expression of ST3Gal-I, working through the prostanoid prostaglandin E2 (PGE2) 
(Sproviero D. et al. 2012). Importantly, COX-2 is overexpressed by about 40% of 
invasive breast carcinoma (Ristimaki A. et al. 2002), and is associated with markers 
of poor prognosis, such as HER2 and aromatase overexpression (Brueggemeier R. 
W. et al. 1999, Ranger G. S. et al. 2004). In the colon carcinoma cell line HT-29, the 
tumour necrosis factor α (TNF-α) can enhance ST3Gal-I expression through NFκB 
binding sites (Higai K. et al. 2006), and in porcine kidney cells, transcriptional 
activation of ST3Gal-I was shown to be induced by tumour growth factor β1 (TGF-
β1) (Son S. W. et al. 2011). Thus, suggesting that the malignant increased expression 
of ST3Gal-I may be caused by several mechanisms.  
 
Sialylation of the first sugar (GalNAc) in a α2,6 linkage is an event, which has been 
found on 25-30% of breast carcinomas (Miles D. et al. 1994, Imai J. et al. 2001). 
ST6GalNAc-I and ST6GalNAc-II, have been identified as the sialyltransferases 
which are able to add sialic acid in α2,6 linkage to GalNAc which is linked to serine 
or threonine, thus creating STn (Ikehara Y. et al. 1999). However, when the 
transcription of ST6GalNAc-I was turned on a correlation was found with STn 
expression in primary breast cancer (Sewell R. et al. 2006), whereas no correlation 
was seen with ST6GalNAc-II expression. Because, ST6GalNAc-I mRNA is not 
detectable in normal human mammary glands, in the 25-30% of breast cancers where 




Changes in Golgi pH 
Although, it is still debatable whether the Golgi apparatus is a distinct organelle or 
just an extension of the endoplasmic reticulum, it remains the most important site for 
several post-synthetic modifications, including O-linked glycosylation (Varki A. 
1998, Brockhausen I. 1999). The lumen of the Golgi apparatus in normal cells is 
weakly acidic, gradually decreasing from neutral in the endoplasmic reticulum (pH 
7.0), to acidic in the trans-Golgi network (pH 6.0-5.5) (Fig 1.16) (Weisz O. A. 2003, 
Paroutis P et al. 2004). Sialic acid terminal glycosylation also requires acidic 
conditions in the Golgi lumen (Thorens B. and Vassalli P. 1986), and acidic pH is 
known to be necessary for the optimal activity and correct localization of the 
glycosyltransferases responsible for sialic acid terminal glycosylation (Bretz R. et al. 
1980, Varki A. 1998, Axelsson M. A. et al. 2001). In recent years, abnormally 
alkaline Golgi pH has been reported in many cancer cells and cancer cell types, 
including those derived from breast, and this appears to correlates with T antigen 
expression (Rivinoja A. et al. 2006).  
 
 
                    
 
Figure 1.16 The secretory pathway and the endosomal system.  
 
Golgi apparatus composed of the cis-Golgi network (CGN), and the Golgi stack and the trans-Golgi 
network (TGN). The Golgi stack can be further divided into cis-, medial-, and trans-Golgi. (Taken 
from Rivinoja A. et al. 2006)  
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Relocation of pGalNAc-Ts 
The process that regulates the addition of O-linked glycans onto mucins is complex, 
and fine-tuning of the expression of particular GalNAc-transferases within the Golgi 
is extremely important. Given the fact that several substrates can be modified by 
several GalNAc-Ts, and as competition between GalNAc-Ts leads to different 
patterns of glycosylation (Bennett E. P. et al. 1999, Hanisch F. G. et al. 2001, Perrine 
C. L. et al. 2009, Kato K. et al. 2001), their localized expression provides a 
mechanism for regulating their actions. While GalNAc-Ts in cells and normal tissues 
are present in the Golgi apparatus (Mandel U. et al. 1999), a recent finding appears 
to indicate that their localization is subject to the cellular physiological state, and 
under certain conditions can be found within the ER (Gill D. J. et al. 2011). Src 
activation has been shown to result in the selective redistribution of Golgi-localized 
GalNAc-Ts to the ER, and that the redistribution is dependent on the retrograde 
transport associated with the COPI protein (Gill D. J. et al. 2011). The relocation of 
GalNAc-Ts to the ER resulted in increased duration of availability to potential O-
glycosylation substrates without competition, which led to an increased density of 
sites with GalNAc attached. This may result in many substrates for the core 1 
enzyme being generated, and indeed, in their experimental system, increased 
expression of Tn and T was observed (Gill D. J. et al. 2011). 
 
Mutations in the Cosmc gene 
Although the altered O-glycan profile of tumour-associated MUC1 can be partly 
explained by the enhanced or reduced expression of certain glycosyltransferases, and 
changes in pH can affect optimal activity and correct localization of 
glycosyltransferases, other cancer-specific changes/mutation may contribute to the 
tumour-associated glycan profile.  For example, another reported explanation for the 
increase in expression of two tumour-associated carbohydrate antigens, Tn and Sialyl 
Tn, is the loss-of function/mutation in the Cosmc gene, which code for the chaperone 
required for the β1,3 galactosyltransferase, the core 1 enzyme (Ju T. et al. 2008). 
Loss of activity of Cosmc results in incorrect folding of the β1,3 
galactosyltransferase resulting in loss of its activity. As it is the only 
glycosyltransferase responsible for the formation of core 1, mutations in Cosmc 
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result in loss of core 1 and expression of Tn or STn if ST6GalNAc-I is expressed by 
the cell. However, the loss-of function of the Cosmc gene will result not only in the 
expression of the tumour-associated carbohydrate antigens Tn and Sialyl Tn on 
MUC1, but on all the O-linked glycoproteins. Thus cellular loss-of function of 
Cosmc, would result in the O-linked glycans expressed by the cells being limited to 
the carbohydrate GalNAc and its sialylated form if ST6GalNAc-I is expressed. 
However, our laboratory recently investigated co-expression of the carbohydrate T 
with Tn on MUC1 in mammary carcinomas (see appendix I) and found that 100% of 
the investigated tumours expressed both types of glycans. If the loss-of function of 
Cosmc contributed to the altered O-glycan profile in these tumours, Tn and T would 
not have been observed together. Thus, the results clearly indicate that the altered O-
glycan profile of these breast cancers did not result from loss-of function of Cosmc.  
 
1.7  Tumour immunology 
 
In 2000 Hanahan and Weinberg described cancer as requiring six steps for its 
formation; an insensitivity to anti-growth signals, avoiding apoptosis, sustained 
angiogenesis, self sufficiency in growth signals, limitless replication potential, and 
tissue invasion and metastasis (Hanahan D. and Weinberg R. A. 2000). Interestingly 
since their publication in 2000, a substantial body of evidence have lead the authors 
to a conceptual progression, and recently they have added further steps including 






Figure 1.17  
Proposed hallmarks of cancer  
 
(Taken from Hanahan D. and 








Evidence that the immune system is able to prevent or control tumour formation has 
been accumulating in recent years, and includes:  
1) Immunocompromised individuals have an increased occurrence of certain cancers 
(Vajdic C. M. and van Leeuwen M. T. 2009) and in individuals who had an organ 
transplant, correlation was found between tumours and immunosuppressive agents 
(Penn I. 2000).  
2) Patients who have tumours that are heavily infiltrated with CTLs and NK cells 
have a better prognosis than those that lack such abundant killer lymphocytes (Pages 
F. et al. 2010, Nelson B. H. 2008).  
3) It is well documented that many tumours lose expression of MHC class I 
(Ochsembein A. F. 2002, Garrido F. et al. 1997).  
4) Experiments which used genetically engineered mice deficient for various 
components of the immune system, helped to clarify that both the innate and 
adaptive cellular arms of the immune system contribute to immune surveillance and 
thus tumour eradication (Kim R. et al. 2007, Teng M. W. et al. 2008).  
 
Following from the fact that the immune system is sometimes capable of eradicating 
or controlling tumour growth, the immune system must be provided with means of 
recognising malignancies by recognizing either tumours-specific antigens (TSA), 
which are only present on tumours cells, or tumours-associated antigens (TAA), 
which are antigens present mostly on tumour cells but also on some normal cells. 
TSAs are the ideal targets for cancer immunotherapy because of their specificity. 
They are largely composed of mutant proteins caused by somatic mutations in the 
original sequence of the protein chromosome relocations or changes in protein 
glycosylation. A major advantage of targeting TSAs is that many of these proteins, 
such as the oncogene RAS and BRAF, have been demonstrated to be essential for 
tumorigenesis and cancer progression (Bendle G. M. et al. 2005, Kudchadkar R. et 
al. 2012). In contrast, TAAs are commonly expressed on tumours with the same 
histology and are often shared among tumours of different origin. A major limitation 
of targeting TAAs is that they are weakly immunogenic due to the tolerance to self-
antigens acquired by the immune system in its developmental stage (Schietinger A, 




Novellino et al. in 2005, classified the TAA into 7 different groups: 
Cancer germ line genes (e.g. MAGE). 
Novel antigens encoded by tumour specific transcripts (e.g. TRP2). 
Viral antigens (e.g. EBV). 
Antigens resulting from altered post-translational modification (PTM) (e.g. MUC1). 
Antigens resulting from mutation (e.g. Bcr-abl). 
Differentiation antigens (e.g. CEA). 
Over expressed tumour antigens (e.g. HER2, MUC1). 
According to this classification MUC1 falls into two groups, as expression levels 
increase markedly in the cancer context (about 100 fold) and MUC1 O-linked 
glycosylation is changed. Thus, MUC1 glycan changes in cancer ought to allow an 
effective immunological response by enabling the immune system to effectively 
differentiate between healthy and cancerous cells, and to destroy the tumour. 
However, the ability of MUC1 positive tumours to proliferate and metastasise shows 
that the immune system is unable to destroy those tumours, perhaps because the 
tumour cells have developed ways of escaping an immune response. 
 
1.8 Immune evasion 
 
Immune evasion can be defined as when the immune system is no longer able to 
recognise the tumour or is handicapped in some way by another factor associated or 
induced by transformation. Transformed cells may have developed many ways of 
escaping an immune response, specifically, a Th1, cellular response. For example: 
 
• The tumour may have simply outgrown the immune system, and is 
proliferating at a rate, which is too great for an effective response. 
• There is an access problem for the cells as tumours are often dense, with a 
necrotic core and a poor blood supply (although this is also problematic for 
the tumour). 
• There is tolerance (anergy) of T cells to the tumour antigen (e.g. due to no co-
stimulation by modulated APCs).  
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• There is a proliferation of Tregs and myeloid-derived suppressor cells 
(MDSCs). These cells dampen down Th1 and Th2 responses and so hamper a 
response. 
• The transformed cells either directly or indirectly confers immunoprivilege 
(e.g. IL-10) or immune subversion (e.g. IL-6 and the production of Th17 
cells). 
• There can be further transformation of the tumour (e.g. loss of antigen, loss of 
TAP which is critical for MHC class 1 processing, increase in cell surface 
FasL, loss of MHC altogether). 
 
Many of these factors come together in the local tumour microenvironment the 
location where effector immune cells must operate (Pawelec G. 2004; Rivoltini L. et 
al. 2005). Transplantation experiments have shown that the transplantation of cancer 
cells originating in immunodeficient mice are generally inefficient at initiating 
secondary tumours in syngeneic immunocompetent hosts, but cancer cells 
originating from immunocompetent hosts are equally efficient at initiating secondary 
tumours in both immunodeficient and immunocompetent hosts (Kim R. et al. 2007, 
Teng M. W. et al. 2008).  A proposed interpretation of the data from transplantation 
experiments was that immunogenic cancer cells are routinely eliminated in 
immunocompetent hosts, and only weakly immunogenic variants grow and generate 
solid tumours, and those weakly immunogenic cells can thereafter colonize both 
immunodeficient and immunocompetent hosts. Instead, when cancer cells are 
generated in immunodeficient hosts, the immunogenic cells are not selectively 
depleted, and when cells from those tumours are transplanted into syngeneic 
recipients, the immunogenic cancer cells are rejected from the immune systems of 
their secondary hosts (Smyth M. J. et al. 2006).    
 
1.9  Tumour microenvironment 
 
Tumours are composed not only of cancer cells but also other cell types constituting 
the stroma, and as much as 50% of the total tumour mass can be composed of 
leukocytes in some invasive breast carcinomas (Eiro N. and Vizoso J. F. 2012). 
Within the tumour microenvironment, non-transformed cells, such as endothelial 
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cells, fibroblasts, other mesenchymal cells, and cells of the innate and adaptive 
immune system (fig 1.18), interact with malignant tumour cells to form a dynamic 
tumour microenvironment in which the non-transformed cells exert both positive and 
negative effects on the growth and spread of cancer cells (Alexander S. and Friedl P. 




Figure 1.18 Example of tumour microenvironment   
(Taken from Hanahan D. and Weinberg R. A. 2011). 
 
During the early stages of cancer its microenvironment appears to be of particular 
importance, as carcinogenesis can result from the inflammation associated with a 
variety of chronic infections e.g. ulcerative colitis (Kuraishy A. et al. 2011). 
Historically, leukocytes infiltrating the tumour have been considered to be the 
manifestation of an intrinsic defence mechanism against developing tumours 
(Johnson J. P. et al. 1989, Lin E. Y. and Pollard J. W. 2004). This is supported by an 
increasing body of evidence, that shows that specific cell populations, from both the 
innate and adaptive immune systems, interact with developing tumours and 
frequently contribute to the arrest of tumour growth as seen by tumour regression in 
animal models and cancer patients (Draghiciu O. et al. 2011). However, evidence 
also indicates that leukocytes can also promote angiogenesis, growth and invasion of 
tumours  (Coussens L. M. and Werb Z. 2002, Daniel D. et al. 2005). This is thought 
to be the result of leukocytes secreting cytokines, growth factors, chemokines and 
proteases such as vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF), chemokine ligand 12 and IL8 (Robinson S. C. and Coussens L. M. 
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2005, Benelli R. et al. 2006), which stimulate proliferation and invasiveness of 
cancer cells. The balance of cellular and secretory-product interactions within the 
early tumour microenvironment appears to determine whether the tumour mass 
regress or grows.  
   
Tumour progression and spread, facilitated by cells of the immune system, has also 
been proposed to be the result of selection of tumour cells intrinsically capable of 
escaping immune recognition (Schreiber R. D. et al. 2011), and any late stage 
antitumor immune response must occur in a mix of transformed cells, stroma, 
fibroblasts, necrotic and apoptotic cells, anergic infiltrating leukocytes and 
immunosuppressive factors. Many of these factors inspire alternatively activated 
macrophages and DCs, ineffective monocyte differentiation and function, Treg 
induction, B cell class switching, Th17 production, NK and neutrophil inactivity. It is 
an extremely difficult environment in which to mount an immune attack (Petrulio C. 
A. et al. 2006; Mantovani A. et al. 2008). 
 
The effects of intratumoral cytokines and tumour cell biology may affect the ability 
of primary breast cancer patients to mount natural immune responses. A recent study 
found that about 40% of breast cancer patients (n=59) had tumour specific CTLs, 
and this correlated with highly differentiated tumours, ER expression, and low 
proliferative activity, which led to an overall reduction in mortality. High tumour 
differentiation also correlated with high local IFNα and low local TGFβ1. The 
presence of tumour specific B cell responses correlated positively with advanced 
tumour stage, increased TGFβ1, reduced IFNα and absence of CTL responses. Thus, 
CTL responses in breast cancer appear to be associated with better prognosis, 
(Domschke C. et al. 2009).  
 
Antibody levels to MUC1 in breast cancer patients have been shown to correlate 
with improved survival (von Mensdorff-Pouilly S. et al. 1996, Blixt O. et al. 2011). 
In the study conducted by Blixt and colleagues, antibodies to aberrant glycoforms of 
MUC1 correlated with improved survival. Changes in glycosylation can induce 
humoral responses that play some role in controlling tumour growth. It is reasonable 
to assume that leukocytes infiltrating the tumours target MUC1, and can mount an 
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intrinsic defence mechanism against developing tumours, and that the tumour 
microenvironment can affect this intrinsic defence mechanism. A recent trial was 
carried out using MUC1-specific autologous CTLs induced ex vivo, followed by 
reinfusion to previously treated metastatic breast cancer patients. Results from this 
trial showed that CTLs generated from patients with high tumour burden had lower 
cytokine production and cytotoxicity against MCF-7 cells than those in remission. 
This adds to the idea that the tumour burden and environment plays a role in 
immunosuppression (Wright S. E. et al. 2009). However, the trial was small, with 
only four patients enrolled. 
 
1.10  MUC1 in immunotherapy 
 
MUC1 has attracted a lot of interest as a potential target for immunotherapy against 
cancer because of three main characteristics. Firstly, because it is underglycosylated 
in cancer, cryptic peptide epitopes within the VNTR region are unmasked, enabling 
tumour-selective binding by several antibodies and autoantibodies (Girling A. et al. 
1989, Tarp M. A. et al. 2007, Blixt O. et al. 2011). Secondly, its transcription is up 
regulated in many tumours, notably breast, ovary, pancreas and lung (Girling A. et 
al. 1989). Thirdly, in cancer cells, cell polarity is lost (Hilkens J. et al. 1984), which 
results in loss of MUC1 apical polarization and so this mucin is found over the entire 
cell surface. Immune responses to MUC1 have been identified in cancer patients, and 
CD8+ T cells specific for MUC1 peptides can be present in the peripheral blood of 
some breast cancer patients (Correa I. et al. 2005), the presence of circulating 
antibodies directed to the aberrantly glycosylated MUC1 correlates with a better 
prognosis for breast cancer patients (von Mensdorff-Pouilly S. et al. 1996, Iurisci I. 
et al. 2000, Blixt O. et al. 2011) both indicating that the immune system is able to 
mount a response to aberrantly glycosylated MUC1.  
 
Several forms of MUC1, including unglycosylated MUC1 TR peptides and MUC1 
expressed in vaccinia virus, have been used in immunisation studies in both mice and 
humans. The different vaccines have in some cases induced humoral and cytotoxic 
immunity against MUC1 (Scholl S. M. et al. 2000, Soares M. et al. 2001, Quoix E. et 
al. 2011), and more recent trials showed improved survival in non small-cell lung 
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cancer patients when given in combination with first line chemotherapy (Quoix E. et 
al. 2011). However, the influence of glycan-specific MUC1 glycoproteins on 
immunity has not yet been fully determined, probably due to the non-availability of 
glycan specific MUC1 glycoproteins. To investigate whether any aberrant MUC1 
glycans have immunological properties, our group (in collaboration with a European 
consortium and this project) have generated recombinant MUC1 glycoproteins 
carrying tumour-associated glycans, developed by expressing the extracellular part of 
human MUC1 fused with murine IgG Fc in CHO-K1 (Chinese-hamster ovary K1) 
cells, and in CHO ldlD mutant cells with or without transfected glycosyltransferases. 
 
1.11 The known immunological effects to cancer associated 
MUC1 glycoforms 
Glycans are a common structure in the body, and MUC1 is a heavily glycosylated 
mucin (see section 1.4.3), however in a normal scenario, the glycans expressed on 
MUC1 would not come in contact with cellular component of the immune system as 
MUC1 is mainly expressed on the apical surface of cells. During tumourigenesis 
MUC1 apical expression is lost, and is expressed on the entire cell surface of the 
tumour cell. Interestingly, it is this aberrant, abundantly repeated and clustered nature 
of the glycans on MUC1 that resembles a pathogen associated molecular pattern 
(PAMP). These structures may therefore confer the same immune responses as seen 
against pathogens, with regards to both immunosuppression and stimulation. 
 
MUC1-Tn 
Recombinant human MUC1-Tn peptides have been observed to bind to the C-type 
lectin MGL, expressed on macrophages and immature DCs (Saeland E. et al. 2007, 
Napoletano C. et al. 2007). The effect of this interaction is currently unknown, 
however MUC1-Tn peptides can be delivered to both class I and II pathways, 
suggesting cross-presentation is possible (Napoletano C. et al. 2007). Furthermore, 
some studies suggest that cleavage of glycoprotein by the immunoproteasome is 
achievable and so presentation of MUC1-Tn on both MHC class I as well as II is 
possible (Lakshminarayanan V. et al. 2012). In mice vaccinated with MUC1-Tn 
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glycopeptides, MUC1-Tn specific CTLs were seen (Xu J. et al. 2004; Stepensky D. 
et al. 2006). Predicted peptides within the MUC1 TR domain carrying GalNAc have 
been shown to bind MHC class I HLA-A 0201 (HLA-A2) molecules (Ninkovic T. et 
al. 2009).  However, the engagement of lectins without danger signals to activate 
TLRs has the potential to induce tolerogenic DCs and induce T cell anergy (Cao H. 
and Crocker P. R. 2011). 
 
MUC1-STn 
The immunomodulatory role of STn-expressing mucins has been investigated for 
many years. They have been shown to inhibit natural killer cell cytotoxicity (Ogata 
S. et al. 1992; Zhang K. et al. 1997), and evidence is building for the 
immunomodulative effects of mucins expressing this glycan by increasing IL6 
production from monocytes (Yokoigawa N. et al. 2005). As with MUC1-Tn, MUC1-
STn peptide immunizations have been shown to elicit strong humoral responses in 
MUC1 Tg mice (Sorensen A. L. et al. 2006) 
 
MUC1-T 
The Thomsen-Friedenreich (T) antigen is frequently expressed in normal physiology 
as well as many cancers (Byrd J. C. and Bresalier R. S. 2004). MUC1 carrying the T 
antigen (MUC1-T) is known to interact with galectins, with much research focusing 
on galectin-3. For example as described in section 1.5.1, circulating galectin 3 can 
associate with MUC1 via T expressed on circulating tumour cells, which results in 
clustering of MUC1 thereby promoting cancer cell adhesion by revealing epithelial 
adhesion molecules (Yu L. G. et al. 2007).  
Very interestingly, MUC1-T is present in the normal stomach, and Helicobacter 
pylori (H. pylori) has been shown to bind to this glycoform (Linden S. K. et al. 
2009). Whether this is beneficial for the host or bacteria is unclear. However, H. 
pylori-infected individuals express anti-MUC1-T antibodies (Klaamas, K. et al. 





Using a transplantable tumour model in human MUC1 transgenic mice, it was 
observed that a murine mammary tumour transfected with human MUC1 carrying 
sialylated core 1-based O-glycans (ST) grow significantly faster than identical 
tumours transfected to carry MUC1 with core 2-based O-glycans. This difference 
can be seen in figure 1.19. As this effect was not observed in immunodeficient mice, 
the mechanism involved was thought to be immunological (Mungul, A. et al. 2004). 
 
Figure 1.19 MUC1-ST tumour cells grow faster in MUC1 transgenic mice than 
MUC1-core 2 tumour cells.                         
E3 cells (410.4 murine mammary cell line transfected with human MUC1) and E3-core 2 cells (410.4 
murine mammary cell line transfected with human MUC1 and murine C2GnT-I) were injected 
subcutaneously into MUC1 transgenic and nude mice. Tumour volume was assessed every 2/3 days. 
(n=20 for MUC1 transgenic, n=10 for nude)(Figure taken from Mungul et al. 2004). 
 
Using recombinant human MUC1-ST (as described in Chapter 3) produced in CHO 
cells, Rughetti and colleagues showed that this glycoform affected the differentiation 
of monocyte-derived DCs. When matured in the presence of MUC1-ST these cells 
produced high levels of IL-10 and low levels of IL-12, whereas cells matured in the 
absence of MUC1-ST produced high IL-12 and low IL-10. In addition, monocyte-
derived DCs treated for 24h with MUC1-ST were less able to stimulate lymphocyte 
proliferation in an allogenic mixed leukocyte reaction (MLR), and were less efficient 
at stimulating a recall response in T cells (Rughetti A. et al. 2005). Furthermore, 
MUC1 isolated from tumour cells (where the dominant glycan is likely to be MUC1-
ST) has been seen to switch DCs to an IL-10high, IL-12low phenotype and thus trigger 




Undefined tumour-associated MUC1 glycoforms 
In a mouse model of spontaneous pancreatic cancer expressing human MUC1, 
tumours expressed higher levels of cyclooxygenase-2 (COX-2) and indoleamine 2,3-
dioxygenase (IDO) compared with tumours lacking MUC1, especially during early 
stages of tumour development. MUC1 expression correlated with an increased 
percentage of regulatory T cells and myeloid suppressor cells in the pancreatic 
tumour and tumour draining lymph nodes. (Tinder T. L. et al. 2008). Another group 
found that cancer-associated MUC1 attracts immature DCs through chemotaxis and 
subverts their function by negatively affecting their ability to stimulate type 1 helper 
T cell responses. MUC1 transgenic mice were shown to mount only a humoral 
response when immunized with tumour-associated MUC1 expressed in murine 
adenocarcinoma cells (Chen D. et al. 2003). A lower infiltrate of CD8 cells was seen 
in sialylated MUC1-expressing eyelid carcinomas (Uehara F. and Ohba N. 2002), 
and affinity-purified MUC1 from ascites was seen to inhibit T cell proliferation, 
which was reversed by the addition of exogenous IL-2 (Agrawal B. et al. 1998).  
An understanding of the specific immunological effects of each tumour-associated 
MUC1 glycoform is just beginning. Evidence suggests that there are differences 
between the glycoforms and that there is an interaction with the immune system. 
This strongly suggests that different MUC1 glycoforms interact with different 
lectins, evoking a glycan-specific immune response. Lectins are known to interact 
with pathogens (e.g. several C-type lectins) but they also interact with other host 
cells (e.g. selectins and Siglecs). It is the interaction between lectins and specific 
tumour-associated MUC1 glycoforms that is believed to be the determining factor in 










Chapter 2  
































Materials and methods used in chapter 3  
 
2.1 Enterokinase cleavage of murine IgG2aFc domain 
 
Concentrated culture supernatant from cells (CHO K1, mutant CHO-ldlD with or 
without the glycosyltransferase ST6GalNAcI) transfected with MUC1-Ig (Fc region 
from mouse IgG2a fused to MUC1) was obtained from Prof T. Noll (Jülich). 
Supernatant was diluted with EKMax buffer (50 mM Tris/HCl, pH 8.0, 0.05% Tween 
20 and 1 mM CaCl2) to yield a concentration of 0.6 mg/ml. 500 U EK (EK Max, 
Invitrogen, Cat No. E180-01) was added, and the mixture was incubated for 24 hours 
at 37oC (83 U/mg). A further 500 U was then added and the mix was incubated for a 
further 24 hours. The efficiency of the cleavage was assessed by silver and Alcain 
blue stains and the samples immediately purified. 
 
2.2 Anion exchange chromatography (Backstrom M. et al. 2003) 
 
Enterokinase cleaved MUC1 from WT CHO cells were purified by anion exchange 
chromatography. A HiPrep 16/10QFF (GE Healthcare, Uppsala, Sweden Cat No 28-
9365-43) sepharose ion exchange column was used. The column was stored at 4oC in 
20% ethanol. The column, superloop (GE Healthcare, Uppsala, Sweden, Cat No 18-
1113-82), waste collectors, fraction collection tubes and solutions were prepared on 
the AKTA purifier (AKTApurifier 10, GE Healthcare, Uppsala, Sweden, Cat No 28-
4062-64). The solutions required were as follows: ‘High salt solution’ (2M NaCl), 
‘Low salt solution’ (50 mM Tris-HCl pH 8.0), warmed and degassed deionized water 
(DW) and 20% ethanol in DW. Air bubbles were removed from system manually 
prior to a run. Degassed DW was run through column for 25 minutes at a rate of 2 
ml/min with a maximum pressure of 0.35 MPa. Low salt solution was run through 
column for 25 minutes at a rate of 2 ml per minute with a maximum pressure of 0.35 
MPa. The superloop was filled with sample manually (10-25 ml). The program was 
started. 
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Outline of the programme: The column was equilibrated to “low salt conditions” (50 
mM Tris-HCl pH 8.0) for 3 column volumes, the sample was then loaded on to the 
column at 1 ml/min before the unbound material was washed out with low salt 
solution into the waste collector (1 column volume). The percentage of high salt 
solution (2 M NaCl) was gradually increased with elution fractions being collected 
every 3 ml (Fraction collector 901, GE Healthcare, Uppsala, Sweden Cat No 18-
1118-97). The percentage of 2 M NaCl was increased from 0-7.5%, before being held 
at 7.5% for 2 column volumes – it is at this plateau that the IgG2aFc domain elutes. 
The percentage of 2 M NaCl then increased from 7.5% to 25% over 5 column 
volumes before increasing sharply to 100%. It is from the 7.5% to 25% 2 M NaCl 
that the rhMUC1-ST elutes. Due to the sticky nature of MUC1, the column was then 
deep cleaned according to manufacturers instructions. 
Deep cleaning of IEX: 80 ml of 2 M NaCl was run through the column at 5ml/min 
(0.35 Mpa max pressure), followed by 50 ml degassed DW. 80 ml of 1 M NaOH was 
then run through the column, followed by 50 ml degassed DW, 80 ml 70% ethanol, 
again followed by 60 ml degassed DW. Finally, 80 ml 20% ethanol was run through 
before ending the programme and storing the column. 
 
2.3 Affinity chromatography (MUC1 without glycans and Tn)  
 
Enterokinase cleaved MUC1 without glycans or carrying Tn secreted by CHO-ldlD 
cells was purified by affinity chromatography.  
Column preparation: CnBr activated sepharose 4B (Sigma) was used at a ratio of 1 g 
per 5 mg of Ab. Sepharose was washed in 1 mM HCl (200 ml/g) using a sintered 
glass filter, before adding the 5E5 antibody for purification of MUC1-Tn or HMFG1 
antibody for purification of MUC1 without glycans were previously dialysed O/N in 
0.1 M NaHCO3, 0.5 M NaCl pH 8.0 (coupling buffer). Ab/sepharose mixture was 
incubated for 2 hours at room temperature, before being washed with 200 ml/g of 
coupling buffer. Non-reacted groups were blocked in 5 ml/g of 1M ethanolamine (pH 
8.0) for 2 hours at room temperature, before activation with low pH buffer (0.1 M Na 
acetate, 0.5 M NaCl pH4.0) follow by coupling buffer. The sepharose/Abs gel was 
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then placed into a disposable plastic column (Thermo scientific cat no: 29924) and 
stored at 4oC. 
Purification:  The procedure was performed at 4oC. Enterokinase cleaved MUC1 
without glycans or Tn from CHO-ldlD cells was added to CnBr/Ab column (flow rate 
1ml/5 minutes), washed with Phosphate Buffer Saline (PBS) (200 ml/mg), before 
elution with 0.1 M glycine (pH 2.5) in 500 µl fractions, which were collected into 
eppendorf tube containing 100 µl of 1 M TRIS (pH 9.0). Concentrations of fractions 
was determined by enzyme-linked immunosorbent assay (ELISA) (see sections 2.11 
and 2.12).  
 
2.4 Neuraminidase treatment of purified recombinant MUC1-ST 
 
Recombinant MUC1-ST was dialysed in 6-8 kDa membrane (Spectropor) against 5 
litres of sodium acetate buffer (50 mM NaAc pH 6.0, 4mM CaCl2, 0.02% azide) 
overnight at 4oC. The next day, the appropriate amount of neuraminidase beads 
(Sigma Cat No N5254) was washed twice in sodium acetate buffer – 0.15 U of beads 
per mg of MUC1-ST. The dialysed MUC1-ST was mixed with the washed 
neuraminidase beads in an Eppendorf and rotated overnight at room temperature 
(RT). The mix was then spun at 100 G in a microcentrifuge, with the supernatant 
being removed to a new tube and 10 µl taken and either a) checked on an Alcian blue 
stain b) checked on a Western using HMFG1, c) checked on a lectin ELISA against 
the starting material. If the treatment was successful, the MUC1-T was further 
dialysed in 8-10 kDa membrane (SpectraPor Cat No 132645) against 5 litres of DW. 
 
2.5 SDS-PAGE (Polyacrylamide gel electrophoresis) 
 
Gradient Gels (commercial): NuPAGE Novex 4-12% Bis-Tris Gel 1.0 mm, 10 well 
(Invitrogen Cat No NP0321BOX). 
10 µl of sample (pooled fractions from IEX, or from affinity columns) was mixed 
with 5ul NuPAGE® LDS Sample Buffer (4X) (Invitrogen Cat No: NP0007), 2 µl 
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NuPAGE® Reducing Agent (10X) (Invitrogen Cat No: NP0004) and 3 µl deionized 
Water. The samples were heated to 95°C for 5 minutes. The running buffer was 
prepared by adding 50 ml 20X NuPAGE® MOPS SDS Running Buffer (Invitrogen 
Cat No: NP0001) to 950 ml of deionized water. The inner buffer chamber was filled 
with 200 ml 1X NuPAGE® SDS Running Buffer containing 500 µl NuPAGE® 
Antioxidant (Invitrogen Cat No: NP0005). The outer buffer chamber was filled with 
600 ml 1X NuPAGE® SDS Running Buffer. 20 µl of sample was loaded onto the 
gel, which was subjected to 200 V over 1 hour. N.B if a Western was carried out 
using precast gels, NuPAGE® Transfer buffer (20X) (Invitrogen Cat No: NP0006) 
was used for the transfer. 
 
Linear gels (non-commercial): Preparation of 7.5% polyacrylamide gel. 
Resolving gel: 10.24 ml deionised water (DW), 4.5 ml 40% Bis-acrylamide, 9 ml 1M 
Tris.HCl pH 8.8, 120µl SDS, 120 µl ammonium persulfate (10% solution), 16 µl 
TEMED were mixed and slowly fed into the gap between glass plates. Water 
saturated butanol was placed on top of the gel and the gel was given time to set (30-
45 minutes). Once set, water saturated butanol was removed and the gel rinsed twice 
with DW.  
Stacking gel: 7.42 ml DW, 1.25 ml 40% Bis-acrylamide, 1.25 ml 1M Tris.HCl pH 
6.8, 50 µl SDS, 50 µl ammonium persulfate (10% solution), 10 µl TEMED were 
mixed and layered on top of the resolving gel. The lane comb was inserted and the 
gel allowed to set (30-45 minutes).  
Pre-run: Once the stacking gel was set, the rubber insert (on the bottom of the plates) 
was removed. The gel was then placed in an electrophoresis running tank and running 
buffer was added (3 g Tris, 144g glycine, 1% SDS, made up to 1 litre in DW) to a 
level above the comb. The comb was removed and the wells rinsed thoroughly with 
running buffer.  
Sample preparation: 0.5-5 µg of sample (in a volume of no more than 20 µl) was 
mixed with sample (Laemmli) buffer (2.4 ml 1M Tris pH 6.8, 0.8g SDS, 4 ml 100% 
glycerol, 0.01% bromophenol blue, 1 ml 2 M DTT (fresh), 2.8 ml water). The 
mixture was heated to 94oC for 5 minutes before the samples were loaded into the 
wells. Full range molecular markers for size analysis (Invitogen) were run in one 
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well. The gels were run for approximately 1 hour (until sample buffer reached base of 
gel) at 100 V. 
 
2.6 Silver staining of proteins on SDS polyacrylamide gels 
 
After electrophoresis the gel was fixed for 1-2 hours in 50 ml Methanol, 12 ml Acetic 
acid, 50 µl formaldehyde (37%) and 38 ml DW on a shaker at RT. The fixed solution 
was removed and the first equilibrating solution was added (50 ml Ethanol, 50 ml 
DW) for 10 minutes on a shaker at RT. The first equilibrating solution was removed 
and replaced by the second (30 ml ethanol, 70 ml DW) for 10 minutes on a shaker at 
RT. All other solutions were now prepared in advance as oxidation and developing is 
rapid. The proteins were oxidised by manually shaking the gel for 1 min with 20 ml 
Na2S2O3.5H20 (1 mg/ml) plus 80 ml DW. The gel was washed three times in 100 ml 
DW, 20 seconds per wash. Silver nitrate solution (100 ml 0.1% AgNO3, 75 µl 
formaldehyde 37%) was added and the gel was placed on a shaker at RT for 20 
minutes. The gel was then washed twice for 20 seconds in 100 ml DW. The 
developer was added (100 ml 6% Na2CO3, 50 µl formaldehyde [37%], 40 µl 
Na2S2O3.5H2O [1 mg/ml]) and the gel was shaken manually until the Ag2(CO3)2 was 
seen to stain the gel. The reaction was stopped by adding 5% acetic acid to the gel for 
5 minutes on the shaker at RT. Finally the gel was washed for 10 minutes in DW 
before being dried on blotting paper using a heated vacuum pump. 
 
2.7 Alcian Blue staining of sialylated glycoproteins on SDS 
polyacrylamide gels 
 
After electrophoresis the gel was fixed for 1-2 hours in 50 ml methanol, 1 ml acetic 
acid, 49 ml DW on a shaker at RT. The fixative was removed and the gel equilibrated 
with 25 ml ethanol, 10 ml acetic acid, 65ml DW twice for 15 minutes on a shaker at 
RT. The gel was stained with 100ml of Alcain blue solution (0.125% Alcian Blue in 
25% ethanol, 10% acetic acid in DW) for 20-30 minutes on a shaker at RT. The gel 
 75 
was destained with 50% ethanol, 10% acetic acid in DW for three sets of 10 minutes, 
or until satisfied with staining contrast ratio. If excessive gel shrinkage occurred, the 
gel was rehydrated with 1% acetic acid in DW for 30 minutes. Finally the gel was 
dried on blotting paper using a heated vacuum pump. 
 
2.8 Western blot 
 
Gel electrophoresis was performed as described. 
Transferring the protein to the membrane: The gel was soaked in transfer buffer 
(running buffer + 20% methanol) for 5 minutes along with 6 pieces of appropriately 
sized blotting paper and a piece of hybond transfer membrane (Amersham 
Biosciences). A sandwich of the above was created - 3 pieces of blotting paper, the 
membrane, the gel and three pieces of blotting paper – and placed in a cartridge in a 
transfer tank. Transfer buffer was added to the tank until the cartridge was covered. 
The transfer takes approximately 1 hour 20 minutes at 100 V, or can be left overnight 
at 4oC at 30 V (both 50 mA).  
Antibody staining of the bound proteins: The membrane was rinsed in Ponceau S for 
5 minutes, to check for successful protein transfer, before being rinsed in PBS. The 
membrane was blocked in 2% BSA, 0.2% Tween 20 and 0.05% NaN3, in PBS for 
>2h on a rocker at RT. The membrane was rinsed in PBS before the primary antibody 
or biotinylated lectin was added (at 1 µg/ml, or 1:1000) in 1% BSA, 0.1% Tween 20 
in PBS on a rocker at RT for >1 hour. The membrane was then rinsed three times 
over an hour with PBS + 0.02% Tween 20. The secondary antibody was then added 
(1:1000 or 1 µg/ml) e.g. anti-mouse IgG HRP or streptavidin HRP 1% BSA, 0.1% 
Tween 20 in PBS on a rocker at RT for >1 hour. The membrane was then rinsed 
twice with PBS + 0.02% Tween 20 and once with PBS over an hour.  
Developing: The blot was developed using the ECL method following the 
manufacturer’s instructions. A 1:1 mix of the ECL solutions was applied to the 
membrane and the resultant luminescence was developed using photosensitive film.  
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2.9  IgG2aFc ELISA from purified fraction 
 
20 µl (plus 80 µl PBS) from every fourth elution fraction was plated on a 96 well 
ELISA plate (IWAKI) in duplicate and incubated overnight at RT. Standard: Mouse 
IgG1 control (R and D cat No MAB002) 1 in 2 dilutions from 5 µg/ml in duplicate. 
The wells were washed three times with 200 µl 0.05% Tween 20 in PBS before being 
blocked with 1% BSA in PBS for 2 hours at RT. The wells were washed three times 
with 200 µl 0.05% Tween 20 in PBS before 100 µl of a secondary (anti-mouse IgG-
HRP) was added at a 1:500 dilution for 2 hours at RT. The plate was washed three 
times (0.05% Tween in PBS) before the substrate (Substrate reagent, R and D 
systems DY999; a 1:1 ration of H2O2 and tetramethylbenzidine) was added and the 
plate was incubated for 20 minutes in the dark at RT. 50 µl stopping solution (1 M 
H2SO4) was then added to each well and the plate was read on a microplate reader at 
450 nm. Concentrations of IgG2aFc in each fraction were calculated against the 
standard curve. 
 
2.10  MUC1 Ab ELISA on recombinant MUC1 glycoforms 
 
ELISA plates (IWAKI) were coated with 500 ng (100µl) of MUC1-IgG glycoform 
and incubated overnight at RT. The wells were washed three times with 200 µl 
0.05% Tween 20 in PBS before being blocked with 1% BSA in PBS for 2 hours at 
RT. The wells were washed three times with 200 µl 0.05% Tween 20 in PBS before 
biotinylated MUC1-specific mAbs were added in serial 2-fold dilutions from 20 
µg/ml to 2 ng/ml. Following incubation the wells were washed three times with 200 
µl 0.05% Tween 20 in PBS before adding the substrate composed of peroxidase-
conjugated streptavidin (DakoCytomation) for 30 minutes. After further washing 
with PBS the substrate O-phenylene-diamine (Sigma-Aldrich.) was added for 10 




2.11 HMFG2/HMFG2 sandwich ELISA 
 
100 µl HMFG2 at a concentration of 1 µg/ml in PBS was plated on a 96 well ELISA 
plate (IWAKI) and incubated overnight at RT. The wells were washed three times 
with 200 µl 0.05% Tween 20 in PBS before being blocked with 1% BSA in PBS for 
2 hours at RT. The wells were washed three times with 200 µl 0.05% Tween 20 in 
PBS before 100 µl standards (2 µg/ml of the MUC1 glycoform being assessed, in 
PBS, with serial 1 in 2 dilutions in duplicate) and 100 µl samples added in duplicate 
and incubated for 2 hours at RT. NB all samples and controls diluted in PBS. 100 µl 
biotinylated HMFG2 was added at a concentration of 1 µg/ml in PBS and incubated 
for 2 hours at RT. The wells were then washed three times with 200 µl 0.05% Tween 
20 in PBS before streptavidin-HRP is added (1:200) in PBS and incubated for 20 
minutes at RT in the dark. The wells were then washed twice with 200 µl 0.05% 
Tween 20 in PBS before a final wash in PBS alone. The substrate solution (Substrate 
reagent, R and D systems DY999; a 1:1 ratio of H2O2 and tetramethylbenzidine) was 
added and the plate was incubated for 20 minutes in the dark at RT. 50 µl stopping 
solution (1 M H2SO4) was then added to each well and the plate was read on a 
microplate reader at 450 nm. Concentrations of MUC1 were calculated against the 
standard curve. 
 
2.12 5E5/5E5 sandwich ELISA 
 
100 µl 5E5 at a concentration of 1 µg/ml in PBS was plated on a 96 well ELISA 
plate (IWAKI) and incubated overnight at RT. The wells were washed three times 
with 200 µl 0.05% Tween 20 in PBS before being blocked with 1% BSA in PBS for 
2h at RT. The wells were washed three times with 200 µl 0.05% Tween 20 in PBS 
before 100 µl standards (2 µg/ml of the MUC1 glycoform being assessed, in PBS, 
with serial 1 in 2 dilutions in duplicate) and 100 µl samples added in duplicate and 
incubated for 2 hours at RT. NB all samples and controls diluted in PBS. 100 µl 
biotinylated 5E5 was added at a concentration of 1 µg/ml in PBS and incubated for 2 
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hours at RT. The wells were then washed three times with 200 µl 0.05% Tween 20 in 
PBS before streptavidin-HRP is added (1:200) in PBS and incubated for 20 minutes 
at RT in the dark. The wells were then washed twice with 200 µl 0.05% Tween 20 in 
PBS before a final wash in PBS alone. The substrate solution (Substrate reagent, R 
and D systems DY999; a 1:1 ration of H2O2 and tetramethylbenzidine) was added 
and the plate was incubated for 20 minutes in the dark at RT. 50 µl stopping solution 
(1 M H2SO4) was then added to each well and the plate was read on a microplate 
reader at 450 nm. Concentrations of MUC1 were calculated against the standard 
curve. 
 
2.13 The LAL endotoxin assay 
 
The Endpoint Chromogenic Limulus Amebocyte Lysate (LAL) Test is a quantitative 
test for Gram-negative bacterial endotoxin. It utilises the horseshoe crab’s normal 
physiology. Instead of a mammalian clotting cascade after exposure to oxygen or 
collagen, upon contact with endotoxin (ubiquitous in the crab’s environment), the 
crab’s amebocytes trigger coagulation.  
Samples were mixed with the LAL supplied in the test kit (Lonza, LAL QCL-1000, 
Cat No 50-647U) and incubated at 37°C (±1°C) for 10 minutes. A substrate solution 
was then mixed with the LAL-sample and incubated at 37°C (±1°C) for an additional 
6 minutes. The reaction was stopped with the stop reagent supplied. The absorbance 
of the sample was determined spectrophotometrically at 405-410 nm. Since this 
absorbance is in direct proportion to the amount of endotoxin present, the 
concentration of endotoxin can be calculated from a standard curve. 
 
2.14 Determining concentration by protein hydrolysis for amino 
acid content 
 
When the composition of an analysed protein is known, it is possible to exploit the 
fact that some amino acids such as: aspartate-aspargine, glutamate-glutamine, 
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alanine, leucine, phenylalanine, lysine and arginine are recovered well after 
hydrolysis. The concentration in n.mole/ml resulting from analysis can be converted 
to weight/ml present in the sample, and as % composition for each amino acids of a 
known protein is available, sample concentration can be determined.  
e.g. 





Alanine 112.000 7.96 17.3 46.01 
 
2.15 Batches of MUC1 glycoforms used in Chapter 4  
 
Purified By: Code Glycan Amount 
in mg  
Endotoxin 
level EU/ml  
EK 
cleaved 
Gianfranco Picco GP001 ST 2.5 <5 Yes 
Gianfranco Picco GP001 T 1 <5 Yes 
Gianfranco Picco GP002 ST 3 <5 Yes 
Gianfranco Picco GP002 T 1 <5 Yes 
Gianfranco Picco GP004 No glycans 4 <5 Yes 
Gianfranco Picco GP005 Tn 3.5 <5 Yes 
Gianfranco Picco GP014 STn 0.2 <5 Yes 
EU consortium 
(Partner 3 see 
appendix II) 
PH5202 ST 3 <5 No 
EU consortium 
(Partner 3 see 
appendix II) 
PH5258 T 1 <5 No 
EU consortium 
(Partner 3 see 
appendix II) 
PH6162 ST 4 <5 Yes 
EU consortium 
(Partner 3 see 
appendix II) 
PH6289 T 1.5 <5 Yes 
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Materials and methods used in chapter 4 
 
2.16 Immunization with recombinant MUC1 glycoproteins 
All animal work was carried out under Project Licence Number: PPL 70/6847, 
strictly adhering to Home Office guidelines 
 
Lyophilised recombinant MUC1 glycoproteins were reconstituted in endotoxin free 
PBS at a concentration of 400 µg/ml, prior to been mixed with an equal volume of 
Freud’s adjuvant to form a water in oil emulsion. Initial injections were composed of 
an equal volume of reconstituted MUC1 glycoprotein and Freund’s complete 
adjuvant (Sigma F5881), and were administered in a total volume of 100 µl 
subcutaneously into right flank of mice. Subsequent immunizations were 
administered at three weekly intervals with reconstituted MUC1 glycoproteins mixed 
with Freund’s incomplete adjuvant (Sigma 5506), and a total volume of 100 µl 
administered subcutaneously into alternate flanks of mice. Seven days following the 
last immunization, mice were sacrificed and the spleen removed for in vitro testing. 
 
2.17 Adjuvant in vivo treatment 
 
Freund’s was chosen as adjuvant as it is the most commonly used adjuvant in 
research. It is water in oil emulsion composed of 85% paraffin oil and 15% mannide 
monooleate (Freund’s incomplete, Sigma F 5506), or additionally containing 1 
mg/ml of heat-killed and dried Mycobacterium tuberculosis (strain H37Ra, Freund’s 
complete, Sigma F5881). Freund’s adjuvant was first developed by Jules Freund in 
the 1940’s, and designed to provide continuous release of antigens necessary for 
stimulating a strong, persistent immune response (Freund J. and McDermott K. 
1942). Antigens tested as immunogen in PBS were mixed with an equal volume of 
the Freud’s adjuvant to form an emulsion, and immunizations were given 
subcutaneously in a total volume of 100 µl. The mycobacterium in Freund’s 
complete has been found to attract macrophages and other cells to the injection site, 
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which enhances the immune response. For this reason, Freund’s complete was used 
for the initial injections. Because Freund’s complete causes granulomas 
inflammation at the inoculation site, in accordance with UK guidelines, Freud’s 
incomplete was used for the following boosts. 
 
2.18  T cell assay  
 
For splenocyte extraction, mouse spleens were squashed and suspended in 35 ml 
RPMI followed by centrifugation (200 G for 5 min) and resuspended in 10 ml RPMI. 
10 ml Ficoll-PaqueTM PLUS (GE Healthcare) was than layered beneath. After 
centrifugation (400 G 15 min with brake turned off) the splenocytes were transferred 
to a new tube and an equal volume of RPMI was added followed by centrifugation 
(200 G for 10 min). Cells were washed twice in RPMI and resuspended in 4-8 ml 
RPMI containing 5% FCS at 107 cells/ml. Finally, cells were filtered through a 50 
µM filter to eliminate clumps. For stimulation of splenocytes, 1 × 106 cells in 100 µl 
culture medium were incubated with 1µg of the recombinant glycoprotein used as 
immunogen, or control (non specific glycoprotein) for 48-60 hours at 37°C and 
5%CO2. As a positive control cells were incubated with 1 µg Concanavalin A lectin. 
Cytokine concentrations (IFN-commercially available two-site sandwich enzyme-
linked immunosorbent assays (ELISA) according to the manufacturer’s instructions 
(R&D Systems). Experiments were performed in triplicate and supernatants were 
collected after 48 hours of CTL induction. 
 
2.19 Bone marrow derived DC preparation 
 
Mouse femur bones (2 bones from 1 mouse) were dissected above and below the 
joint (knee and hip), and using small dissection scissors the majority of muscles were 
removed prior its transfer into a dish containing RPMI medium. Bones were then 
held with tweezers, and using scissors, both end of the bone ware cut to expose the 
bone marrow. The marrow was washed out with RPMI media using a syringe. Gentle 
pipetting up and down of the media containing the bone marrow using a syringe was 
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performed in order to prepare a single cell suspension, prior to plating the cells in 10 
cm culture dish at a concentration of a million cells per ml in IMDM media 
containing 5% Foetal Calf Serum (FCS), 20 ng/ml GM-CSF and 200 IU/ml IL-4. On 
day 3 of cell culture (37oC with 10%CO2), media was removed and a gentle wash 
with fresh media was applied using a pipette to remove non-adherent cells from the 
culture. The adherent cells were then supplied with fresh media and placed back into 
culture. On day 6, culture media was removed and non-adherent DC cells were 
separated from adherent progenitor by gently washing the culture dish, held at 45 
degree angle, with PBS using a pipette. The DCs were collected to be used for 
further testing. 
                 
2.20 In vitro T-cell depletion 
 
In vitro CD4 and/or CD-8 T cells subsets were separated from mouse single cell 
suspensions using MACS® technology from Miltenyi Biotec. Cells in a single cell 
suspension were labelled with CD4 (L3T4) bound to magnetic microbeads 
(catalogue number 130-049-201), or CD8 (Ly-2) microbeads (catalogue number 130-
049-401). Samples were then applied to MACS column in a MACS separator, which 
retains the labelled cells. The flow-through was collected as the unlabelled cell 
fraction. Cells positively selected for CD4 or CD-8 T cells subsets were then used for 
in vitro testing. 
 
2.21 In vivo T-cell depletion 
 
In vivo depletion of CD4 and/or CD-8 T cells subset was performed using rat anti-
CD4 (Clone GK1.5) and rat anti-CD8 (Clone 2.43) MAb. The Abs were produced by 
Cancer Research UK from hybridoma cells and shown to be endotoxin free. Initial 
depletion in adult mice was performed by injecting the antibodies intraperitoneally 
for three consecutive days, at a concentration of 20 mg/kg diluted into 100 µl of 
endotoxin free PBS. To determine the depletion efficiency at day 6 mice were 
sacrificed, and a single cell suspension from the spleens was made. Flow cytometry 
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was performed on the cells after staining with directly labelled (FITC) anti-CD4 or 
anti-CD8 MAbs. Maintenance of the depletion was obtained by injecting 20 mg/kg 
the antibodies intraperitoneally every three days. 
 
2.22 Flow cytometric analysis 
 
Cells were gently removed from culture, counted using a CASY counter, and spun 
down at 200 G before being resuspended at 5x105 cells/ml in cold 0.5% BSA in PBS. 
200 µl (1 x 105 cells) of this solution per test was placed in a round bottom 96 well 
plate and incubated in buffer for 10 minutes to block non-specific binding before 
being spun down at 200 G and resuspended in 50 µl cold 0.5% BSA in PBS. 
Appropriate amount of each antibody was then added to the appropriate well and the 
cells were incubated for 45 minutes on ice in the dark. Cells were then washed in 200 
µl/well cold 0.5% BSA in PBS and resuspended in 150 µl cold 0.5% BSA in PBS and 
100 µl 1% paraformaldehyde solution (in PBS). The cells were then run through the 
flow cytometer (Beckman Coulter Epics XL) and analysed using winMDI software. 
 
2.23 IFNγ  sandwich ELISA (R & D; DY285) 
 
100 µl of 4 µg/ml capture anti-mouse IFNγ antibody in PBS was plated on a 96 well 
ELISA plate (IWAKI) and incubated overnight at RT. The wells were washed three 
times with 200 µl 0.05% Tween 20 in PBS before being blocked with 1% BSA in 
PBS for 2 hours at RT. The wells were washed three times with 200 µl 0.05% Tween 
20 in PBS before 100 µl standards (serial 1 in 2 dilutions from 2000 pg/ml) and 100 
µl samples added in duplicate and incubated for 2 hours at RT. All samples and 
controls were diluted in reagent dilutant: 1% BSA in PBS. 100 µl biotinylated anti-
mouse IFNγ was added at a concentration of 50 ng/ml in reagent dilutant and 
incubated for 2 hours at RT. The wells were then washed three times with 200 µl 
0.05% Tween 20 in PBS before streptavidin-HRP was added (1:200) in reagent 
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dilutant and incubated for 20 minutes at RT in the dark. The wells were then washed 
twice with 200 µl 0.05% Tween 20 in PBS before a final wash in PBS alone. The 
substrate solution (Substrate reagent, R and D systems DY999; a 1:1 ration of H2O2 
and tetramethylbenzidine) was added and the plate was incubated for 20 minutes in 
the dark at RT. 50 µl stopping solution (1M H2SO4) was then added to each well and 
the plate was read on a microplate reader at 450nm. Concentrations of IFNγ were 
calculated against the standard curve. 
 
2.24 Detection of antibodies from mouse serum by ELISA 
 
100 µl of PBS containing 500 ng of either recombinant MUC1, 60mer MUC1 
peptide or lipopolysaccharides LPS were placed on each well of a 96 well ELISA 
plate (IWAKI) and incubated overnight at room temperature (RT). The wells were 
washed three times with 200 µl 0.05% Tween 20 in PBS before being blocked with 
1% BSA in PBS for 2 hours at RT. The wells were washed three times with 200 µl 
0.05% Tween 20 in PBS before 100 µl of mouse serum diluted 1/40 in PBS (prior 
and after immunizations) was applied in duplicate to the ELISA’s plate wells and 
incubated for 2 hours at RT. The wells were washed three times with 200 µl 0.05% 
Tween 20 in PBS before 100 µl of a secondary (anti-mouse IgG-HRP) was added at 
a 1:500 dilution for 2 hours at RT. The plate was washed three times (0.05% Tween 
in PBS) before the substrate (Substrate reagent, R and D systems DY999; a 1:1 ratio 
of H2O2 and tetramethylbenzidine) was added and the plate was incubated for 10 
minutes in the dark at RT. 50 µl stopping solution (1 M H2SO4) was then added to 
each well and the plate was read on a microplate reader at 450 nm.  
 
2.25 Biotinylation of antibody and recombinant MUC1 
glycoforms 
 
The biotinylation buffer was made (51.9 g NaHCO3 and 25.8 g Na2CO3 in 3 litres 
DW pH 9.30) and chilled to 4oC before use. A minimum of 0.5 mg/ml solution of 
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Abs or MUC1-glycoforms were made up and placed in dialysis tubing (NB for 
unglycosylated MUC1 biologically inert, biotech cellulose ester is used to minimise 
loss; Spectrumlabs ‘float-a-lyzer’ G2; G235031) before being placed in the buffer at 
4oC overnight. The buffered Abs or MUC1 glycoforms were then mixed with 120 µg 
(per mg) biotin/DMSO premade stocks (1 mg/ml). The mix was rotated at RT for a 
minimum of 4 hours before being dialysed against cold 3 litres PBS + 0.1% azide 
overnight at 4oC. The Abs or MUC1 glycoforms were removed from the dialysis 
tubing and the concentration was calculated from the change in volume. 
 
Materials and methods used in chapter 5 
 
2.26 Development of hST3Gal-I transgenic mice 
 
Human ST3Gal-I (+889 to +1951) (Accession number: L29555, EC:2.4.99.4) was 
amplified by PCR from a plasmid containing hST3Gal-I full cDNA with the 
following primers designed to insert restriction sites for Not 1 at both 5’ and 3’ ends 
of the amplicon: 
Forward primer: 5’-ATCAGCTAGCGCGGCCGCTTCCTGCTACCCATCGT-3’  
Reverse primer: 5’-TAGAAGTTCCCCTCTACTCCTAGGCGC-3’. 
Using these Not I sites, the resulting cDNA was inserted into the pNASSβ plasmid 
(Clontech), downstream of the promoter region of human MUC1 (from -1401 to 
+33) previously cloned in this plasmid (Graham R. A. et al. 2001). A 2.5kb Sal I-Sca 
I fragment containing the MUC1 promoter fused to ST3Gal-I was purified (Qiagen 
kit) and dissolved in injection buffer (10 mM Tris, 0.1 mM EDTA pH 7.4 prepared 
in ultrapure water). DNA (5 ng/l) was injected into the pronucleus of pure C57/Bl6 
mouse embryos that were subsequently transferred into day 1-plugged 
pseudopregnant C57/Bl6 female mice (Injections performed by CR-UK Biological 
Resource unit). 
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Transgenic mice were identified by PCR on DNA isolated from tail snips, 
amplifying a 550 bp segment of DNA using oligonucleotides primers within the 3’ 
end of the MUC1 promoter and within the 5’ end of the ST3Gal-I: 
Forward primer: 5’-GCCGTTGTGGGCAACTCGGGC-3’  
Reverse primer: 5’-GCTCACCACCCACTCCAAGTCT-3’. 
Two founder mice were identified that expressed hST3Gal-I in the expected tissues 
and from one founder, mice homozygous for hST3Gal-I were developed by 
littermate mating. Homozygosity was confirmed by backcrossing mice onto WT 
C57Bl/6, which resulted in 100% of the offspring carrying hST3Gal-I.  
 
2.27 Development of spontaneous tumours in hST3Gal-I 
transgenic mice  
 
Homozygous hST3Gal-I female mice on a pure C57Bl/6 background were mated 
with FVB male mice heterozygous for the Polyomavirus middle T antigen driven by 
the mouse mammary tumour virus (MMTV-PyMT mice (Guy C. T. et al. 1992) 
promoter to obtain the ST3Gal-I/PyMT mice. Heterozygous males mice for the 
Polyomavirus middle T antigen were used for breading as spontaneous tumours 
appear at a very early age on homozygous and also heterozygous MMTV-PyMT 
mice female mice. Control mice (Control/PyMT mice) were derived by crossing 
female C57Bl/6 mice with MMTV-PyMT male mice. The offspring were screened 
for the polyoma middle T antigen by PCR of DNA prepared from tail snips using the 
following primers: 
Forward primer: 5’-CCAGAACTCCTGTATCCAGAAGCG-3’  
Reverse primer 5’-GGATGAGCTGGGGTACTTGTTCCCC-3’.  
Female mice carrying the PyMT were examined three times per week for the 






Frozen sections of mouse tissue were fixed in ice-cold acetone for 10 minutes, and 
formalin fixed paraffin embedded sections were used after xylene removal of 
paraffin and gradual ethanol rehydration. For staining for mouse Muc1, endogenous 
peroxidase activity was blocked in 1/100 H2O2/methanol for 10 minutes. After 
rehydration and/or blockage of endogenous peroxidase activity, sections were 
blocked with 50% foetal calf serum and then incubated with a monoclonal antibody 
4B10 to human ST3Gal-I (Vallejo-Ruiz V. et al. 2001) or a polyclonal antibody to 
the human MUC1 cytoplasmic tail that also reacts with mouse Muc1 (Pemberton L. 
et al. 1992). After extensive washing the slides were incubated with biotinylated 
rabbit anti-mouse Ig or biotinylated goat anti-rabbit Ig (DAKO), respectively, for 30 
minutes, washed and incubated with streptavidin biotin complexes linked to horse 
radish peroxidase (DAKO). Binding was visualised with diaminobenzidine (DAKO) 
and the sections counter-stained with haematoxylin. Haematoxylin and eosin (H&E) 
staining on formalin-fixed paraffin embedded tissue was used for additional 
histological analysis. 
 
2.29 Glycosyltransferase assays (performed by Prof. Inka Broakhausen’s group) 
 
Homogenates of mouse tissues were prepared by mincing tissues and hand 
homogenizing in 5 times volume of 0.25 M sucrose. Protein contents were 
determined by the BioRad protein assay (Bradford) using BSA as the standard. All 
enzymes were assayed in at least duplicate determinations, and results varied by 
<10% between duplicates. Assays lacking exogenously added acceptor substrate 
provided the background radioactivity. 
 
Sialyltransferase 
ST3Gal transferase assay mixtures contained in a total volume of 40 ml: 2 mM 
Galβ1-3GalNAcα-p-nitrophenyl (Galβ1-3GalNAcα-pnp) acceptor substrate, 0.1 M 
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Tris-HCl, pH 7, 0.125 % Triton X-100, 5 mM MnCl2, 0.4 mM CMP-[3H]sialic acid 
(2420 cpm/nmol), and 10 ml homogenate (0.08 to 0.15 mg protein). The mixtures 
were incubated for 1 hour at 37oC. Reactions were stopped with 0.2 ml water and 
freezing, and mixtures filtered through 0.1 ml of Bio-Gel P2, washed three times 
with 0.4 ml water. After lyophilizing combined eluates, 120 ml water were added 
and 80 ml injected into HPLC, using an analytical amine column and acetonitrile/15 
mM K-phosphate, pH 5.2 = 75/25 as the mobile phase. The absorbance at 195 nm 
and radioactivity of 2 minutes fractions were monitored. Sialic acid eluted at about 
25-30 min and enzyme product at 14-18 min. Radioactivity of fractions was 
determined by scintillation counting. Radioactive CMP-sialic acid did not elute 
under these conditions, but can be eluted with acetonitrile/15 mM K-phosphate, pH 
5.2 = 50/50.  
 
Polypeptide GalNAc-transferase 
Polypeptide GalNAc-transferase activity was assayed in mixtures containing in a 
total volume of 40 ml: 0.5 mM acceptor substrate AQPTPPP, 0.125 M MES buffer, 
pH 7, 0.125 % Triton X-100, 10 mM AMP, 10 mM MnCl2, 0.9 mM UDP-
[3H]GalNAc (3795 cpm/nmol), and 10 ml homogenate (0.08 to 0.15 mg protein). 
The mixtures were incubated for 1 hour at 37oC. Reactions were stopped with 0.6 ml 
water and freezing. Mixtures were applied to columns of 0.4 ml AG1x8, which were 
washed twice with 0.6 ml water. Eluates were lyophilized and enzyme product 
separated by HPLC using a C18 column and acetonitrile/water = 6/94 as the mobile 
phase. The absorbance at 195 nm and radioactivity of 2 minutes fractions were 
monitored. Radioactivity of fractions was determined by scintillation counting. 
 
Core 2 β6GlcNAc-transferase 
Core 2 β6GlcNAc-transferase assay mixtures contained in a total volume of 40 ml: 
2 mM Galβ1-3GalNAcα-Bn acceptor substrate, 0.125 M GlcNAc, 0.125 M MES 
buffer, pH 7, 0.125 % Triton X-100, 10 mM AMP, 0.5 mM UDP-[3H]GlcNAc (5230 
cpm/nmol), and 10 ml homogenate (0.06 to 0.24 mg protein). The mixtures were 
incubated, in duplicates, for 1 hour at 37oC. Product was isolated as described for 
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polypeptide GalNAc-transferase by AG1x8 and HPLC using a C18 column and 
acetonitrile/water = 12/88 as the mobile phase. 
 
2.30 Analysis of O-glycans of mice tumours (performed by Prof. Anne 
Dell’s group) 
 
Snapfrozen mouse tumours were sent to Imperial College on dry ice where they were 
processed. All mouse tumours were treated as described in (Sutton-Smith M. et al. 
2007). Briefly, each tumour sample was subjected to reduction in 4M guanidine-HCl 
(Pierce, Cramlington, Northumberland, UK), carboxymethylation and trypsin 
digestion. The digested glycoproteins were purified by C18-Sep-Pak (Waters Corp, 
Hertfordshire, UK). O-glycans were released by reductive elimination and then 
permethylated using the sodium hydroxide procedure. Finally, the permethylated O-
glycans were purified by C18-Sep-Pak. 
MS and MS/MS data were acquired using a 4800 MALDI-TOF/TOF (Applied 
Biosystems, Darmstadt, Germany) mass spectrometer. Permethylated samples were 
dissolved in 10 µl of methanol and 1 µl of dissolved sample was premixed with 1 µL 
of matrix (20 mg/ml 2,5-dihydroxybenzoic acid (DHB) in 70% (v/v) aqueous 
methanol), spotted onto a target plate (2×0.5 µl) and dried under vacuum. The 
collision energy was set to 1 kV, and argon was used as collision gas. The 4700 
Calibration standard kit, calmix (Applied Biosystems), was used as the external 
calibrant for the MS mode and [Glu1] fibrinopeptide B human (Sigma-Aldrich) was 
used as an external calibrant for the MS/MS mode. 
The MS and MS/MS data were processed using Data Explorer 4.9 Software (Applied 
Biosystems). The spectra were subjected to manual assignment and annotation with 
the aid of the glycobioinformatics tool GlycoWorkBench (Ceroni A. et al. 2008). 
The proposed assignments for the selected peaks were based on 12C isotopic 
composition together with knowledge of the biosynthetic pathways. The proposed 
structures were then confirmed by data obtained from MS/MS experiments. 
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2.31 TGFβ  ELISA 
 
The concentration of TGFβ in mouse serum was measured by a commercially 
available two-site sandwich enzyme-linked immuno-absorbent assay (ELISA) from 
R&D Systems according to manufacturer’s instructions. Assays were performed in 




Snap-frozen tumours were crushed using a Mikro-dismembrator II (B Braun Biotech, 
Melsungen, Germany). Tumour powders were dissolved in lysis buffer (Tris/HCl 50 
mM, NaCl 150 mM, Triton X100 0.1%) containing the complete-mini anti-protease 
cocktail (Roche, Lewes, UK) and incubated for 6 hours. Lysates were homogenised 
with an Ultra-Turrax T8 (Ika, Fisher Scientific, Loughborough, UK) and further 
incubated for 2 hours. Total tumour lysates (2 mg of proteins) were pre-cleared using 
50 µl of A/G proteins agarose-beads (Roche) for 2 hours. The lysates were then 
incubated with 5 µg of anti-c-Src antibody (Santa Cruz) or 100 µl of anti-CT 
supernatant (CT2 antibody), overnight at 40C.  
A/G proteins beads (100 µl) were subsequently added and incubated for 4 hours. 
Immunoprecipitated proteins were washed using PBS, then eluted from the bead 
using elution buffer (0.1 M glycine at pH 2.5) for two incubations of 15 minutes 
each. All procedures were carried out at 4oC using ice-cold reagents.   
 
2.33 Electrophoresis and Western blotting  
 
The immuno-precipitates were loaded onto 4 to 12% gradient acrylamide gels, 
separated by SDS-PAGE electrophoresis under reducing conditions and electro-
transferred on to nitrocellulose membranes (Biotrace NT; Gelman Science) in 
accordance with standard procedures. Membranes were blocked in 1% BSA in Tris 
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Buffered Saline (TBS) and incubated with primary antibodies, anti c-Src or a 
polyclonal antibody (CT1) to the cytoplasmic tail of Muc1, in TBS 0.05% Tween-20, 
for 1 hour. After washing, labelled proteins were revealed using appropriate 
secondary antibodies conjugated to alkaline-phosphatase and NBT/X-phosphate 
revelation reagent (Roche, Lewes, UK). 
Western blots for AKT and Phospho-AKT were performed using antibodies from 
Cell Signaling Technology using a phospho-Ser473 specific antibody and visualized 
using ECL system (GE Healthcare). 
 
2.34 RNA extraction, reverse transcription and quantitative real-
time-PCR 
 
Cell pellets were snap frozen in 50 µl of RNA Later reagent (Qiagen, Crawley, UK). 
Total RNA was extracted from cells using the Nucleospin RNA II kit (Macherey 
Nagel, Düren, Germany), according to manufacturer’s instructions. The integrity of 
the extracted RNA was controlled using a Bioanalyser (Agilent Technologies, 
Wokingham, UK). DNased RNA (0.6 µg) was reverse transcribed using random 
hexamer primers and superscript III reverse transcriptase (Invitrogen, Paisley, UK). 
QRT-PCR was performed using SYBR Green I technology (Sigma-Aldrich, Poole, 
UK) and Opticon qRT-PCR analysis system (MJ Research, Waltham, MA). Briefly, 
each reaction mix contained 10 ng of cDNA and 10 pmol of the ST3Gal-I primers:  
Forward primer: 5’-CGGTACCCGGGGATCAATTCGAG-3’  
Reverse primer 5’-TCCCATCACAAATCACCATGGACC-3’. 
Cycles were as follows: 15 seconds denaturation at 94°C, 30 seconds annealing at 



























We hypothesized that aberrant glycoforms of MUC1 can induce an immune response 
and therefore have the potential to be used as an immunotherapeutic agents. 
Therefore, the objective of this chapter was to purify specific tumour-associated 
glycoforms of MUC1 to be used as immunogens in experiments designed to evaluate 
their efficacy for the immunotherapy of breast and other MUC1 expressing cancers. 
In this chapter the purification of recombinant MUC1 glycoproteins expressing 
predominantly either the glycan Tn, Sialyl-Tn, T, Sialyl-T or no O-linked glycans 
will be described. These glycoforms were produced in CHO and CHO ldlD cells, and 
purified from the media by anion exchange or affinity chromatography. Amino acids 
analysis, Western blotting, Silver staining and endotoxin testing confirmed the 
purity.  
 
The utilization of mammalian cell lines for the production of biopharmaceutical 
agents has been studied since the late 1940s, and by the early 1980s biological agents 
produced in tissue culture included vaccines for polio, mumps and measles. Since 
then, a wide variety of cell lines have become available to produce biological agents, 
with the Chinese Hamster Ovary (CHO) cell line being the most widely used. CHO 
cells are well suited as a production cell line for many reasons, and these include the 
fact that the cells are widely available, fast growing, easily transfectable, can adapt 
well to growth in monolayer or in suspension and have been grown successfully in a 
variety of production systems. Furthermore, and most importantly in this case, 
MUC1 O-linked glycosylation carried out by CHO cells has been found to be very 
similar to that seen on MUC1 from breast cancer (Backstrom M. et al. 2003), 
represented as an extreme case by the cell line T47D (Lloyd K. O. et al. 1996) 
derived from a metastatic breast cancer. For these reasons CHO cells, either wild-
type, mutant or expressing a specific glycosyltransferase were chosen for the large 
scale production of recombinant MUC1 glycoproteins expressing predominantly 
either the glycan Tn, Sialyl-Tn, T, Sialyl-T or with no O-linked glycans.  
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3.2  Large scale production of MUC1 glycoproteins 
 
 
As part of an EU funded consortium co-ordinated by the Breast Cancer Biology 
Group, recombinant MUC1, composed of the amino end of MUC1 and 16 tandem 
repeats fused to the Fc region of mouse IgG-2a (fig 3.1A) for efficient secretion, was 
expressed in CHO-K1 (Chinese-hamster ovary K1) cells, CHO ldlD mutants 
(Kingsley, D. M. et al. 1986) and CHO cells transfected with glycosyltransferases. 
The expression construct consisted of 16 tandem repeats, as shown by digesting the 
CHO DNA with the enzyme Hinf-1 that cuts just outside the tandem repeat region of 
MUC1 (fig 3.1B), and all of the sequence of MUC1 5’ to the tandem repeats fused at 
the 3’ end to exons 1-3 of the Fc region of mouse IgG2a. The cells were cultured in 
bioreactors, by the German partners in the EU consortium (see appendix II), and the 
supernatant was concentrated through ultrafiltration, mixed with a 50mM Tris/HCl 
pH8 buffer, and sent to us for further purification and testing. Additionally, the 
Swedish partner within the EU consortium determined the glycan profile of the 
purified MUC1 produced by CHO cells, which was shown to be mainly MUC1-ST, 
or MUC1-STn when the CHO cells were also stably transfected with the cDNA for 
the glycosyltransferase ST6GalNAc-I (Sewell R. et al. 2006) (table 3.1). Moreover, 
CHO ldlD cells, which are deficient for the enzyme UDP-galactose and UDP-N-
acetylgalactosamine (GalNAc) 4-epimerase were transfected with the recombinant 
MUC1. This deficiency makes the cells incapable of converting glucose to galactose 
or N-acetylgalactosamine and therefore these cells cannot add any O-linked glycans. 
Thus, the use of these cells allows MUC1 without O-linked glycans to be purified. 
However, the defect can be reversed by providing the cells with exogenous sources 
of sugars (Kingsley, D. M. et al. 1986), so by culturing the cells in media containing 
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Figure 3.1  MUC1 fused to the Fc region of mouse IgG2a used to express the 
mucin in CHO cells. 
 
A: Schematic drawing of the MUC1-IgG construct used for the large-scale production in CHO-K1, 
and CHO ldlD mutant cells. B: Southern blot of restriction-enzyme-digested genomic DNA probed 
with a MUC1 TR-specific DNA probe. Lane 1, Molecular-mass marker; lane 2, digestion with HinfI 
(predicted size for 16-TR MUC1 gene 2.4 Kb); lane 3, digestion with EcoRI (predicted size for 16-TR 
MUC1 gene 6.4 Kb).    
 
 
Table 3.1:     Structure of O-glycans on MUC1 expressed in CHO cells and CHO 
cells transfected with ST6GalNAc-I    
 
Detailed comparison of O-glycans on MUC1-IgG produced in wild-type CHO cells (CHO MUC1) 
















MUC1 Signal sequence Introns 
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3.3  Results 
 
 
3.3.1  Purification of MUC1 without O-linked glycosylation 
 
 
To purify MUC1 without O-linked glycosylation, MUC1-Ig transfected CHO ldlD 
cells were cultured in the absence of GalNAc in bioreactors, concentrated and re-
buffered as described in 3.2, before being sent to our lab. The IgG portion was 
cleaved off using 48 hours of enterokinase (EK) treatment (see materials and 
methods), and MUC1 without O-linked glycosylation purified by affinity 
chromatography, using the HMFG1 mAb (Taylor-Papadimitriou J. et al. 1981) 
bound to sepharose beads to capture the unglycosylated MUC1. Bound material was 
eluted from the column using 0.2 M glycine pH 2.5, and the MUC1 containing 
fractions identified by HMFG1 sandwich ELISA. Pooled fractions containing MUC1 
were run on SDS PAGE followed by Silver staining and Western blotting (fig 3.2).     
 
In figure 3.2A (HMFG1 Western blot) the majority of MUC1-IgG appears to migrate 
on a SDS PAGE gel at around 200 kDa (lane 1), and after EK cleavage a single band 
is notable at about 55 kDa level (lane 2) which is very close to the calculated size of 
51 kDa for the unglycosylated MUC1-16TR. As no other bands are present in lane 2, 
all the starting material appears to be cleaved by the EK. Furthermore, the HMFG1 
affinity column appears to retain all the MUC1, as no bands are present in the flow-
through shown in lane 3 of the HMFG1 Western blot. Lane 5 shows the pooled 
fractions containing the eluted MUC1 with the major band being at 55 kDa. There 
appear to be a low level of degradation as a ladder appearance of bands at less than 
50 kDa level is visible. 
 
Figure 3.2B (anti-IgG Western blot) also indicates that the majority of MUC1-IgG 
appears to migrate on a SDS PAGE gel at around 200 kDa (lane 1), and confirms 
that the majority of the material is cleaved after treatment with EK, as a single band 
is present in lane 2. The Fc region of mouse IgG2a-Fc also, like MUC1-16TR, 
migrates on a SDS PAGE gel at around 55 kDa (lane 2), but is not retained by the 
HMFG1 column as a 55 kDa band is present in the flow-through material (lane 3), 
and absent from the eluted materials (lane 5). 
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To identify potential protein impurities a silver stain was performed (fig 3.2C). A 
single band was found in the starting material, after EK cleavage, in the flow-through 
and in the eluted fractions shown in lane 1, 2, 3 and 5 respectively. This indicates 
that the unglycosylated MUC1 had a good level of purity prior, during and after the 





Figure 3.2 Purification of MUC1 without O-linked glycans 
 
Purification stages of MUC1 produced in CHO ldlD cells without the addition of exogenous sugars: 
Lane 1, MUC1-IgG; lane 2, after enterokinase cleavage treatment; lane 3, column flow-through; lane 
4, empty; lane 5, pooled fractions 8-10 after elution with 0.2 M glycine pH 2.5. 
A: HMFG1 Western blot. B: Anti-IgG Western blot. C: Silver staining. 
 
Purified unglycosylated MUC1 material was assessed by HMFG1 sandwich ELISA, 
using the quantified (by IgG ELISA) MUC1-IgG as a standard (fig 3.3A), to 
calculate the amount of purified material in the various eluted fractions. The total 
amount in the pooled fractions was found to be 0.5mg from each mg of starting 
material, and this agrees with the theoretical amount that can be purified, as both 
MUC1 and Fc portion have similar molecular weight (about 50 kDa). To further 
confirm the purity the unglycosylated MUC1 was sent for amino acid (a. a.) analysis. 
The purified product was extensively dialysed against PBS to remove the 0.2 M 
glycine used during the elution step, prior to being analysed. Unfortunately, possibly 
due to its stickiness, the majority of the unglycosylated MUC1 was lost during the 
dialysis step. However, enough was recovered for the a. a. analysis (performed by 
Alta Bioscience Birmingham), which showed a high level of concordance with the 
HMFG1 IgG Silver stain 
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theoretical composition. Only the amino acids glycine and glutamine and glutamic 
acid were substantially different from the theoretical level. In the case of glycine this 
was probably due to some glycine from the elution buffer still being present (table 
3.2). 
 
Figure 3.3B shows that HMFG1, HMFG2 and SM3 mAb (Taylor Papadimitriou J. et 
al. 1981, Burchell J. et al. 1989, Girling A. et al. 1989), three monoclonal antibodies 
to the core protein of MUC1, can bind to MUC1 purified from CHO ldlD cells but 
that the MUC1-Tn specific 5E5 (Sorensen A. L. et al. 2006) monoclonal antibody 
does not bind. This suggests that there was no GalNAc on the purified material. 
Moreover, as the migration pattern of the product on a SDS PAGE gel was found to 
be of the predicted size for unglycosylated MUC1 (about 51 kDa), it was concluded 
that the purified material contained no O-linked glycans. 
 
















Figure 3.3 ELISA testing of MUC1 without O-linked glycans after EK cleavage 
 
A: HMFG1 sandwich ELISA of purified MUC1-Ig without O-linked glycans (used as a standard), 
using 50 ng per well of purified HMFG1 as a capture antibody, and 1µg per well biotinylated 
HMFG1 as a detection antibody. B: ELISA titration, of various MUC1 MAbs using MUC1 without O-
linked glycans as target coated plates (1 µg/well).  
Antibody	  concentration	  μg/ml	  
 







Table 3.2:  Amino acid analysis of recombinant MUC1-16TR without O-linked glycans  
 
Amino acid Theoretical value 




Asx 6.2 7.7 
Thr 14.6 12.8 
Ser 12.6 12.9 
Glx 1.7 4.5 
Pro 21.2 17.7 
Gly 9.8 22 
Ala 17.3 16.2 
Val 5.5 5.6 
Met 0.2 0 
Lle 0 0.5 
Leu 1 1.7 
Tyr 0 0 
Phe 0 0 
His 4.5 6.1 
Lys 0.8 1.2 
Arg 4.0 3.5 
Trp 0.2 0 




3.3.2  Purification of MUC1-Tn 
 
As with the production of unglycosylated MUC1 engineered CHO ldlD cells 
transfected with the recombinant MUC1 were used. However, by culturing the cells 
in medium containing GalNAc, MUC1 carrying only Tn was produced. ldlD-16TR-
MUC1-Ig mutant cells were cultured in the presence of GalNAc in bioreactors and 
the supernatant concentrated and re-buffered as previously described, before being 
sent to our lab. The IgG portion was cleaved by 48 hours of enterokinase treatment 
(see materials and methods), and purification carried out by affinity chromatography, 
using the 5E5 mAb (specific for Tn and STn carried only on MUC1) bound to 
sepharose beads. Bound material was eluted from the column using 0.2 M glycine 
pH 2.5, and the eluted fractions tested in a 5E5 sandwich ELISA to determine which 
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fractions contained the eluted material. SDS PAGE followed by silver staining and 
Western blotting (fig 3.4) was then carried out to analyze the purified material. 
 
In figure 3.4A (HMFG1 Western blot) the majority of MUC1-IgG appears to migrate 
on a SDS PAGE gel at around 250 kDa, however a large smear is observed (lane 1). 
After EK cleavage (lane 2) a diffuse band is observed ranging from around 200 to 55 
kDa. This appears to be the MUC1-Tn migrating as a diffuse band possibly due to 
variation in the number of sites glycosylated within each of the TR. A single band is 
notable at about 55 kDa, which is the migratory size for the MUC1-16TR without O-
linked glycans. The 55 kDa single band could be MUC1-16TR without O-linked 
glycans, while the diffused band is believed to be the MUC1-Tn. In lane 3 (flow-
through), the single band of 55 kDa range is present, indicating the presence of 
MUC1-16TR without O-linked glycans that was not retained by the 5E5 column. 
The eluted EK cleaved MUC1-Tn was identified by 5E5 sandwich ELISA, and a 
sample from the fraction containing the largest amount was run in lane 4.  
 
Figure 3.4B (5E5 Western blot) is very similar to the HMFG1 Western blot, however 
as a band of about 55 kDa is also present in lane 3 it was concluded that a portion of 
the MUC1-Tn had very few glycosylation sites that did not affect its migration on a 
SDS PAGE gel. Moreover, this low level of glycosylated MUC1-Tn is not retained 
by the 5E5 column but is recognised by 5E5 on the Western blot.   
 
Figure 3.4C (anti-IgG Western blot) also indicates that the majority of MUC1-Tn-
IgG appears to migrate on a SDS PAGE gel at around 250 kDa (lane 1), that the 
majority of the material is cleaved after EK treatment, as a major band at around 55 
kDa is present in lane 2, and that the Fc region of mouse IgG-2a is not retained by 
the 5E5 column, as a major band is also present in lane 3 (flow-through) and absent 
from the eluted material (lane 4). 
 
Silver stain was used to assess the purity of the MUC1-Tn (fig 3.4D). A band at the 
very top of the gel was observed in the starting material, with additional weaker 
bands throughout (lane 1). After EK cleavage and in the flow-through, a band of 
around 55 kDa was seen with additional bands in the EK cleavage lane. However, 
only a very weak diffused band running around 250 kDa was observed in the MUC-
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Tn fraction. Silver ions are reduced to insoluble silver metal granules in the vicinity 
of the protein molecules but not proteins carrying glycans, thus as expected MUC1-







Figure 3.4 Purification of MUC1-Tn from CHO-ldlD cells 
 
Purification stages of MUC1-Tn produced in CHO ldlD cells cultured in the presence of GalNAc 
using a 5E5 affinity column: Lane 1, MUC1-Tn-Ig; lane 2, MUC1-Tn after enterokinase cleavage 
treatment; lane 3, column flow-through; lane 4, pooled fraction 7-9 after elution with 0.2 M glycine 
pH 2.5. A: HMFG1 Western blot B: 5E5 Western blot C: Anti-IgG Western blot. D; Silver Staining.  
 
 
The concentration and purity of MUC1-Tn was determined by amino acid analysis 
(table 3.3), after extensively dialysing the glycoprotein against PBS to remove the 
glycine. The results indicate a very high level of purity. Mass spectrometry 
performed by our Swedish collaborator determined that an average 3.8 of the 
possible 5 sites in each TR were glycosylated on the recombinant MUC1-Tn. Thus, 
as GalNAc molecular weight is 203 Dalton, it was possible to estimate that about 
11% of the total weight of recombinant MUC1-Tn-Ig was due to the sugars, or in 
other words, that about 60% of the total weight was made up by the glycosylated 
MUC1-Tn. Indeed about 0.6mg of MUC1-Tn from each mg of starting material was 
purified.   
 
 
HMFG1 IgG Silver stain 5E5 
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Table 3.3:  Amino acid analysis of MUC1-Tn purified product 
 
Amino acid Theoretical value 
(% by frequency) 
ldlD MUC1 Tn 
 (mol %) 
Asx 6.2 7.1 
Thr 14.6 14 
Ser 12.6 12.2 
Glx 1.7 2.6 
Pro 21.2 20 
Gly 9.8 9.2 
Ala 17.3 16 
Val 5.5 6.5 
Met 0.2 0.2 
Lle 0 0.1 
Leu 1 1.2 
Tyr 0 0 
Phe 0 0 
His 4.5 6.2 
Lys 0.8 0.9 
Arg 4.0 3.3 
Trp 0.2 0 
Cys 0 0 
 
3.3.3  Purification of MUC1-ST  
 
The concentrated supernatant from wild-type CHO cells transfected with MUC1-Ig 
was treated with enterokinase to remove the Ig domain (see materials and methods). 
The effectiveness of this treatment was assessed by running the supernatant on an 
SDS PAGE gel followed by silver stain for protein, which stains Ig but not MUC1-
ST (fig 3.5A), and Alcian blue for sialylated glycans, as the dye stains acid 
mucopolysaccharides and glycosaminoglycans, thus staining MUC1-ST but not IgG 
(fig 3.5B). Following the cleavage of the Ig portion, MUC1 was purified using anion 
exchange chromatography, which was preferentially chosen as a large scale 
purification method as the conditions for MUC1’s purification have previously been 
developed (Backstrom M. et al. 2003). Negatively charged proteins were retained by 
the column and are eluted by increasing the ionic strength of the buffer, thus 
separating MUC1-ST glycoprotein from other contaminants (fig 3.5C). Collected 
fractions were run on SDS PAGE and sialic acid bearing proteins identified by 
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Alcian blue staining and the purity of each fraction was determined by silver staining 
(fig. 3.5D).  
 







































Figure 3.5.  Purification of MUC1 ST from WT CHO cells 
 
A, Silver stain; Removal of Ig region from ST-MUC1-IgG from CHO K1 cells via enterokinase 
cleavage results in loss of silver staining. B, Alcian blue; Removal of Ig region of ST-MUC1-IgG 
from CHO K1 cells via enterokinase cleavage results in a size ‘shift’ on Alcian blue staining. C; 




Fractions that stained for Alcian blue, and which were virtually clear of background 
silver staining, were pooled, dialysed against water and then lyophilised. The weight 
was calculated after lyophylisation, and 20 µg sent for amino acid analysis for a 
more precise quantity and quality measure (table 3.4 and materials and methods 
2.14). The quantity of MUC1-ST purified was as expected by its molecular weight 
(ratio between predicted unglycosylated versus glycosylated) to be 0.7 mg purified 
from each mg of starting material.  
 
 
Table 3.4:  Amino Acid analysis of purified MUC1-ST 
            




CHO MUC1 ST 
(mol %) 
Asx 6.2 7.2 
Thr 14.6 13.3 
Ser 12.6 12.4 
Glx 1.7 3.5 
Pro 21.2 18 
Gly 9.8 9.5 
Ala 17.3 16 
Val 5.5 6.4 
Met 0.2 0.2 
Lle 0 0.6 
Leu 1 2.1 
Tyr 0 0.5 
Phe 0 0.5 
His 4.5 3.9 
Lys 0.8 1.4 
Arg 4.0 4 
Trp 0.2 Not available 




3.3.4  Purification of MUC1-T  
 
 
To produce MUC1-T, the MUC1-ST was treated with neuraminidase-coated agarose 
beads to remove the sialic acid as described in material and methods. The resultant 
MUC1 was checked by Alcian blue and Western blot. For the Western blot, two 
lectins specific for particular glycans were used for detection: peanut agglutinin 
(PNA) specific for Gal-β1-3-GalNAc the T glycan and Maakia amurensis 
hemagglutinin (MAA) specific for α2-3 linked sialic acid. Figure 3.6 shows that after 
neuraminidase treatment PNA staining is drastically increased with a smear type of 
staining reflecting the variable migration on a SDS PAGE gel, probably due to the 
variable glycosylation of MUC1-T. MAA staining was found to be weak, however, 
the disappearance of the band on the neuraminidase treated glycoprotein further 

















3.3.5  Purification of MUC1-STn 
 
Material derived from large scale production of MUC1 secreted by CHO-K1 cells 
transfected not only with the MUC1 construct, but also with a construct containing 
the ST6GalNAc-I cDNA, resulted in secreted MUC1 expressing mainly the glycan 
STn (Sewell R. et al. 2006). To purify MUC1-STn the Ig portion was cleaved off 
using 48 hours of enterokinase treatment (Fig 3.7A). The purification of the 
Figure 3.6.  CHO K1 MUC1 PNA and MAA 
Western blot  
 
PNA and MAA lectin Western blots of MUC1-ST from 



























concentrated secreted material was achieved by affinity chromatography, using 5E5 
mAb (specific for Tn and STn only on MUC1) bound to sepharose beads. Bound 
material was eluted from the column using 0.2 M glycine pH 2.5, and the quantity 
calculated by 5E5 mAb sandwich ELISA using MUC1-STn-Ig as a standard (fig 
3.7B). Unfortunately, the yield of purified materials was extremely low, with only 50 
µg of protein being purified from each mg of starting materials, probably due to 
weaker affinity to MUC1-STn as compare to MUC1-Tn of the 5E5 Abs (fig 3.7C). In 
the future it may be possible to improve the yield by using either HMFG1 or 
HMFG2 antibodies bound to sepharose beads or by ion exchange chromatography.
 













Figure 3.7.  Purification of MUC1 STn 
 
A; Removal of Fc region from STn-MUC1-Ig expressed by CHO K1-ST6GalNAc-I cells via 
enterokinase cleavage results in loss of silver staining of the major band and in a size ‘shift’ seen on 
Alcian blue staining. B; MUC1-STn-Ig standard using 5E5 sandwich ELISA. C; 5E5 ELISA titration 
on plate coated with 1 ug per well of either MUC1-Tn-Ig or MUC1-STn-Ig.  
 
3.3.6  Binding of MUC1 MAbs to the CHO produced MUC1 glycoproteins  
 
In order to further characterize the purified MUC1 glycoforms, the reactivity of three 
MUC1 antibodies to each of the glycoforms was determined (fig 3.8). Of the panel of 
antibodies used HMFG1, HMFG2 and SM3 are known to react with peptide epitopes 
within the tandem repeat of MUC1, although their binding is influence by the 
glycans. HMFG1 reacts with MUC1 with long glycans but its binding is inhibited by 
5E5 Abs µg/ml 
Alcian Blue        Silver 
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sialic acid (Burchell J. and Taylor-Papadimitriou J. 1993). HMFG2 binding to 
MUC1 is reduced by long glycan chains (Burchell J. and Taylor-Papadimitriou J. 
1993) while SM3 binding is blocked by core 2 glycans (Dalziel M. et al. 2001, 
Mungul A. et al. 2004). All three antibodies were shown to bind to all four forms of 




























Figure 3.8  Reactivity with 
tumour-associated glycoforms of 
MUC1. 
Binding of biotinylated MUC1 Abs 
(HMFG1, HMFG2, and SM3) to specific 
immobilized MUC1 glycoforms detected 
using an ELISA and peroxidase-
conjugated streptavidin to detect 



















3.3.7 Endotoxin testing 
 
Sterile techniques were applied throughout the purification procedures; however, 
there is always the possibility of pathogenic contamination, therefore before any 
immunological studies were carried out, all MUC1 recombinant glycoproteins were 
tested for endotoxins. Following purifications, endotoxin testing was performed 
using the LAL-1000 kit from Lonza as described in materials and methods, and only 
batches with < 5 EU/ml of endotoxin per µg of protein were used for further studies 




















Figure 3.9  Endotoxin testing 
 
A; Standard curve of endotoxin test using the LAL-1000 assay. B; examples of purified MUC1 
glycoforms tested at a concentration of 1 µg/ml
MUC1 glycoform tested (1 µg)  








3.4  Discussion 
 
In this chapter the purification of MUC1 glycoforms carrying the specific tumour-
associated glycans Tn, Sialyl-Tn, T and Sialyl-T has been described. The glycoforms 
were characterised by the following methods: 
1. Their binding to four monoclonal antibodies to MUC1 was determined. 
These antibodies showed differential binding to the different glycoforms with 
5E5, which is specific to MUC1 carrying Tn and STn, only binding the 
MUC1-Tn and STn glycoforms.    
2. The purity of the glycoforms was determined by silver staining of SDS 
polyacrylamide gels and amino acid analysis. 
3. All the batches of the different glycoforms were analysed for endotoxin 
contamination. 
4. The glycosylation status was initially analysed by Alcian blue and lectin 
staining of material run on polyacrylamide gels and the precise nature of the 
glycans determined by mass spectrometry by the Hansson Lab in Sweden 
(Backstrom M. et al. 2003, Link T. et al. 2004).  
 
MUC1 has been widely studied in the cancer context; indeed it is estimated that 75% 
of all solid tumours express MUC1 (Tang C. K. and Apostolopoulos V. 2008), and 
that MUC1 positive cancers account for the majority of cancer deaths (Greenlee R. 
T. et al. 2001). MUC1 is aberrantly glycosylated and overexpressed in 90-96% of 
breast carcinomas (Burchell J. et al. 1987, Girling A. et al. 1989, Rakha E. A. et al. 
2005). The cancer-associated change in the O-linked glycans carried by MUC1 
exposes predominantly the glycans Tn, Sialyl-Tn, T, Sialyl-T and these are the 
glycoforms produced in this chapter. However, other O-linked glycans can be found 
in breast cancers although it is unclear if these can be carried on MUC1 (Julien S. et 
al. 2011).  
This aberrant glycosylation results in the MUC1 mucin expressed by carcinomas 
being antigenically distinct from that expressed by normal mammary epithelial cells 
as it been shown to induce immune responses. Autoantibodies (IgG and IgM) to 
cancer-associated MUC1 are common in breast cancer patients and increased levels 
of these antibodies have been correlated with increased survival in breast cancer (von 
Mensdorff-Pouilly S. et al. 1996; von Mensdorff-Pouilly S. et al. 2000b). 
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Furthermore, antibodies to MUC1 tumour-associated glycoforms found in the sera of 
early breast cancer patients are significantly associated with reduced incidence of 
and increased time to metastasis (Blixt O. et al. 2011). However, at present the 
contribution of each specific glycan to cancer and their immunogenicity is poorly 
understood. 
In collaboration with a European Consortium led by our group we have generated a 
mammalian expression system for the production of recombinant MUC1 in CHO-K1 
or CHO ldlD mutants. Chinese hamster ovary (CHO) cells were chosen because 
these cells are the most widely used mammalian cells for recombinant protein 
expression and large-scale production. They provide stable and accurate 
glycosylation, offering a post-translationally modified product and thus a more 
accurate in vitro rendition of the natural protein (Sheeley D. M. et al. 1997, Werner 
R. G. et al. 1998). In our system, it was found that CHO cells and their derivatives 
are powerful tools for the preparation of glycan-specific MUC1 glycoproteins. 
 
With regard to unglycosylated and the Tn (GalNAc) carrying MUC1 glycoprotein, 
their production was made possible by exploiting the deficiency of UPD-Gal/UDP-
GalNAc 4-epimerase present in the ldlD mutant CHO cells (Kingsley D. M. et al. 
1986), which leaves these cells unable to synthesise galactose and GalNAc. The 
process can be reversed by providing the cells with exogenous sources of sugars, 
which are utilized via a salvage pathway that does not require participation of the 4-
epimerase enzyme lacking in these cells (Segal S. 1983). Thus, the ldlD mutant when 
transfected with MUC1 (16TR)-IgG construct, secreted unglycosylated MUC1. This 
was confirmed by the migratory size of the product on an SDS/PAGE gel and the 
absence of staining by the monoclonal antibody 5E5, which specifically recognizes 
MUC1-Tn. The ldlD mutant transfected with the MUC1 (16TR)-IgG construct 
grown in the presence of GalNAc secreted MUC1 carrying only the Tn antigen. This 
had an average site occupancy of 3.4 out of a possible 5 for each tandem repeat, and 
as expected by the type of purification (affinity chromatography using 5E5 mAb), 
the material bound to the 5E5 mAb. 
 
MUC1 produced in wild-type CHO K1 cells and purified by ion exchange 
chromatography was found to carry mostly the glycan sialyl T (84.3%), or disialyl T 
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(13.3%), with only 1.9% T as determined by the Hansson lab (Backstrom M. et al. 
2003). Because of this predominance of the sialyl T glycan, we have considered this 
glycoprotein as being virtually pure MUC1 sialyl T, with a similar O-glycosylation 
pattern to that of MUC1 from some breast cancer cell lines, like the extreme case of 
the human metastatic breast cancer cell line T47D which only express MUC1-T and 
sialyl T (Backstrom M. et al. 2003), and many primary breast cancers (see appendix 
I).  Furthermore, the site occupancy of the MUC1 sialyl T glycoprotein was found by 
the Hansson lab to be on average 4.3 glycosylated sites out of a possible 5 per 
tandem repeat, which is similar to that previously reported for endogenous MUC1 
from the breast carcinoma cell line T47D (4.8 per TR) (Muller S. et al. 1999). 
Speculatively, the small difference could possibly be due to the presence of the Fc 
tail in the construct, which may induce faster transit time through the Golgi, 
preventing the complete action of the polypeptide-GalNAc-transferases that initiates 
the synthesis of the O-glycosylation. On the other hand, different cell lines differ in 
their glycosylation ability and have variable levels of polypeptide GalNAc-
transferases.  
    
 A very effective way to remove the sialylation on proteins is by treating them with 
neuraminidase (Backstrom M. et al. 2003), and so this method was used on the 
purified MUC1-ST produced in CHO K1 cells.  The neuraminidase treated MUC1 
glycoprotein carried only the glycan T (Gal β 1-3 GalNAc), which was confirmed by 
the absence of MAA staining (Western Blotting), which selectively stains α2-3 sialic 
acids and the increase in PNA staining. 
 
CHO K1 cells co-transfected with MUC1-16TR-IgG, and ST6GalNAc-I secreted 
mostly sialylated GalNAc (83%) with a small amount of disialyl T (12%), and sialyl 
T (4%) (Professor Gunnar Hansson personal communication). The purification of 
this glycoform has shown that MUC1-STn can be purified by affinity 
chromatography using the 5E5 mAb which has been reported to cross-react with 
MUC1-STn (Tarp M. A. et al. 2007). However, the yield was deemed to be very 
poor, with only 5% of product being retained on the column, leaving considerable 
room for improvement. Perhaps by using other MAbs such as HMFG1 or HMFG2 in 
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an affinity chromatography system or by using an anion exchange chromatography 
system it may be possible to improve MUC1-STn yield.  
 
The availability of these pure glycoforms of MUC1, carrying defined and specific 
sugars, gives us an opportunity to investigate whether any of these MUC1 
glycoforms can provide protective immunity against cancer, and to investigate how 
specific glycans of MUC1 interact with lectin receptors of the immune system.    


































To address the hypothesis that specific glycoforms of MUC1 can induce immune 
responses, the MUC1 glycoforms produced in chapter 3 were used to measure their 
effectiveness in eliciting immune responses in MUC1 transgenic mice. It was 
hypothesized that the repetitive nature of the glycans carried on MUC1 tandem 
repeats could be similar to that observed in pathogen-associated molecular patterns 
and therefore may induce an immune response. 
 
In a project conducted by the USA’s National Cancer Institute MUC1 was listed 
second most optimal immunotherapeutic target out of 75 candidates (Cheever M. A. 
et al. 2009). The characteristics that make MUC1 such a good target for 
immunotherapy include over-expression in carcinomas the repetitive nature of the 
glycans and aberrant O-linked glycosylation as compared to normal epithelial cells. 
Moreover, there is increasing evidence that MUC1 is involved in tumour growth 
(Mungul A. et al. 2004, Raina D. et al. 2009). Preclinical studies using MUC1 
transgenic mouse models offer the best preclinical models to evaluate the 
effectiveness of immune responses at present. However, even though the MUC1 
transgenic mouse model allows evaluation of MUC1 immunogens as self-antigens, 
the response relies on the mouse immune system, which undoubtedly has differences 
from the human system.  
 
Preclinical studies using MUC1-Tn or MUC1-STn peptides have already uncovered 
the immune system’s ability in eliciting strong humoral responses against cancer-
associated glycoforms of MUC1 in MUC1 transgenic mice (Sorensen A. L. et al. 
2006). Various glycans abundantly expressed in the cancer-associated form of 
MUC1, have been shown to bind receptors present on cells of the immune system 
(Van Gisberger K. P. et al. 2005, Napoletano C. et al. 2007). Furthermore, antigen 
presenting cells can process MUC1 expressing simple O-linked glycans and 
presentation on both MHC classes I and II is possible (see chapter 1.11, 




4.2  Results  
 
4.2.1 In vivo immune response to MUC1 glycoforms 
 
In order to investigate if any of the various tumour-associated MUC1 glycoproteins 
were able to raise either cellular and/or humoral immunological responses to MUC1, 
transgenic mice for human MUC1 (Peat N. et al. 1992) were immunized with 
various tumour-associated MUC1 glycoproteins, purified as described in chapter 3. 
The immunization consisted of three subcutaneous injections, given at three week 
intervals, of either 10 µg of unglycosylated, Tn, ST or T MUC1 glycoproteins 
emulsified in Freund’s complete adjuvant for the first immunization, then Freund’s 
incomplete for the following two (see Freund’s adjuvant in materials and methods). 
Seven days after the last immunization, a single cell suspension was prepared from 
the spleens and splenocytes stimulated in vitro with the same immunogen for 52 
hours before assaying the supernatant for cytokine production (see materials and 
methods). As notable in figure 4.1, the only glycoprotein that was able to stimulate a 
cellular immunological response as determined by IFN-γ secretion was MUC1-T.  
                 
Fig 4.1:  Cellular response to various MUC1 glycoproteins 
 
Single cell suspension of splenocytes from MUC1 transgenic mice immunized with various purified 
MUC1 glycoproteins (10 µg per injection x 3) were incubated with the same MUC1 glycoprotein in 
vitro (10 µg/ml) for 52 hours. The supernatant was then analyzed for IFN-γ production by ELISA. 
The results shown are the average of 4 mice per group.  
 
 
In vivo priming / In vitro stimulation 
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4.2.2 Immune response to MUC1-T 
 
The reproducibility of the cellular response present in MUC1 transgenic mice 
immunized with MUC1-T was assessed by repeating the experiment four times 
(n=12). Moreover, different purifications of MUC1-T were used in order to eliminate 
the possibility of a batch specific contaminant. The number and frequency of MUC1-
T immunization were also optimized (fig 4.2). The results found that MUC1-T was 
capable of consistently eliciting immune responses, measured by IFN-γ, that the 
response was not batch specific, and that three 10 µg immunization given at three 










Fig 4.2:  Optimizing the number and intervals for CHO MUC1-T immunization 
 
Four MUC1 transgenic mice per group were immunized with 10 µg of MUC1-T either once (X1), 
twice at two weekly intervals (X2 / 2W), three times at two weekly intervals (X3 / 2W), or three times 
at three weekly intervals (X3 / 3W). Seven days after the last immunization single cell suspensions of 
splenocytes from the immunized mice were incubated in vitro with 10 µg/ml of MUC1-T for 52 hours 
prior to ELISA analysis for IFN-γ production. The results shown are the average IFN-γ level from 
each group (n=4) and their standard deviation.  
  
In general a Th1-type of response tends to produce a pro-inflammatory response 
responsible for killing and for perpetuating immune responses, while Th2 responses 
are associated more with anti-inflammatory responses and so can counteract 
excessive pro-inflammatory responses that can lead to uncontrolled tissue damage. 
The optimal scenario would therefore be the one that produces a well balanced Th1 
and Th2 response, to allow maximal T cell efficacy (Sallusto F. et al. 2004). With 
that in mind, we investigated the secretion of several cytokines that are known to be 
unique to the Th1 type of response (IFN-γ, TNF-α and IL-2) or to the Th2 type of 
response (IL-4 and IL-5). Figure 4.3 represents examples of responses in four mice 
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immunized with three injections of 10 µg of MUC1-T, three weeks apart. After the 
final injection the splenocytes were removed and stimulated in vitro for 48 hours 
with 10 µg/ml of MUC1-T (see materials and methods). Three mice out of four 
elicited a relatively strong Th1 type of response indicated by the presence of IFN-γ 
and IL-2 in the media. Furthermore, the four investigated mice also appear to elicit a 
Th2 type of response as seen by the presence of IL-5 and IL-4 in the media. 
However, the Th2 response was weak as the amount of IL-4 secreted into the media 
was very low, so it can be concluded that for three mice out of four the response 
generated is predominantly Th1. In addition, as seen with mouse number four, the 
generated Th2 type of response is weak even in mice that do not elicit a strong Th1 
type of response. 
 
Fig 4.3:  MUC1-T induces mainly a Th1 type of response 
TH1/TH2 CBA (Cytometric Bead Array) analysis of various cytokines secreted into the culture media 
from splenocytes stimulated in vitro by 10 µg/ml of MUC1 glycoprotein carrying the T antigen 
(Galβ1-3GalNAc), following the in vivo priming (10 µg x 3) with MUC1-T. C57Bl/6 MUC1 TG mice 
(mice 1, 2, 3, and 4 represented).   
 
Identification of T cell subsets  
To establish which subset within the splenocytes was responding to MUC1-T, CD4 
and/or CD8 T cells were depleted prior to in vitro stimulation. After immunization of 
the mice with MUC1-T, the CD8+ or CD4+ expressing cells were removed from 
splenocyte single cell suspension using CD4 or CD8 specific antibodies with the 
Amaxa system (see methods). The efficiency of depletion was measured by flow 
cytometry and as can be seen in figure 4.4A the vast majority of CD8+ or CD4+ T 
cells were removed. The depleted splenocytes were stimulated in vitro with 10 µg/ml 
pg/ml 
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of MUC1-T glycoprotein for 52 hours prior to IFN-γ secretion measurements  (fig 
4.4B). As a control for depletion of the T cells mice immunized with ovalbumen, and 
stimulated in vitro with the peptide SIINFEKL were included. This response is 
known to be of a Th1 type elicited through CD8 cells (Arnaboldi P. M. et al. 2009), 
as shown in figure 4.4C. The results presented in figure 4.4 clearly indicated that the 
response to MUC1 T requires CD4 expressing cells. 










Fig 4.4: IFN-γ responses following in vitro depletion of CD4/8 +ve T cells. 
Splenocytes from MUC1 TG mice following in vivo priming (10 µg x 3) with MUC1-T, or control 
(10 µg x 3, ovalbumen), were depleted of CD4+ or CD8+ cells prior to in vitro stimulation with 10 
µg/ml of MUC1-T (Galβ1-3GalNAc) or SIINFEKL peptide. A: FACS analysis of spleen cells before 
and after CD4+ or CD8+ T cells removal, stained with FITC directly labelled anti CD4 or CD8 Abs. 
B: IFN-γ secreted by stimulated splenocytes from MUC1-T primed mice, with or without T cell 
removal and with or without in vitro stimulation (N=2). C: ELISA for IFN-γ in ovalbumen primed 
mice, with or without T cell removal and with or without in vitro stimulation with SIINFEKL (N=2). 
 
In order to confirm that CD4 positive T cells were the sole cells responsible for the in 
vivo response, T lymphocytes expressing CD4 and/or CD8 were depleted in vivo, 
using monoclonal antibodies to CD4 and/or CD8 (see materials and methods) before 
and during vaccination with MUC1-T. Spleen cells from these mice were stimulated 
in vitro with MUC1-T for 52 hours before assaying the supernatant for cytokine 
production. Figure 4.5B, also shows that CD4 + cells are essential for the response to 
MUC1-T. One mouse out of three of the CD4 + in vivo depletion, appear to respond 
after in vitro stimulation. However, as illustrated in figure 4.5A in vivo depletion was 
variable, and in particular for the mouse that responded in vitro following priming 
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Depletion in vitro 
with MUC1-T, a considerable number of CD4+ T cells were not depleted in vivo. 
With regard to the involvement of T lymphocytes expressing CD8, their in vivo 
depletion did not affect the response, leading to the conclusion that mainly CD4+ 
cells are responding to MUC1-T glycoprotein immunization, and concord with the 
data derived by the CD4 +/CD8 + in vitro depletion analysis. 
      



















Fig 4.5:  IFN-γ  responses following in vivo depletion of CD4/8 +ve T cells. 
 
Splenocytes from MUC1 TG mice, in vivo depleted of CD4+ and/or CD8+ cells and in vivo primed 
(10 µg x 3) with MUC1-T were in vitro stimulation with 10 µg/ml of glycoprotein carrying the T 
antigen (Galβ1-3GalNAc). A: % of CD4 and CD8 +ve cells following CD4 and/or CD8 +ve depletion 
and MUC1-T immunization. B: ELISA for IFN-γ from splenocytes stimulated in vitro by 10 µg/ml of 
MUC1 carrying the T antigen (Galβ1-3GalNAc). 
 
 
Depletion in vivo 
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   Unstimulated 
   CHO T 
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4.2.3 Processing and presentation of MUC1-T by DC 
 
In order to understand the mechanisms involved in processing and presentation to T 
lymphocytes of MUC1-T epitopes, we used bone marrow derived dendritic cells 
(bmDC) to present MUC1-T epitopes in vitro. Adherent cells derived from mouse 
bone marrow were cultured for 7 days in the presence of GM-CSF, stained for the 
surface marker CD11c (DC marker) and CD86 (mature DC marker) and then 
analysed by flow cytometry. As illustrated in figure 4.6A most of the cultured cells 
expressed the surface marker CD11c, while not expressing the surface marker CD86, 
thus indicating a homogeneous immature DC population. Bone marrow derived 
immature DC were pulsed in vitro for six hours with recombinant purified MUC1-T 
(10 µg per million cells), washed in PBS, than added at a ratio of 10:1 (Spleen cells : 
DC) to single cells suspension from spleen of mice previously immunized with 
MUC1-T or from control mice. As shown in figure 4.6B, IFNγ secretion was found 
in the supernatant of cells stimulated in vitro with bmDC pulsed with the MUC1-T.  
MUC1-T must therefore be taken up by the DCs, processed through the MHC class 
II antigen-presenting pathway and presented on the cell surface where it can 















Fig 4.6:   Presentation in vitro of MUC1-T by bmDC 
Splenocytes stimulated in vitro by bone marrow derived DC A: expression of the surface molecule 
markers CD11c (DC marker), and CD86 (mature DC marker) in cultured bmDC from mice. B) 
ELISA for IFN-γ of splenocytes, derived from MUC1-T immunized MUC1 TG mice, stimulated in 
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Based on the fact that antigens from MUC1 glycoprotein carrying the T antigen 
appear to be capable of being taken up and presented to T lymphocytes by bmDC in 
mice, we investigated binding of MUC1-T to bmDC. Moreover, as the MUC1-Tn 
and MUC1-STn (MUC1-STn currently under investigation in our laboratory, 
unpublished data) glycoforms have been shown to bind calcium dependent type 
lectins such as the macrophage galactose C-type lectin (MGL) (Napoletano C. et al. 
2007) on human monocyte derived DCs, MUC1-T calcium dependent binding to 
bmDC was investigated. MUC1-T was biotinylated and coupled to FITC microbeads 
(see materials and methods) prior to incubation with bmDC in the presence or 
absence of calcium. As illustrated in figure 4.7, MUC1 glycoprotein carrying the T 
antigen binds to immature bone marrow derived DC in a calcium dependent manner, 
and that this particular binding can be abolished by pre-incubating the bmDC with 



















Fig 4.7:  MUC1-T binding to murine DC 
 









4.2.4 Humoral responses to MUC1-T glycoprotein 
 
In cancer, O-linked changes in glycosylation of MUC1 affects the profile of epitopes 
presented to B cells, and this concept is one of the factors that instigated interest in 
MUC1 as an immunotherapeutic target. Although, the role of the humoral response 
in tumour immunology is by no means clear, it is established that antibody levels to 
MUC1 in breast cancer patients can correlate with metastatic free survival and 
improved overall survival (von Mensdorff-Pouilly S. et al. 1996, Blixt O. et al. 
2011). Moreover, as a small increase in cytokines unique to the Th2 type of response 
was observed in mice immunized with 10 µg of MUC1-T, the humoral response 
represented by the production of antibodies to MUC1 was investigated. 
 
Figure 4.8 shows the results from an ELISA for MUC1 glycoforms using serum 
samples from MUC1 transgenic mice taken pre and post immunization with PBS and 
adjuvant (Freund’s) or MUC1-T plus adjuvant. The immunization schedule consisted 
of 10 µg of the immunogen plus adjuvant given three times three weeks apart (see 
materials and methods). The results indicate that 11 out of 12 tested sera derived 
from the post-immunized mice contain antibodies to the immunogen MUC1-T (fig 
4.8A). In addition a number of mice appear to have produced antibodies able to 
recognize MUC1 expressing a different glycostructure from the one of the 
immunizing immunogen. Moreover, antibodies have been found to recognize MUC1 
core protein, which was tested by using a 60mer peptide consisting of three tandems 
repeats (fig 4.8B), and to MUC1 carrying sialyl T (Neu5Ac-α2,3Galβ1,3GalNAc) 
(fig 4.8C). 
 
Although all our glycoproteins and peptides used in our immunization and in vitro 
studies contained extremely low endotoxin levels (>1 EU/ml). Sera from mice 
immunized with MUC1-T or control (PBS + adjuvant) were tested for antibodies to 
LPS. As seen in figure 4.8D, four out of twelve mice immunized with MUC1-T 
appear to have generated antibodies, which bind LPS, while no antibodies to LPS 
were generated in the control mice.     
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In vivo Immunogen 
Fig 4.8:  Humoral responses in MUC1 TG mice immunized with MUC1-T 
glycoprotein  
Antibody levels in sera (1:40 dilution) from mice pre and post immunization with PBS + adjuvant 
(n=11), or MUC1-T + adjuvant (n=12) were assayed in an ELISA against: A, 50 ng/well of purified 
MUC1-T. B, 50 ng/well of 60mer MUC1 peptide. C, 50 ng/well of purified MUC1-ST. D, 50 ng/well 
of LPS.  





4.2.5 Lack of response to MUC1-T in MUC1 Tg mice living in SPF 
environment. 
 
Due to high incidence of bacterial and viral pathogens, within the animal unit 
housing the MUC1 Tg mice, the facility underwent a re-derivation program of all the 
mice to become a specific pathogen free (SPF) facility.  Following the re-derivation 
program, the response induced by the immunization in MUC1 Tg mice, was lost (fig 
4.9). Unfortunately from this time only MUC1 Tg mice housed in the SPF facility 









Fig 4.9: Cellular response to MUC1-T glycoprotein was lost when the MUC1 
Tg mice were re-derived into SPF facility. 
 
Single cell suspension of splenocytes from mice immunized with MUC1-T glycoprotein or PBS 
control (10 µg per injection x 3) were incubated with MUC1-T glycoprotein (10 µg/ml) for 52 hours. 
The supernatant was then analysed for IFN-γ production by ELISA. The results shown are the average 
of 8 mice per group. 
 
The disappearance of the cellular response in MUC1 Tg to MUC1-T has been a 
major setback, as further experiments were not possible.  However, the testing of 
MUC1 based immunogens on the MUC1 transgenic mice living in a non SPF 
environment indicates that under particular conditions MUC1 tolerance can be 
broken. The lack of response of the clean mice is almost certainly due to the 
environment affecting their immunological predisposition. Mice living in a less clean 
environment would have a more educated immune system. For example the mice 
living in the “dirty” area were carriers of Helicobacter pylori (H. pylori), a bacterium 
that resides in the stomach, which has been linked to the increase in antibodies to 
MUC1 (Klamas K. et al. 2007) and T antigen (Klamas K. et al. 2002). Thus 
speculatively, in MUC1 Tg mice living in a dirty environment the recombinant 
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MUC1-T used as an immunogen may be able to induce an immune responses with 
help from other cellular components of the immune system primed by common 
antigenic structures such as the T antigen.     
 
4.2.6 Response to MUC1 sialyl T 
 
Vaccination of MUC1 transgenic mice, living in a “dirty” environment, with MUC1 
carrying sialyl T (Neu5Ac-α2,3Galβ1,3GalNAc) failed to induce an immune 
response (fig. 4.1). Furthermore, MUC1-ST could not induce cellular or humoral 
immune responses even in wild-type mice where the immunogen was foreign (fig 
4.10, and table 4.1). However, in wild-type mice a fusion protein of MUC1-ST and 
mouse Fc could induce a humoral response that was directed to MUC1-ST (table 4.1) 
indicating that the common sialyl-T glycan (present on both glycoproteins) was not 
masking immunogenic epitopes. These data are in keeping with the mounting 
evidence that MUC1 carrying sialylated-T may have immunosuppressive properties 
(Mungul A. et al. 2004, Monti P. et al. 2004, Rughetti A. et al. 2005). 
 
 














Fig 4.10: Cellular response to MUC1 carrying sialyl T in WT mice  
 
ELISA for IFN-γ from splenocytes stimulated in vitro by 10 µg/ml of MUC1 carrying the Sialyl-T glycan 
(Neu5Acα2,3Galβ1,3GalNAc), following the in vivo priming (10 µg x 3) with MUC1-ST, in A:  Balb/c (n=6) B: 
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Table 4.1: Humoral response to MUC1 carrying sialyl-T in WT mice. 
 
Table representing mAb responses to MUC1 peptide (60 mer), recombinant MUC1-ST and MUC1-T by ELISA on 
sera (dilution 1/40) +ve = 3 fold or more Optical Density increase from pre-immunization control. 
 
Immunogen Sera tested on 
MUC1-T 
Sera tested on 
MUC1-ST 
Sera tested on 
MUC1 60 mer 
MUC1 ST-IgG 6/7 +ve 10/10 +ve 4/7 +ve 
MUC1 ST 7/7 –ve 10/10 -ve 7/7 –ve 





In this chapter it has been shown that MUC1-T can induce a cellular response, which 
is mainly Th1 in MUC1 transgenic mice. However, this immune response was lost 
when the mice were re-derived into a SPF environment. It has also been shown that 
MUC1-ST could not induce an immune response even in wild-type mice where the 
protein is foreign. This was not due to the non-immunogenic sialyl-T glycan masking 
the protein core as when the MUC1-ST-Ig fusion protein was used as an immunogen 
an immune response could be generated.  
 
As mentioned in the introduction of this chapter, the over-expression and aberrant O-
linked glycosylation of MUC1 make it an attractive immunotherapeutic target for the 
treatment of breast and other cancers. Thus, having MUC1 expressed in large 
amounts on the entire cell surface and having the formation and exposure of novel 
glycan epitopes should, without external intervention, prime the immune system. 
Indeed early breast cancer patients have been found to have naturally occurring anti-
MUC1 antibodies in their sera, which are reactive with tumour-associated 
glycoforms, and these patients have a decreased incidence of breast cancer metastasis 
and an increased time to progression (von Mensdorff-Pouilly S. et al. 2000a, Blixt O. 
et al. 2011). 
 
As described in chapter 1, the abnormal glycosylation of MUC1 in breast cancer 
results in the exposure of tumour specific Tn (GalNAc), and sialyl-Tn (Neu5Acα2-
6GalNAc), and tumour-associated T (Galβ1-3GalNAc) and sialyl-T 
(Neu5Acα2,3Galβ1,3GalNAc) glycans. Thus, MUC1 expressing these glycans is of 
particular interest as a target for immunotherapeutic treatment of cancer. Indeed, 
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studies with MUC1-based immunogens, using glycopeptides from the TR of MUC1, 
have found that immunization with MUC1-Tn and MUC1-STn glycopeptides elicits 
strong humoral responses even in MUC1 Tg mice (Sorensen A. L. et al. 2006). A 
clinical trial which used STn linked to KLH (Keyhole limpet hemocyanin), named 
Theratope®, as a vaccine was started a few years ago. This vaccine reached phase 
III, but failed to demonstrate a significant effect versus the control vaccine 
(Holmberg L. A. and Sandmaier M. A. 2004). However, the trial failed to include as 
an entry requirement that patients’ tumours should express sialyl-Tn, and as only 25-
30% of breast cancers express this glycan the possibility of benefit in a subset of 
patients whose tumours expressed sialyl-Tn could have been missed. Moreover, in a 
mouse model the sialyl-Tn linked to KLH formulation (Theratope®) was found to 
succesfully promote antibody-mediated inhibition of tumour growth by targeting 
multiple sialyl-Tn-carrying proteins, not just MUC1, and crucially this inhibition 
required sialyl-Tn expression by the tumour (Julien S. et al. 2007).  
 
Testing of MUC1 glycoproteins carrying either Tn, T, sialyl-T or no O-linked 
glycans found that of these only MUC1 carrying the glycan T was able to break 
cellular tolerance in MUC1 Tg mice and induce a cellular response measured by 
IFN-γ and IL-2 secretion. IFN-γ is the main cytokine secreted by the Th1 subset of T 
lymphocytes expressing CD8 (cytotoxic T cells) or CD4 (helper T cells). Depletion 
of CD4 and/or CD8 T cell subsets showed that the cells expressing CD4 were the 
source of the IFN-γ. Furthermore, we demonstrated that dendritic cells are able to 
present peptide from MUC1-T glycoproteins to primed CD4 +ve T lymphocytes in 
vitro. Binding studies showed that MUC1-T can bind to murine bone marrow-
derived DC in a calcium dependent manner, suggesting a C-type lectin interaction 
that may involve mMGL-2.  
 
In the human system MUC1 glycoproteins carrying GalNAc have been shown to 
bind to MGL on immature DC, and it has been speculated that MGL-MUC1-Tn 
interactions could be involved in the maintaining the localization of immature DC at 
strategic sites. This is of particular importance as MGL appears to mediate DC 
migratory capability (Van Vliet S. J. et al. 2008). Furthermore, it has also been 
demonstrated that MGL functions as an antigen uptake receptor that facilitates 
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antigen presentation by the MHC (Napoletano C. et al. 2012). In the mouse system, 
two C-type macrophage galactose-type lectins (mMGL1 and mMGL2) appear to be 
orthologs of the human MGL, however the preferential carbohydrate specificity is 
different, with mMGL2 preferentially binding α- and β-GalNAc conjugated soluble 
polyacrylamides, whereas mMGL1 preferentially binds Lewis X conjugated soluble 
polyacrylamides. However, mMGL1 could also bind to the T glycan on 
polyacrylamide (Tsuiji M. et al. 2002).  The ability of the glycan Galβ1-3GalNAc to 
block binding of MUC1-T to immature murine dendritic cells confirms that the 
binding is dependent on the glycan and suggests that MGL1 may be the lectin 
involved. This could be confirmed by the use of blocking antibodies to MGL. This 
could explain how MUC1-T is taken up by mouse immature DC and possibly 
macrophages, and epitopes presented to CD4+ T cell. 
 
Interestingly, the response in MUC1 TG mice brought about by the immunization 
with MUC1-T was not seen in mice derived and bred in a specific pathogen free 
environment, thus suggesting that the environment affected their immunological 
predisposition and this is discussed further in Chapter 6. Mice living in a less clean 
environment have been shown to have a more educated immune system (Makinodan 
T. et al. 1971). Moreover, the MUC1 transgenic mice in the “dirty” area were 
carriers of Helicobacter pylori (H. pylori) (determined during health screening), a 
bacterium that resides in the stomach, which has been linked to the increase in 
antibodies to MUC1 (Klamas K. et al. 2007) and T antigen (Klamas K. et al. 2002). 
Thus, possibly H. pylori bacterial infection may have contributed by epitope 
spreading to an increased immune response to MUC1-T cellular responses.    
 
MUC1-ST immunisation did not elicit immunological responses even in wild-type 
mice where it is a foreign antigen. However, it was found that by immunising wild-
type mice with the fusion protein of MUC1-ST and the Fc region of mouse Ig2a, a 
humoral response directed to MUC1-ST was induced. The fact that the fusion protein 
MUC1-ST-Ig elicited a MUC1-specific humoral response suggests that this is routed 
through a different pathway in the cells and may be taken up through binding to Fc 
receptors (Revetch J. V. and Bolland S. 2001). However the lack of immunological 
responses in wild-type mice after immunization with MUC1-ST without the Ig, 
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suggests that this glycoprotein may have immunosuppressive properties.  Indeed, 
secreted cancer-associated MUC1, which is also likely to contain MUC1-ST has 
been associated with immunosuppression through inhibition of T-cell proliferation 
and maturation of dendritic cells (Agrawal B. et al. 1998, Rughetti A. et al. 2005). 
Moreover, sugars associated with aberrant glycosylated MUC1, have been suggested 
to be responsible for the observed anti-proliferative effects on cancer cell lines, such 
as the T47D (Paul S. et al. 1999). In addition to this, recent data generated Dr 
Beatson in our lab indicate that recombinant MUC1-ST binds to several sialic-acid-
binding immunoglobulin-like lectins (Siglec). The vast majority of Siglecs have been 
found on immune cells, including DC, macrophages, T cells, B cells and NK cells, 
mediating a wide range of activities including cell death (Jandus C. et al. 2011). 
Inhibitory signals can be mediated through the ITIMs present in the cytoplasmic tails 
of the majority of Siglecs (Avril T. et al. 2006, Crocker P. R. et al. 2007).  
 
At the present time, evidence is mounting on the possible immunosuppressive role of 
the MUC1-ST glycoform that is commonly found on MUC1 in breast cancer. 
Although the ST glycoform is not itself tumour-associated, it is not normally carried 
on epithelial mucins as in the tumour situation which results in this glycan being 
repeated hundreds of time on a single molecule. This may allow the strong 
interaction with inhibitory lectins. 
 
The results in this chapter have shown that only a specific glycoform of MUC1, 
MUC1-T, can induce a cellular immune response, whereas the MUC1-ST glycoform 
may be immunosuppressive or at the very least be unable to induce immunity. The 
results are important for any studies on the use of the MUC1 glycoprotein in 
immunotherapy and could have far reaching implications for the efficacy of 
immunological responses to cancer and perhaps immunological responses in general.  
The sialyltransferase responsible for the expression of sialyl-T is ST3Gal-I which is 
over-expressed in breast cancer. In the next chapter the effect of over-expression of 
this enzyme in the mammary gland on the development of spontaneous mammary 






Development of human ST3Gal-I transgenic 


















The previous results chapter has covered how aberrant glycosylation of MUC1 can 
induce an immune response as seen with MUC1-T, in MUC1 transgenic mice. 
However the MUC1-ST glycoform was unable to induce an immune response even 
in wild-type mice where this antigen was foreign. Moreover, these data and data 
from other groups (Monti P. et al. 2004, Rughetti A. et al. 2005) suggest that MUC1-
ST may be immunosuppressive. The glycosyltransferase responsible for the 
formation of ST is ST3Gal-I, thus in this chapter the influence of over-expressing 
ST3Gal-I on tumorigenicity in vivo was examined.   
 
The major mechanism in breast cancer that results in aberrant O-linked glycosylation 
is changes in the expression of glycosyltransferases. In breast cancer, the 
sialyltransferase ST3Gal-I is over-expressed compared with normal mammary 
epithelial cells (Burchell J. et al. 1999). This sialyltransferase adds sialic acid to the 
galactose residue of core 1 (Galβ1,3GalNAc) O-glycans, resulting in sialyl-T being 
found in many breast cancers. The ability of up-regulated ST3Gal-I to sialylate core 
1, even in the presence of the competing enzyme C2GnT1 has been demonstrated in 
vitro by transfection experiments (Dalziel M. et al. 2001) as described in the 
introduction chapter. To further understand the relation between ST3Gal-I 
overexpression and breast cancer, this chapter describes the development of 
transgenic mice that overexpress human ST3Gal-I in epithelial cells, including those 
of the mammary gland. This was achieved by driving expression of the ST3Gal-I 
transgene from the human MUC1 promoter and resulted in ST3Gal-I expression in 
tissues where MUC1 is found in humans. Once these mice had been characterized, 
the effect of overexpressing this sialyltransferase was investigated by crossing them 







5.2.1 Generation of the human ST3Gal-I transgenic mouse 
 
To enable expression of human ST3Gal-I in the mammary gland and its upregulation 
during pregnancy, lactation and in mammary tumours, the translated region of 
hST3Gal-I (+889 to +1951, GenBank L29555) was placed under the control of the 
MUC1 promoter (see materials and methods for construct details). The region of the 
MUC1 promoter used was -1401 to +33 which is 74% homologous with the mouse 
Muc1 promoter (Spicer A. P. et al. 1991), and has been shown to be sufficient to 
direct tissue-specific expression in murine models, allowing up-regulation during 
pregnancy and lactation and in PyMT inducible mammary tumours (Graham R. A. et 
al. 2001). This region of the MUC1 promoter and the ST3Gal-I cDNA was cloned 
into the vector pNASSβ (see materials and methods) and the ST3Gal-I together with 
the MUC1 promoter was isolated from the vector by cutting the section with the 
restriction enzymes Sal I and Sca I (fig 5.1), before running it into 0.7% agarose gel 
and purifying the insert using a gel extraction kit from Qiagen (see materials and 
methods). DNA was dissolved in injection buffer (0.1 mM 
ethylenediaminetetraacetic acid, 10 mM Tris pH 7.4 prepared in ultrapure water), 
and 5ng were injected into the nucleus of pure C57/Bl6 mouse embryos. These 
embryos were subsequently transferred into day 1-plugged pseudopregnant C57Bl/6 




Figure 5.1:  Diagrammatic representation of hST3Gal-I DNA construct used for 
the generation of ST3Gal-I transgenic mice 
 
Transgenic mice were identified by PCR on DNA isolated from tail snips, 
amplifying a 550 base pair segment of DNA using oligonucleotide primers within the 
3’ end of the MUC1 promoter region and the 5’ end of the ST3Gal-I region (see 
materials and methods for details). Two founder mice were identified, but only one 
expressed ST3Gal-I in the expected tissues. Further expansion of the line was 
-1401 to +33 of the 5’ MUC 1 promoter region           +889 to +1951  ST3Gal-I   




developed by littermate mating, and homozygosity confirmed by backcrossing mice 
onto WT C57Bl/6.  
 
5.2.2 Characterisation of hST3Gal-I transgenic mice 
 
Expression of hST3Gal-I was determined by immunohistochemistry using the 
monoclonal antibody 4B10, which specifically reacts with human ST3Gal-I and not 
with the mouse enzyme (Vallejo-Ruiz V. et al. 2001). As expected from the activity 
of the MUC1 promoter (Graham R. A. et al. 2001), the hST3Gal-I enzyme was 
found expressed in the epithelial cells of tissues where Muc1 is found (Peat N. et al. 
1992), such as mammary glands, stomach, lungs (fig 5.2A), pancreas and salivary 
glands. To ensure that the expressed human ST3Gal-I was enzymatically active, 
ST3Gal activity was measured in the mammary glands, lungs and intestine in 
collaboration with Dr Inka Brockhausen. As shown in figure 5.2B, the ST3Gal 
activity, which includes human and mouse using this assay, was found to be higher 














Figure 5.2: Human ST3Gal-I is expressed in the correct tissues and is active in 
ST3Gal-I transgenic mice    
 
A: Immunohistochemical staining (frozen sections) of tissue from the hST3Gal-I transgenic mouse 
strain and C57Bl/6 WT control, using anti human ST3Gal-I antibody. Scale bar represents 100 µm. 
B: Enzymatic ST3Gal activity of tissue from the hST3Gal-I transgenic mice and C57Bl/6, using 
Galβ1-3GalNAcα-pnp as the acceptor substrate (performed by Dr Inka Brockhausen). 
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Homozygous hST3Gal-1 Tg mice developed normally and had no overt abnormal 
physical or behavioural characteristics, but initially appeared to be smaller at birth. 
Thus, in order to assess whether the mice grow at the normal rate after birth, the 
weight of pups were recorded and compared to wild-type C57Bl/6 mice. The 
individual weights from four litters of mice derived from the hST3Gal-I Tg and four 
litters from the WT C57Bl/6 mice were compared (fig 5.3). At days 5 and 10 the 
weight of the majority of the hST3Gal-I pups was less, as compared to the control 
group, and these differences were found to be statistically significant by unpaired T 
test, with respective p values of >0.001 and 0.0246. However, by day 15 and just 
before weaning at day 20, there was no difference in the weight of the hST3Gal-I Tg 
pups compared to the control group. As no gross differences in the mammary gland 
was observed (see below), it is possible that the close-relative breeding could be the 
cause for the reduced birth weight in the hST3Gal-I mice. However, a defect in milk 














Figure 5.3:  Weight of hST3Gal-I pups      
 
Weight in grams of pups from hST3Gal-I homozygous parents and WT C57Bl/6 mice parents taken 
individually at day 5,10,15 and 20 after birth. Results represent the mean ± SD of 4 litters (20 pups 






5.2.3 Mammary gland development in pregnant and lactating 
ST3Gal-I mice 
 
Muc1 is highly expressed in mammary epithelial cells during pregnancy and 
lactation (Schroeder J. A. et al. 2001). As the expression of the human ST3Gal-I is 
being controlled by the MUC1 promoter, it was of interest to investigate any 
morphological differences in breast tissue of the hST3Gal-I Tg mice. At a gross 
visual examination, the shape and size of the mammary glands of hST3Gal-I, their 




















Figure 5.4:  Mammary gland appearance in mice   
 
A; Diagram of mammary gland (www. Atlas of laboratory mouse histology). B; Examples of sub 
epidermal gross appearance of mammary glands from the hST3Gal-I Tg mice and C57Bl/6 WT 
littermate. 
Left thoracic mammary glands  
Left abdominal mammary glands  
ST3Gal-I Control 
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In order to assess any possible microscopic morphological changes, mammary 
glands from the hST3Gal-I mice and the control mice were carmine stained (fig. 5.5). 
Mammary glands at day 16 of pregnancy, and day 10 of lactation were chosen for 
assessment as at 16 days of pregnancy the mammary gland is actively proliferating 
and by day 10 of lactation the majority of the rapid proliferation of the mammary 
epithelium would have occurred (fig. 5.5B and 5.5C).  Comparison of the carmine 
staining did not reveal major differences in numbers or branching of alveoli between 
the two groups. However, to definitively show that increased expression and activity 
of ST3Gal-I did not alter the morphology of the mammary gland, a more detailed 
investigation, which would involve taking glands at different days during 
development, pregnancy, lactation and involution needs to be undertaken. 



















Figure 5.5:  Carmine staining of mammary glands from hST3Gal-I TG mice 
A: Example of carmine staining of mouse mammary glands from a virgin and a lactating mouse. B 
and C: Example of carmine staining of mouse mammary glands from hST3Gal-I and C57Bl/6 mice, at 







5.2.4 Development of spontaneous mammary tumours over-
expressing ST3Gal-I  
  
To evaluate the impact of increased ST3Gal-I enzyme levels on mammary tumour 
formation, ST3Gal-I Tg mice were crossed with mice carrying the polyoma middle T 
antigen (PyMT mice). Since their generation, PyMT mice have been well established 
as a murine model resembling human breast cancer (Gendler S. J. and Mukherjee P. 
2001). PyMT mice carry the middle T oncogene under the transcriptional control of 
the mouse mammary tumour virus promoter/enhancer which results in widespread 
transformation of the mammary epithelium with rapid growth of multi-focal 
mammary adenocarcinomas (Guy C. T. et al. 1992). The original investigation by 
Chanteale Guy et al. in 1992 used FVB mice and found that 100% of the mice 
expressing the promoter/enhancer developed adenocarcinomas and all the tumours 
become detectable by palpation between the ages of 3 to 6 weeks. However, 
differences in tumour development were found in different founder mice, and it was 
suggested that these differences might be the result of different sites of gene 
integration. When PyMT FVB mice were crossed with C57Bl/6 mice or crossed with 
C57Bl/6 mice homozygous for the MUC1 gene, 100% of the mice developed 
mammary adenocarcinomas, similarly to that described by Guy and colleagues. 
However the time for the tumours to be detectable by palpation was found to be 
between 8 to 15 weeks of age (Chen D. et al. 2003, Mukherjee P. et al. 2007). Thus, 
as the appearance of tumours in different stains of mice have substantial timing 
differences, the importance of using mice of an identical strain as controls when 













Figure 5.6:  Schematic representation of crossing of ST3Gal-I with PyMT mice 
and WT (C57Bl/6) with PyMT mice 
 
In investigating the kinetics of tumour initiation in PyMT control (C57Bl/6 x PyMT) 
and ST3Gal-I/PyMT mice, the percentage of palpable tumour-free mice per total 
number of mice observed over time was calculated. Between the PyMT control 
(n=23) and ST3Gal-I/PyMT (n=33) we observed a clear significant difference 
(p<0.001), in the time to tumour development (fig. 5.7). In the control PyMT mice, 
the mammary tumours started to appear from day 60 and by day 100 all of the mice 
had at least one palpable tumour. Within two weeks of the appearance of the first 
palpable tumour, all of the females went on to develop multifocal tumours in the 
remaining glands. In contrast, in the ST3Gal-I/PyMT mice tumours started to appear 
significantly earlier at day 38, and by day 77 all of the mice had developed palpable 
mammary tumours, also becoming multifocal within two weeks of the appearance of 







          
Figure 5.7:  ST3Gal-I/PyMT mice develop tumours faster than control mice on the 
same background 
 
Kinetics of tumour formation in female F1 control/PyMT (C57Bl6/PyMT +/- n=23) (        ), and F1 
ST3Gal-I/PyMT (hST3Gal-I+/-/PyMT+/- n=33)  (----). Percentage of mice without tumours was 
calculated as the number of tumour-free mice compared with the number of mice observed for the 
initiation of a palpable tumour. The difference between the curves was (p<0.001) evaluated by the 
Breslow test, where a p value of less than 0.1 is considered significant.  
 
 
5.2.5 Expression of hST3Gal-I and Muc1 in PyMT mammary 
tumours 
 
Expression of human ST3Gal-I and murine Muc1 in three formalin fixed, paraffin 
embedded mammary tumours was analysed by immunohistochemistry (see materials 
and methods), using a human monoclonal antibody for human ST3Gal-I  (4B10) 
(Vallejo-Ruiz V. et al. 2001) and a polyclonal antibody to the human MUC1 
cytoplasmic tail that also reacts with mouse Muc1 cytoplasmic tail (CT1) 
(Pemberton L. et al. 1992). Human ST3Gal-I sialyltransferase was found to be 
express only in tumours derived from the ST3Gal-I/PyMT Tg mice, while the 
expression of Muc1 was found to be similar in tumours from the transgenic and 
control mice (fig 5.8A). In addition, ST3Gal enzyme activity (carried out by Dr Inka 
Brockhausen) was increased in tumours arising from the ST3Gal-I/PyMT Tg mice, 































Figure 5.8:  hST3Gal-I and murine Muc1 expression in mammary tumours. 
 
A: Staining for ST3Gal-I (frozen sections) and Muc1 (formalin fixed paraffin embedded sections) of 
tumours from C57Bl6/PyMT +/- (control/PyMT) and hST3Gal-I+/-/PyMT+/- (ST3Gal-I/PyMT) mice. 
Scale bars represent 100µm and arrows point to strong area of staining. 
B: Enzymatic expression in tumours from the transgenic mouse strain ST3Gal-I/PyMT and 
control/PyMT, using Galβ1-3GalNAcα-pnp acceptor substrate. 
 
The activities of two other families of glycosyltransferases were also measured. The 
polypeptide GalNAc transferases that are responsible for adding GalNAc to serine 
Control/PyMT	  	  ST3Gal-­‐I/PyMT	  	  







and/or threonine and C2Gn transferase that add GlcNAc to core 1 (see section 1.3.4, 
table 1.3 and figure 1.7). As can be seen from figure 5.8B, no differences in activity 
of these glycosyltransferases were observed from tumours samples arising from 
ST3Gal-I/PyMT Tg mice, as compared to tumours samples arising from the controls 
PyMT mice.  
 
 
5.2.6 Mass spectrometry O-glycans profiles of hST3Gal-I 
tumours 
 
In order to investigate possible differences in the O-glycan profiles of ST3Gal-I 
tumours and those arising in the controls, two tumours derived from hST3Gal-
I/PyMT mice and three tumours derived from the control/PyMT mice were analysed 
by mass spectrometry by the group of Professor Ann Dell (Imperial College) (fig 
5.9). It is notable that the O-glycan profiles are very variable, irrespective of the 
group’s provenience, with the exception of one of the tumours derived from the 
control group that had a low level of the core 1 type of O-glycans which included T, 
and ST (fig 5.9B). However, to further explore this type of variability an increased 
number of tumour samples would need to be tested, which are not available. As 
murine mammary tumours show changes in O-linked glycosylation with increased 
core 1 glycans (Graham R. A. et al. 2001), it is possible that in these end point 





















Figure 5.9:  MALDI-TOF spectra of permethylated O-glycans derived from 
control/PyMT and ST3Gal-I/PyMT mice tumours.  
 
A, B and C O-glycan profiles are from control/PyMT mice tumours; D and E O-glycan profiles are 
from ST3Gal-I/PyMT mice tumours. Profiles of O-glycans are from the 35% MeCN fraction from a 
C18 Sep-Pak. All molecular ions are [M+Na]+. Putative structures based on composition, tandem 
mass spectrometry and the literature are shown. Cartoon structures are according to the Consortium 
for Functional Glycomics (http://www.functionalglycomics.org) guidelines. Structures that show 
sugars outside a bracket have not been unequivocally defined. Performed by Professor Anne Dell’s 
group at Imperial College London. 
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5.2.7 Histology of tumours 
 
Forty-two tumours developed by 33 hST3Gal-I/PyMT mice and 33 tumours 
developed by 22 control C57/PyMT mice were used to assess the microscopic 
anatomy. The tumours were fixed, paraffin embedded and H&E stained as described 
in the materials and methods, before being assessed blindly by Professor Sarah 
Pinder (Breast Pathologist). Tumour grade is a powerful indicator of prognosis and 
the three main characteristics used in grading human breast carcinomas, are 
glandular differentiation, nuclear pleomorphism and mitotic count. This grading 
system was used to assess the tumours from the mice (Table 5.1, 5.2 and 5.3). Each 
element is given a score of 1 to 3. The lowest possible score (1+1+1=3) is given to 
well define tumours that form tubules and have a low mitotic rate measured by high 
power field (HPF) of <10/10 HPF. The highest possible score is 9 (3+3+3=9), and 
the score of all three components (glandular differentiation, nuclear pleomorphism 
and mitotic count) are added together to give the "grade" (3-5= grade 1, 6-7= grade 2 
and 8-9= grade 3) (Bloom H. J. and Richardson W. W. 1957). According to the 
above grading system called Scarff-Bloom-Richardson grading system, the majority 
of the tumours developed by hST3Gal-I/PyMT or by the control C57/PyMT mice 
have a similar grade (grade 2). 
 
In addition to the characteristics used to grade the tumours, the degree of apoptosis 
(Table 5.4), necrosis and heterogeneity was estimated (Table 5.5). The results 
indicate that the tumours developed by hST3Gal-I/PyMT or by the control 
C57/PyMT mice were similar, with no major morphological differences. There was a 
small trend for the ST3Gal-I tumours to have a smaller % of cells undergoing 
apoptosis. However, this was only a slight trend (P=0.0983 unpaired T test) and so it 
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Score C57xPyMT ST3Gal-IxPyMT 
1 - - 
2 89% 98% 
3 11% 2% 
 
Table 5.1: Glandular score  
 
Glandular % score, equivalent of human breast cancer glandular score (score 1 = >75%, score 2 = 
10-75%, score 3 = <10% ) 
 
Score C57xPyMT ST3Gal-IxPyMT 
1 3% 2% 
2 73% 75% 
3 24% 23% 
 
Table 5.2: Pleomorphism Score 
 
Pleomorphism score, equivalent of human breast cancer pleomorphism score: 1= mild (little 
difference from normal), 2= moderate, 3= large (pleomorphic cancer cells) 
 
Score C57xPyMT ST3Gal-IxPyMT 
 1  12% 14% 
2 21% 19% 
3 67% 67% 
 
Table 5.3: Mitotic count per 10 HPF 
 
Numerical mitotic score, equivalent of human breast cancer mitotic score: 1=>10, 2= 10 to 20, and 3 
=<20 
 
Category C57xPyMT ST3Gal-IxPyMT 
Mild 24% 37% 
Moderate 45% 37% 
Marked 31% 26% 
 
Table 5.4:  Estimation of the degree of apoptosis 
 
Estimate % of cells undergoing apoptosis (Categories: mild, moderate, marked) 
 
 C57xPyMT ST3Gal-IxPyMT 
A: Heterogeneity 72% 74% 
B: Necrosis 45% 38% 
 
Table 5.5: Estimation of the degree of heterogeneity and necrosis 
 
% of tumours with: A, heterogeneity (presence of different cytological appearances within the 
tumour). B, necrosis 
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5.2.8 TGF-β  in serum of ST3Gal-I/PyMT mice  
  
Expression of sialylated core 1 glycans on MUC1 results in increased tumour growth 
in a transplantable tumour model in immuno-competent mice, but not in immuno-
compromised mice, suggesting an immunological mechanism (Mungul A. et al. 
2004). As it is known that neoplastic cells themselves, including tumours cells from 
PyMT mice generate immunosuppressive molecules, including transforming growth 
factor-β (TGF-β) (Fischer J. R. et al. 1994), and that TGF-β produced by many 
cancers results in increased regulatory T cells (Treg), immuno-incompetent immune 
cells and poor prognosis (Flavell R. A. et al. 2010) it was decided to investigate the 
presence of TGF-β in sera from the mice. Thus, sera from female mice, 
Control/PyMT and ST3Gal-I/PyMT, were taken before the appearance of the 
palpable tumours (20 to 40 days old), and the level of TGF-β tested by ELISA.  
TGF-β levels in the sera from ST3Gal-I/PyMT mice were found to be higher as 
compared with the levels in the sera from the control/PyMT mice (P < 0.001 
unpaired t test) of similar age (fig. 5.10A). However, as TGF-β levels in serum 
increased with tumour size (fig. 5.10B), it seems likely that the higher level of TGF-
β found in sera from the ST3Gal-I/PyMT mice is a consequence of the early 
development of the tumours. Moreover, no different was observed in TGF-β 
expression when analyzed by qRT-PCR using RNA derived from the Control/PyMT 
control and ST3Gal-I/PyMT tumours (fig. 5.10C). Thus again indicating that the 
differences in serum level of TGF-β are reflecting the increased tumour size of the 
ST3Gal-I/PyMT tumours, confirming that the ST3Gal-I/PyMT mice develop 








































Figure 5.10: ST3Gal-I/PyMT mice have increased TGF-β in their serum which 
reflect increased size of their tumours  
 
A) Sera from Control/PyMT (C57Bl6/PyMT +/- n=14), and ST3Gal-I/PyMT (hST3Gal-I+/-/PyMT+/- 
n=21) mice, taken between the age of 20 to 40 days, and analysed for TGF-β by ELISA. The 
difference between groups was evaluated by two-tailed T test (p<0.001). B) Sera from PyMT control 
(C57Bl6/PyMT +/- n=6) mice, taken at 30 and 60 days of age, analysed for TGF-β by ELISA. The 
difference between the two time points was evaluated by two-tailed T test (p<0.001). C) Level of 
mRNA expression for TGF-β measured by real time polymerase chain reaction and represented as 
fold change relative to actin mRNA level. RNA was derived from cell lysate of 4 tumours from 





5.2.9 MUC1 signalling in hST3Gal-I/PyMT tumours  
   
As discussed in Chapter 1 the interaction of MUC1 cytoplasmic tail with a variety of 
proteins has long been recognized (Singh P. K. and Hollingswoth M. A. 2006). For 
example MUC1-CT interacts with EGFR, c-Src, and β-catenin, which are involved 
in neoplasia and cell-cell interaction (Pandey P. et al. 1995, Yamamoto M. et al. 
1997, Li Y. et al. 2001, Ren J. et al. 2002). c-Src activation is essential for the 
induction of mammary tumours in the PyMT Tg mice and murine Muc1 has been 
demonstrated to interact with c-Src in PyMT induced mammary tumours (Al Masri 
A. and Gendler S. J. 2005). Moreover, in Muc1 null mice the development of PyMT 
induced tumours is significantly delayed (Spicer A. P. et al. 1991)  
 
As Muc1 carries so many O-linked glycans that may be affected by the over-
expession of ST3Gal-I, we investigated whether the expression of hST3Gal-I in 
PyMT tumours alters the interaction between Muc1 and cSrc, leading to the observed 
early appearance of the tumours. The tumour cell lysates from three hST3Gal-
I/PyMT or control/PyMT were used to immunoprecipitate Muc1 and c-Src with 
either a monoclonal antibody to the cytoplasmic tail of Muc1 (CT2) or with an anti-
c-Src antibody (Molecular Probes) (see figure 5.11A). Indeed, c-Src Western blot 
staining of Muc1 immunoprecipitated tumour samples (fig 5.11A upper panels), and 
Muc1 staining of c-Src immunoprecipitated tumours samples (fig 5.11A lower 
panels), confirm the previously reported (Al Masri A. and Gendler S. J. 2005) 
interactions of Muc1 with c-Src. However, no consistent difference between tumours 
derived from the two groups of mice was observed. 
 
PI3-kinase is also a direct target of PyMT oncogenesis and phosphorylates AKT, 
which is itself a protein kinase. We therefore investigated the phosphorylation of 
AKT. Figure 5.11B shows four tumours cell lysates derived from hST3Gal-I/PyMT 
or control/PyMT mice that were used to assess the levels of AKT and its 
phosphorylation. In figure 5.11B lower panel it is possible to see that the levels of 
AKT, evaluated using a AKT specific monoclonal Ab (Cell Signaling 9272), which 
runs at about 60 kDa in a SDS gel, are similar. Figure 5.11B upper panel, shows the 
reaction with a monoclonal antibody to phosho AKT (Cell Signaling 4058S). 
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However, there appears to be no consistent differences in the phosphorylation of 














Figure 5.11: Increased ST3Gal activity does not affect the interaction of Muc1 with 
c-Src or down-stream signalling.  
 
A; Tumour lysates (1 mg) from control/PyMT (n=3), and ST3Gal-I/PyMT (n=3) mice were 
immunoprecipitated with anti c-Src or anti Muc1 (CT2) and immunoblotted for c-Src (upper panels) 
or Muc1 (CT1) (lower panels). B; Tumour lysates (30 µg) from control/PyMT mice (n=4), and 
ST3Gal-I/PyMT mice (n=4) were immunoblotted for phosphorylated-AKT (upper panel), or total AKT 










In vitro studies have shown that over-expression of ST3Gal-I is sufficient to cause 
the change from core 2 based glycans to sialyl core 1 glycans (sialyl-T) carried on 
mucins commonly found in breast cancer (Brockhausen I. 2006, Dalziel M. et al. 
2001). However, it is not clear if the expression of the sialyl-T glycan by epithelial 
cancers has any direct role in driving tumourigenesis.  To address this question we 
developed a transgenic mouse that expresses hST3Gal-I from the MUC1 promoter to 
induce this sialyltransferase expression in epithelial tissues including the mammary 
gland and mammary tumours (Graham R. A. et al. 2001). These mice were crossed 
with MMTV-PyMT mice that develop spontaneous mammary tumours (Guy C. T. et 
al. 1992) and the progeny developed tumours significantly faster than the controls. 
This is the first report that shows that an enzyme involved in O-linked glycosylation 
promotes tumorigenesis.  
 
Mice transgenic for the human ST3Gal-I sialyltransferase were generated by 
pronuclear injections into early C57/Bl6 mouse embryos (see materials and 
methods), a well-establish technique that results in insertion of the chosen gene into 
the genome. Due to the nature of this technique, the hST3Gal-I could have been 
inserted at a single or multiple sites into the genome.  However, from 1000 injected 
embryos only two out of 40 mice born expressed the transgene, thus the likelihood of 
multiple insertions is believed to be low. Southern analysis can be performed at this 
stage to assess if the transgene is intact and if the transgene has integrated into 
multiple sites, however, tissue expression and enzyme activity were chosen to assess 
the expression and the integrity of the transgene. The mice expressing the hST3Gal-I 
were found to express the sialyltransferase in tissues where Muc1 is expressed, such 
as stomach, lungs, liver, intestine, salivary glands and the mammary glands, in 
accordance with the data from Graham and colleagues (Graham R. A. et al. 2001). 
This confirms that -1401 to +33 of the MUC1 promoter has all the elements required 
for expression in these tissues. Furthermore, the glycosyltransferase was found to be 
active in tissues such as the intestine, lungs and mammary glands. Although the 
enzyme assay cannot distinguish between enzymes from different species, the 
increased activity observed in the ST3Gal-I Tg mice indicates that a proportion of 
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this is human ST3Gal-I. The generated hST3Gal-I transgenic mice had no overt 
abnormal physical or behavioural characteristic. 
 
Altered ST3Gal-I sialyltransferase expression in organs such as the mammary glands 
could have affected their lobuloalveolar development, or even the biosynthesis of 
milk produce. Thus, particular attention was paid to the growth of the pups from the 
hST3Gal-I Tg mice. Indeed pups derived from hST3Gal-I mice were found to weigh 
less soon after birth and up to day 10 of age as compared to mice of the same 
background, however this difference was small and the weight was recovered by day 
20. Moreover, no overt differences in mammary gland morphology between the 
hST3Gal-I and control mice were observed. 
 
In order to better understand ST3Gal-I involvement in oncogenesis, the hST3Gal-I 
transgenic mice were crossed with MMTV-PyMT mice that develop spontaneous 
mammary tumours (Guy C. T. et al. 1992). In this in vivo context, which has been 
designed to be as close as possible to human breast cancer development, we have 
been able to assess the effect of the overexpression of ST3Gal-I on tumour 
development. The data presented here clearly show that ST3Gal-I promotes 
mammary gland carcinogenesis, as tumours arose significantly earlier in hST3Gal-
I/PyMT mice than in control mice.  
 
Increased ST3Gal-I activity was detected in the ST3Gal-I/PyMT tumours. However 
despite this, the glycosylation pattern of these tumours cannot be distinguished from 
the control/PyMT tumours, as determined by mass spectrometry. This might indicate 
that changes of glycosylation induced by increased ST3Gal-I only affects a specific 
and restricted portion of the tumour glycoproteins, which would not be detected 
using this gross analysis. Alternatively, when the tumours have developed and are 
larger enough to necessitate culling of the mice, the effect of expression of the 
ST3Gal-I transgene may not be able to compound the effect of endogenous aberrant 
glycosylation (Graham R. A. et al. 2001).  
 
Glycosylation of extracellular domains can affect signalling and interactions of 
intracellular domains of a protein (Guo H. B. et al. 2007). We therefore looked at the 
interactions of murine Muc1, which carries many O-glycans and has been implicated 
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in the tumorigenesis of PyMT-induced tumours. Although the interaction with c-Src 
reported by others (Al Masri A. and Gendler S. J. 2005) was confirmed, no 
differences could be observed in tumours from the two sets of animals and no 
differences were observed in down-stream signalling. Moreover, when analysed at 
the endpoint of the experiment, the tumours derived from the hST3Gal-I/PyMT mice 
or control mice did not show significant differences in terms of morphology or 
mitotic index, suggesting that ST3Gal-I expression did not affect the 
histopathological type of the tumour.  
 
Comparison of the levels of circulating TGFβ suggest that the difference in the 
development of the tumour had already occurred in the mice prior to the detection of 
palpable tumour masses. Taken together, our results indicate that ST3Gal-I exerts its 
influence early in tumour development. It is therefore important to analyse any 
differences at this early stage (see discussion in Chapter 6), perhaps by using tumour-
imaging techniques. Several mechanisms could be responsible for promoting 
tumourigenesis, one of them being the ability of the tumour to escape the immune 
surveillance early in tumour development. Certainly, changes in mucin-type 
glycosylation can affect how MUC1 interacts with the immune system, and while the 
expression of some glycans may be active in stimulating an immune response 
(Napoletano C. et al. 2007, and this thesis), other glycans such as sialyl-T, may 
inhibit a response (Mungul A. et al. 2004, and this thesis), suggesting that the type of 
O-glycans expressed by cancer cells may be able to modulate the immune response 
to the tumour. Thus, investigating the early tumour development in the hST3Gal-
I/PyMT mice has the potential of uncovering the mechanism by which ST3Gal-I can 
promote mammary gland carcinogenesis.     
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Chapter 6  
































6.1 Production and purification of recombinant MUC1 
glycoproteins 
Post-translational modifications are vital for the function, stability and in vivo half-
life of many proteins. Thus, mammalian cell expression systems are the preferred 
method of choice in the biopharmaceutical industry for the production of therapeutic 
glycoproteins, and the most commonly used cell type is the Chinese hamster ovary 
(CHO) cell (Hossler P. et al. 2009, Li F. et al. 2010). CHO cells have proven over 
the years to be a reliable system to produce the quantity and quality of therapeutic 
agents required; The list of approved therapeutic agents by the European Medicine 
Agency that are produced in CHO cells is extensive and includes Herceptin 
(Trastuzumab) from Genentech and NeoRecormon from Roche.  
 
As our understanding of the specific glycan profile of glycoproteins grows, so does 
our understanding of the effects of this specific glycosylation on their therapeutic 
efficacy. Glycans play a very important role in the therapeutic effectiveness of 
proteins and in determining their in vivo half-life (Elliott S. et al. 2003). Ideally, the 
production of individual proteins should be guided by a thorough understanding of 
their optimal glycan profile. 
 
The glycosylation of specific glycoproteins relies on the glycosyltransferases 
expressed by the parent cell, therefore, by knowing the glycosyltransferase 
expression profile it is possible to predict, to some degree, the glycans carried on the 
proteins produced. For example, and in regard to the production of MUC1 
glycoproteins, CHO cells do not express the glycosyltransferase core 2 β1,6-N-
acetylglucosamyltransferase-1 which is responsible for the formation of the core 2 
structure (VanderElst I. E. and Datti A. 1998), therefore it was predicted that the type 
of O-linked glycosylation would be mainly core 1. This indeed turned out to be the 
case as the glycosylation on the MUC1 produced in wild-type CHO K1 cells was 
found to be mainly core 1 based with no core 2, which is similar to that previously 
reported for endogenous MUC1 from the breast carcinoma cell line T47D (Lloyds K. 
et al. 1996, Muller S. et al. 1999). Furthermore, in our hands the CHO K1 clone was 
optimal to produce recombinant MUC1 on a large scale, with further purification 
steps limiting the level of contaminants.  
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In order to produce recombinant MUC1 glycoproteins with another very specific 
tailored glycan profile, mutant CHO ldlD cells were also used in this study. The 
deficiency of UPD-Gal/UDP-GalNAc 4-epimerase present in the ldlD mutant CHO 
cells leaves them unable to synthesize galactose and GalNAc (Kingsley D. M. et al. 
1986). However, as the wild-type glycosyltransferases are present the process can be 
reversed by providing the cells with exogenous sources of sugars, which are utilized 
via a salvage pathway that does not require participation of the 4-epimerase enzymes 
(Segal S. 1983). By culturing CHO ldlD cells transfected with the MUC1 (16TR)-
IgG construct with or without an exogenous source of GalNAc, it has been possible 
to produce in large quantities recombinant MUC1 without O-linked glycosylation or 
recombinant MUC1 carrying only O-linked GalNAc. Thus the work reported in this 
thesis, the first of this kind, shows how mutant CHO ldlD cells can be used in the 
production of recombinant MUC1 glycoprotein without O-linked glycosylation or 
carrying only O-linked GalNAc. 
 
 
6.2 In vivo immune response to MUC1 glycoforms 
 
Over-expression and aberrant O-linked glycosylation of MUC1, coupled to the fact 
that loss of polarity of cancer cells results in MUC1 being found over the entire 
surface, make MUC1 an attractive immunotherapeutic target for the treatment of 
breast and other cancers. Moreover there is now evidence to suggest that MUC1 may 
play a role in driving tumorigenesis (Mungul A. et al. 2004, Ahmad R. et al. 2011, 
and this thesis). In a National Cancer Institute (NIH, USA) study to prioritize cancer 
antigens, MUC1 was ranked the 2nd (out of 75) most optimal antigens for vaccine 
development (Cheever M. A. et al. 2009), and its popularity as an antigen target is 
demonstrated by the numerous ongoing clinical trials (Beatson R. E. et al. 2010). It is 
well establish that cancer-associated changes in the glycans carried by MUC1 
exposes predominantly the glycans Tn, Sialyl-Tn, T and Sialyl-T, however the role 
that each tumour associated glycan plays in tumorigenesis still remains elusive. In 
this thesis the immune response to specific MUC1 glycoforms has been explored to 
determine their potential for the immunotherapy of MUC1 expressing cancers.  
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In recent years work with glycopeptides in vitro has contributed substantially to the 
understanding of glycopeptide processing and presentation by APCs, and priming of 
T and B cells. Ninkovic and colleagues suggested in 2007 that in order to enable 
efficient processing by immunoproteasomes, MUC1 tandem repeat domain 
glycopeptides should fulfil some specific requirements when used in a synthetic 
vaccine formulation. These included: site specificity O-glycosylation (in red are the 
permissive sites: AHGVTSAPDTRPAPGSTAPPA) which should only carry the O-
glycan moieties GalNAc (Tn) or Galβ1-3GalNAc (T), and sialylated extension of 
these glycans should not be included as this reduces or blocks the processing by 
immunoproteasomes and prevents the glycosylated peptide fragment fitting into the 
binding groove of MHC class 1 proteins. Thus, immunization using densely 
glycosylated and sialylated MUC1 peptides is believed to be ineffective as a vaccine. 
However, this thesis demonstrates that MUC1-T with an average of 4.3 glycosylation 
sites per repeat could induce an immune response. 
 
MUC1 tandem repeat peptides carrying GalNAc have been shown to bind antigen 
presenting cells such as DC and macrophages through MGL (Saeland E. et al. 2007, 
Napoletano C. et al. 2007), and that antigen presenting cells are capable of 
processing and presenting MUC1-Tn on both MHC class I and II (Napoletano C. et 
al. 2007, Lakshminarayanan V. et al. 2012). Moreover, it is possible, by using 
MUC1-Tn peptides, to generate MUC1-Tn specific CTLs in murine models ( Xu J. 
et al. 2004; Stepensky D. et al. 2006, Lakshminarayanan V. et al. 2012), and the 
peptide within the MUC1 repeat domain (SAPDT-α/GalNAc-RPAPG) was predicted 
to be able to bind MHC class I HLA-A 0201 (HLA-A2) molecules (Ninkovic T. et 
al. 2009). In the study conducted by Lakshminarayanan and colleagues, MUC1 
peptides glycosylated with a single GalNAc (TSAPDT-α/GalNAc-RPAP) was linked 
to TLR2 agonist and a T helper peptide epitope (Lakshminarayanan V. et al. 2012). 
The resulting glycosylated MUC1 tripartite vaccine was found to be more effective 
than the unglycosylated MUC1 tripartite vaccine in generating therapeutic responses 
in MUC1 transgenic mice. The inclusion of a helper T cell epitope would increase 
the efficacy of this vaccine but it is also possible that optimal TLR2 stimulation is 
required. On the other hand, the TLR2 agonist may also instigate APC uptake 
allowing cross presentation.  
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In the present study the heavily glycosylated (average 4.3 sites out of a possible 5 per 
TR) MUC1-T recombinant glycoprotein elicited both Th1 and mild Th2 cellular 
responses in MUC1 Tg mice. Moreover, it was demonstrated that CD4 positive T 
cells were responsible for the response. T antigen expression has already been shown 
to be linked to poor prognosis in breast cancer patients (Wolf M. F. et al. 1988),  and 
as described in the introduction, T glycans on MUC1 may play a role in metastasis 
(Yu L. G. et al. 2007). Interestingly, during the eighties and early nineties Dr. 
George Springer conducted a series of clinical studies in breast cancer patients using 
a vaccine composed of human, neuraminidase treated group O red blood cell 
membranes expressing predominantly the T antigen, with about 10% of the glycans 
being Tn antigen. The vaccine was administered with Ca3(PO4)2 and contained traces 
of Salmonella typhi, which also contains the T antigen, as the vaccine adjuvant. The 
patients were vaccinated over the course of years and this resulted in improved 5 and 
10 years survival which was higly significant when compared to independent 
statistics of the United State National Cancer Institue (Springer G. F. 1997). 
Eventhough the Springer studies did not provide conclusive evidence on the efficacy 
of an anti-T antigen vaccine because of the design of the study and the use of 
historical controls, this early success, in my opinion should have led to further 
investigations. In a more recent study led by Professor Kate Rittenhouse-Olson, 
peptides that mimic the T antigen were used to vaccinate mice. The peptides were 
given with Alum adjuvant (aluminium hydroxide) and contained traces of inactivated 
Bordetella pertussis bacteria (Heimburg-Molinaro J. et al. 2009). The immunized 
mice produced T antigen reactive antibodies. I believe this study contributes further 
to the notion that immunological responses to T antigen can be elicited, and as 
inactivated bacterial were used in the vaccine formulation, this further supports the 
notion that specific danger signals are essential to T antigen priming.    
  
The response observed to MUC1-T was however, only observed in mice living in a 
non-SPF environment, thus suggesting that in our murine model priming of cells 
required an educated immune system to perpetuate their immunological responses to 
this antigen. Many years ago it was reported that mice living in a SPF environment 
developed a less educated immune system compared to mice living in a non-SPF 
environment (Makinodan T. et al. 1971). Moreover, the involvement of microbiota 
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in immune responses has been illustrated in graft-versus-host disease (GVHD), a 
common complication following tissue transplantation that is particularly associated 
with hematopoietic stem cell transplantation (Heidt P. J. and Vossen J. M. 1992). 
When mice were treated with broad-spectrum antibiotics to eliminate aerobic and 
anaerobic bacteria in the gut, clinical symptoms of GVHD were completely 
eliminated and tissue pathology in the liver and colon reduced (Brandon J. A. et al. 
2011). In addition, in a recently developed murine treosulfan-based allogenic 
transplantation model for intestinal GVHD, it was shown that the induction of the 
disease was accompanied by a shift in gut flora towards pro-inflammatory bacterial 
species mediated by TLR9 signalling (Heimesaat M. M. et al. 2010). Thus it would 
be interesting to further explore the relationship between flora and the induction of 
MUC1-T immunological responses and TLR9 signalling. 
 
Further evidence of the importance of microbiota in influencing the immune 
response to non-bacterial antigens is illustrated by the induction of oral tolerance in 
SPF mice but not in totally germ free mice (Ishikawa H. et al. 2008). The SPF mice 
had an increased systemic proportion of CD25+ CD4+ regulatory T cells (Treg) 
compared to germ-free mice, and these Tregs produce greater quantities of 
interleukin IL-10 and TGF-β.  
 
It has been shown in this thesis that MUC1-ST did not induce an immunological 
response in MUC1 Tg mice, or even in wild-type mice. However MUC1-ST-Fc, 
possibly through binding to APCs through their Fc receptors, has the potential of 
being processed by cellular components of the immune system. These results lead to 
the reasonable assumption that MUC1-ST may have immunoevasive and/or 
immunosuppressive properties.  
 
Sialic acid on the non-reducing ends of oligosaccharides chains on the surface of 
cells has been shown to play a role in preventing cell-cell interactions through 
charge-repulsion (Kelm S. and Schauer R. 1997, Schauer R. et al. 1997). Thus, high 
sialic acid content found on the non-reducing ends of cleaved, serum MUC1 could, 
by charge-repulsion, inhibit binding and internalization by certain cellular 
components of the immune system such as DCs. In contrast to charge-repulsion, it is 
well documented that sialic acid binds immunoglobulins-like lectins (Siglecs), and 
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that sialic acids in an α-2,3 linkage to Gal on MUC1 can bind Siglec-1 (Nath D. 
2001), and Siglec-4 (Swanson B. J. et al. 2007). However, Siglec-1 does not contain 
an ITIM motif, and Siglec-4 is not expressed by haematopoietic cells. However, the 
vast majority of Siglecs do express an ITIM motif and are expressed mainly by 
haematopoietic cells (see introduction section 1.5.1). Furthermore, sialic acid in an α-
2,3 linkage is the preferred ligand for Siglecs-5, 9 and 10. Other Siglecs have, as 
their preferred ligand, sialic acid in an α-2,6 linkage, and include Siglecs-2, 3 and 7, 
however this is only the preferred linkage and these Siglecs may bind sialic acid with 
other linkages.  
 
On the whole, evidence appears to indicate that the primary function of Siglecs is to 
dampen host immune responses and Siglecs can be targeted by sialylated pathogens 
to evade the immune response (Cao H. and Crocker P. R. 2011, Jandus C. et al. 
2011). Thus, a possible mechanism by which tumour cells evade 
immunosurveilliance is through expression of high level of sialic acids on surface 
proteins such as MUC1, which would be able to dampen immune responses by 
engaging receptors of the Siglec family. Indeed, Mungul in 2004 proposed an 
immunosuppressive role for MUC1-ST (see section 1.11 on MUC1-ST and Mungul 
A. et al. 2004). Moreover, secreted cancer-associated MUC1, which has been shown 
to contain sialyl-T (Storr S. J. et al. 2008), has been associated with 
immunosuppression through inhibition of T-cell proliferation (Agrawal B. et al. 
1998, Monti P. et al. 2004). However, at the moment the mechanism by which the 
cancer associated MUC1 and/or other surface/secreted proteins, high in sialic acid 
contents may dampen down possible immunological responses remains to be 
clarified. Currently the functional consequence between binding of recombinant 
MUC1-ST to various Siglecs is on-going in our laboratory (see section 6.5). 
 
6.3 Development of human ST3Gal-I transgenic mice  
 
As discussed in the introduction (section 1.7) at least four mechanisms have been 
attributed to the promotion of the altered O-glycan profile in cancer; changes in 
expression of glycosyltranferases, changes in Golgi pH, changes in the location of 
glycosyltransferases and mutations in the Cosmc gene.  
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Cosmc loss of function/mutation has been found in neoplastic cell lines, including 
human colorectal carcinomas LSC, and in human cervical cancer (Ju T. et al. 2008). 
However, Cosmc loss of function/mutation does not appear to be a common event in 
breast cancer (Yoo N. J. et al. 2008, and personal data in appendix I). Alternatively, 
pH alteration is commonly associated with malignant transformation and growth 
(Yuan J. et al. 2000, Hill R. P. et al 2001). Moreover, Golgi pH is known to be 
necessary for the optimal activity and correct localization of glycosyltransferases 
(Bretz R. et al. 1980, Varki A. 1998, Axelsson M. A. B. et al. 2001) and alterated pH 
correlates with T-antigen expression in cancer cells derived from breast (Rivinoja A. 
et al. 2006). However, the major mechanism in breast cancer that results in aberrant 
O-linked glycosylation are changes in the expression of glycosyltransferases, and in 
particular the increase in ST3Gal-I expression. Furthermore, ST3Gal-I increased 
expression has been correlated with tumour grade (Burchell J. et al. 1999), and in 
vitro studies have shown that over-expression of ST3Gal-I is sufficient to cause the 
change from core 2 based glycans to sialyl core 1 glycans (sialyl-T) carried on 
mucins commonly found in breast cancer (Dalziel M. et al. 2001, Brockhausen I. 
2006). 
 
In this project, in order to increase the understanding of the relationship between 
ST3Gal-I overexpression and breast cancer, transgenic mice that overexpress 
ST3Gal-I in epithelial cells, including those of the mammary gland were generated. 
In order to have a model as close as possible to the human system, human ST3Gal-I 
cDNA was used. Crucially, a portion of the MUC1 promoter region was use to drive 
the expression of the ST3Gal-I transgene in order to selectively express the 
sialyltransferase in tissues where MUC1 is expressed, including the mammary 
glands.  
 
Indeed, in our system and as reported by Graham and colleagues (Graham R. A. et 
al. 2001) the section of the MUC1 promoter used contained all the elements for 
expression of hST3Gal-I in mammary glands and in other tissues where MUC1 is 
expressed. The generated hST3Gal-I transgenic mice had no overt abnormal physical 
or behavioural phenotypes, and when crossed with MMTV-PyMT mice a unique 
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strain of mice that developed spontaneous tumours in the mammary glands was 
generated.   
 
6.4 Involvement of ST3Gal-I in tumourigenesis    
 
Similarly to the way that Charles Darwin described evolutionary changes by natural 
selection, a way of looking at tumorigenesis is perhaps to think that functional 
changes that occur in tumour cells that result in a survival benefit, will be selected. 
As ST3Gal-I is found to be over-expressed in the majority of breast cancers it was 
hypothesized that this increase conferred an advantage to tumour cells. Therefore, as 
an increase in ST3Gal-I results in an increase in O-linked sialylated core 1 type 
glycans the resulting glycosylation should provide the tumour cells with a survival 
advantage, perhaps through dampening the immune response as discussed earlier.  
 
In order to test if over-expression of ST3Gal-I did indeed confer an advantage to 
tumour cells, human ST3Gal-I Tg mice were crossed with MMTV-PyMT mice. 
Crossing of the hST3Gal-I Tg mice with PyMT mice clearly indicated, for the first 
time, that ST3Gal-I expression is beneficial to tumour cells as spontaneous tumours 
arose significantly earlier in these mice. The tumours did not show significant 
differences in terms of morphology or mitotic index, suggesting that ST3Gal-I 
expression did not affect the histopathological type of the tumour. Interestingly, a 
recent study conducted by Ma and colleagues, found that at least four distinct cellular 
populations can be recovered from PyMT tumours, and include two populations, one 
epithelial and one mesenchymal, which survive and proliferate in vitro. The 
epithelial population of cells studied by Ma, exhibited a strong tumour initiation 
potential needing as few as 10 cells to establish a tumour in syngeneic immune-
competent mice suggesting that this population contains the cancer stem cells or 
cancer initiating cells (Ma J. et al. 2012). By definition of a tumour as defined by 
Hanahan (Hanahan D. and Weinberg R. A. 2011) these tumour cells may be able to 
evade the immune system even without having a fully developed tumour 
microenvironment. Interestingly, it has been reported by the Finn group that a 
population of cells within the total MCF-7 population have stem cell characteristics 
and express MUC1 carrying sialylated core 1 glycans (Engelmann K. et al. 2008). 
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Thus, perhaps tumour-initiating cells described by Ma and colleagues may be able to 
evade immune surveillance due to functionally advantageous changes resulting in the 
expression of sialyl-T. Tumour cells derived from hST3Gal-I/PyMT Tg mice may, 
from the onset, have the potential to limit immunological killing by expressing 
increased levels of sialylated core 1 on proteins. Indeed in the eye, the limbal stem 
cells do not express α-2,3 sialylation but the initial differentiation involves 
sialylation of  core 1 and the loss of expression of peanut agglutinin (PNA) binding 
(Wolosin J. M. and Wang Y. 1995). These sialyl T expressing cells were found to be 
highly proliferative as compared to the limbal stem cells, and their surface 
glycosylation was associated with proliferative properties (Wolosin J. M. and Wang 
Y. 1995).  In our model, by the time the tumour reached the palpable size required to 
start measurements the total α-2,3 sialylation on tumour cells derived from the two 
groups was found to be similar as detected by mass spectrometry. However, it is 
possible that the tumour initiating cells within these mammary tumours in PyMT 
mouse model only start to be highly proliferative when the cells acquire an increase 
in α-2,3 sialylation. This could potentially explain the significant earlier appearance 
of the tumours in the mice overexpressing ST3Gal-I.  
 
6.5 Strategic plan / further investigations      
 
Data included in this thesis contribute to the understanding of how MUC1 carrying 
specific and defined O-linked glycans can be expressed and purified using wild-type 
CHO cells and mutant CHO cells. CHO cells were well suited for the production of 
the MUC1 glycoproteins for many reasons including the fact that the cells are widely 
available, fast growing, easily transfectable, can adapt well to growth in monolayer 
or in suspension and have been grown successfully in a variety of production 
systems, and very importantly do not express the core 2 glycosyltransferase 
(Bierhuizen M. F. A. and Fukuda M. 1992) and so the O-linked glycans carried by 
proteins expressed in these cells are core 1 based. The MUC1 glycoform produced in 
WT CHO cells is mainly sialylated core 1, one of the dominant cancer-associated 
glycoforms of MUC1 (Backstrom M. et al. 2003). However, it would be interesting 
to evaluate the production of MUC1 glycoproteins in human cell lines such as Hek 
293, Per-C6 and CAP cells, which are emerging as powerful alternatives for the 
 164 
production of human therapeutic proteins. These cell lines are easily grown in serum-
free suspension cultures (Swiech K. et al. 2012), and would only incorporate 
Neu5Ac (when grown in serum free media) as humans have lost the ability to 
synthesize Neu5Gc (Deng L. et al. 2013). However, it is debatable if this would be 
an advantage as when using MUC1 glycoforms as immunogen to induce antibodies, 
MUC1 carrying Neu5Gc maybe desirable, as tumours appear to accumulate more of 
this sialic acid variant which is available from the diet. Moreover, Hek 293 cells can 
make core 2 based glycans (Brautigam J. et al. 2013); therefore expression of MUC1 
in these cells may result in the secretion of MUC1 carrying core 2 glycans rather 
than the tumour-associated core 1. Interestingly, a recent study has shown that anti-
apoptotic agents such as N-acetylcysteine and thiolactic acid can enhance 
glycoprotein production in CHO cells (Chang K. H. et al. 2013). This high 
production of glycoproteins can however result in a decrease in sialylation, but this 
could be compensated in the case of the production of MUC1-ST by the transfection 
of ST3Gal-I into the cells. Thus, I believe that given the right resources further 
optimization of the production system, perhaps using anti-apoptotic agents during the 
culture, could be achieved for the large-scale production of MUC1 glycoproteins for 
use as potential therapeutics.  
 
The observation that the immune response to MUC1-T was lost when the MUC1 
transgenic mice were rederived into a SPF unit suggests that the environment 
affected their immunological predisposition perhaps by influencing their indigenous 
microbiota. Indeed, as discussed under section 6.2 above, this is reminiscent of the 
lack of graft versus host disease observed in mice lacking gut flora. Although the T 
cell response to MUC1-T was measured in the SPF mice, due to time constraints the 
presence of circulating antibodies was not measured nor was the secretion of Th2 
type cytokines. Thus we are unable to say if a humoral immune response could be 
generated in these SPF mice. Future studies should evaluate the levels of MUC1 
antibodies in the sera of SPF immunised mice and the presence of Th2 cytokines.  
 
Interestingly, the experimental MUC1 transgenic mice living in a dirty environment 
were found to carry Helicobacter pylori (H. pylori), a bacterium linked to the 
increase in antibodies to MUC1 (Klamas K. et al. 2007) and T antigen (Klamas K. et 
al. 2002).    
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Thus, there appears to be a link between the development of T cell responses and 
microbial flora, and a number of experiments could be performed in order to further 
investigate this link: 
1) A detailed analysis of the immune system of MUC1 transgenic mice living in a 
“dirty” environment or a SPF environment could be performed. This would include 
measurement of circulation cytokines including IL-4, IL-5, IL-6, IL-10, IL-12, TNFα 
and TGFβ, and the frequencies of CD25+, CD4+ Tregs in the mesenteric lymph 
nodes.  
2) By infecting mice living in an SPF environment with H. pylori and/or other 
bacteria in a controlled manner it may be possible to assess the extent by which 
indigenous microbiota may contribute to the induction of an immune response to 
MUC1-T. Moreover, perhaps probiotic adjuvants such as Lactobacillus (e.g. L-
reuteri ATCC no 23272) which is suggested to play an important role in modulating 
immunological function by promoting Th1 responses (Mohamadzadeh M. et al. 
2005) could be included with the MUC1-T immunizing agent. 
 
If an immune response could be generated by adding back bacterial flora, the 
investigations into the use of MUC1-T as a cancer vaccine could continue. The 
efficacy of MUC1-T vaccination in preventing tumour formation in a prophylactic 
and therapeutic setting should be tested. In a transplantable tumour setting the 
murine tumour cell lines RMA or MC38 expressing human MUC1 could be used. 
The presence of MUC1 carrying T on these lines can easily be established by 
ELISAs using HMFG2 to pull down MUC1 followed by PNA detection before and 
after sialidase treatment. The presence of MUC1-T could be confirmed by the 
binding of the MUC1-T specific monoclonal antibody 1B9 (Tarp M. A. et al. 2007).  
However, the necessity of MUC1-T expression by the tumour cells is unclear as the 
T glycan may be the means by which the MUC1 is taken up by the antigen 
presenting cell to allow processing and presentation on MHC class II to CD4 (see 
chapter 4). Engineering the glycan expression by transfecting or knocking-down the 
relevant glycosyltransferases in the tumour cell line could answer this question. 
Furthermore, the use of an in vivo system such as the one that spontaneously 
develops mammary tumours (MMTV-PyMT) crossed with MUC1-Tg mice 
(MMTV-PyMT/MUC1) could be used to test the potential of MUC1-T as a true 
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vaccine (immunization before tumour development). These experiments would give 
important preclinical data and could form the basis of work aimed at an initial phase 
I clinical trial.  
 
Work carried out in this thesis using recombinant MUC1-ST 
(Neu5Acα2,3Galβ1,3GalNAc) suggests that this particular glycan carried on MUC1 
may have immunosuppressive properties. Indeed, MUC1 has already been associated 
with immunosuppression through inhibition of T-cell proliferation or inhibition of 
the maturation of dendritic cells (Agrawal B. et al. 1998, Rughetti A. et al. 2005), 
and our investigation appears to have defined the glycoform responsible. A number 
of further studies could be initiated to confirm the immunosuppressive properties of 
recombinant MUC1-ST and these include: 
 
1) Immunizing wild-type mice with MUC1-ST in conjunction with immunogenic 
proteins such as recombinant MUC1-T, Tn or unglycosylated MUC1. A preliminary 
experiment has already been attempted by immunizing mice with ovalbumin in the 
presence of MUC1-ST. However, in this instance MUC1-ST did not abolish the T 
cell response to SIINFEKL, but as this is an extremely strong immunogen, perhaps 
this is not too surprising.  
2) Investigating the potential interactions of MUC1-ST with Siglecs. The preferred 
ligand for many Siglecs is the α-2,3-linked sialic acid, and Siglecs are involved in 
dampening down the immune response to self, suggesting a mechanism whereby 
MUC1-ST could inhibit immune responses. Previous studies have shown that MUC1 
can bind Siglec-1 (Nath D. 2001) and our laboratory also found that recombinant 
MUC1-ST binds to Siglec-1 (unpublished data). Unlike most other Siglecs, Siglec-1 
does not have an immunoreceptor tyrosine-based inhibitory motif (ITIM) and it has 
been suggested to act as a scavenger receptor removing sialylated molecules from the 
system. Thus, it would be interesting to investigate recombinant MUC1-ST 
immunization in Siglec-1 KO and Siglec-1 KO/MUC1 TG mice.  
 
The data presented in this thesis clearly show for the first time in an in vivo model, 
that increased ST3Gal-I levels in epithelial tissues, including the mammary gland, 
promotes mammary gland carcinogenesis, as tumours arose significantly earlier in 
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hST3Gal-I/PyMT mice than in control mice. However, at present the mechanism by 
which ST3Gal-1 promotes carcinogenesis is unclear. It is apparent that by the time 
samples were taken for analysis any acquired tumorigenic advantage in hST3Gal-
I/PyMT as compared to the control mice, would have been mitigated. Thus in order 
to further explore the role of ST3Gal-1 in tumorigenesis, it will be necessary to 
investigate early tumorigenic events in hST3Gal-I/PyMT mice as compared to PyMT 
control mice.  
Several mechanisms could be responsible for promoting tumorigenesis, including the 
ability for the tumour to escape immune surveillance early in tumour development 
and indeed data from a transplantable tumour model suggest that this may play an 
important role (Mungul A. et al. 2004).  In order to address this the number of 
infiltrating lymphocytes including NK, CD4, CD8 and Treg and the level of 
expression of cytokines such as IFN-γ, TNF-α, TGF-β, IL-2, IL-4, IL-5 and IL-10 in 
hyperplastic mammary glands in hST3Gal-I/PyMT mice as compared to the PyMT 
control mice could be measured in sections of the gland. 
Many of the pathways activated in the PyMT tumours are those that are also 
activated in human cancers (Al Masri M. and Gendler S. J. 2005). Therefore, further 
experiments could determine which, if any, of these pathways are perturbed in the 
ST3Gal-1/PyMT mammary glands at the early stage of tumour development. As 
Muc1 has been shown to play a role in the tumorigenesis of PyMT, initial 
investigations could involve the pathways that this mucin has been shown to play a 
role in (Al Masri M. and Gendler S. J. 2005). This could involve looking at the: 
• Interaction of β-catenin and c-Src in hyperplastic glands from ST3Gal-I 
tumours and controls. 
• Interaction of cSrc with PI3Kinase and the phosphorylation status of AKT in 
hyperplastic glands. 
• The phosphorylation status of Stat3. 







6.6 Final remarks 
 
Data included in this thesis contributes to the understanding of how MUC1 carrying 
specific and defined O-linked glycans can be expressed and purified using CHO cells 
and CHO derivatives systems. Furthermore, different O-linked cancer-associated 
MUC1 glycoforms are found to have different immunological properties. This is 
important as if MUC1 is to be used in any immunotherapeutic strategies the data 
presented here show that it is of vital importance to select a specific and immune 
activating glycoform. Evidence is now mounting that the MUC1-ST glycoform may 
have immunosuppressive effects or at the very least is non-immunogenic.  In 
addition, we have demonstrated that the high expression of the glycosyltransferase 
that adds sialic acid to core 1 to form ST results in a significantly decreased time to 
tumour presentation in a murine model of spontaneous mammary tumours. This is 
the first demonstration that an enzyme involved in O-linked glycosylation can 
promote tumorigenesis. However, the mechanism involved remains elusive, although 
previous data (Mungul A. et al. 2004) and our studies on the immune response of 
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Expression of MUC1-Tn and MUC1-T in primary breast carcinomas.  
Serial formalin fixed paraffin embedded sections from primary breast carcinomas was stained with the 
5E5 and IB9 monoclonal antibodies. The monoclonal 5E5 recognises Tn, and to a lesser extent STn, 
but only when the glycan is carried on a MUC1 backbone (Sorensen A. L. et al. 2006, Tarp M. A. et 
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Human ST3Gal-I sequence (L29555) 
 
gaggaggagg aagaagagcg gagagagaag gaagaggcga tgtgagctgg 
gaagggggca agtgtccggg acacccacac ccctgtattc tcctccgaac 
cccttcatgc ccaaatcccg gaaactccag cgtgtctcca gccgtgttgg 
taccattttc agatttcatc ttcctaaact ggaaatgtca atgagaggaa 
attaacaccc ccaagagctg cagtgagcaa atgcattgag cttgggtcag 
gacaattcca tttggggacc agagatggac ggtcactcag cctatggaga 
tgaagaaact gaggttcaga gaggttaaga gactccactg aggtcacaca 
gccgatgaca gacaaccttc tgtgccttca tcaagctggt tgtgtaccca 
ccatgtccct ggcgacagga tgggaaagaa aaagccctaa ttaaggatcg 
tcagaaacca cagttggagg aggacggcag agacagtttc cctccccgct 
ataccaacac ccttccttcg aggtcctcgc tcctgaggga ccctggactg 
tcacagagat taatgacccc ttatcttctt tggatgtgaa aggaaatcac 
tggttaaagc ttgatcgaga gacattatca gctctttaag gattgcagga 
gaataggcta ctttattttc tgaaaaggta aatatatgca agcaaagcca 
acatgccacg aatggcgttg gtctaccaca cagccgtgtc tgggacacag 
ttgggggtca tcccccagca ggagtgaagt cgagcttagc ggcccttgtg 
tcctcccttg gaattcctgc catccctttt gattgagcct ccacctctgg 
gatttttctt ccatttttct cctctcttag gagggagttc ctgctaccca 
tcgtgggagg ccaccatcag gactgcgaag atggtgaccc tgcggaagag 
gaccctgaaa gtcgtcacct tcctcgtgct cttcatcttc ctcacctcct 
tcttcctgaa ctactcccac accatggtgg ccaccacctg gttccccaag 
cagatggtcc tggagctctc cgagaacctg aagagactga tcaagcacag 
gccttgcacc tgcacccact gcatcgggca gcgcaagctc tcggcctggt 
tcgatgagag gttcaaccag accatgcagc cgctgctgac tgcccagaac 
gcgctcttgg aggacgacac ctaccgatgg tggctgaggc tccagcggga 
gaagaagccc aataacttga atgacaccat caaggagctg ttcagagtgg 
tgcctgggaa tgtggaccct atgctggaga agaggtcggt gggctgccgg 
cgctgcgccg ttgtgggcaa ctcgggcaac ctgagggagt cttcttatgg 
gcctgagata gacagtcacg actttgtcct caggatgaac aaggcgccca 
cggcagggtt tgaagctgat gttgggacca agaccaccca ccatctggtg 
taccctgaga gcttccggga gctgggagat aatgtcagca tgatcctggt 
gcccttcaag accatcgact tggagtgggt ggtgagcgcc atcaccacgg 
gcaccatttc ccacacctac atcccggttc ctgcaaagat cagagtgaaa 
caggataaga tcctgatcta ccacccagcc ttcatcaagt atgtctttga 
caactggctg caagggcacg ggcgataccc atctaccggc atcctctcgg 
tcatcttctc aatgcatgtc tgcgatgagg tggacttgta cggcttcggg 
gcagacagca aagggaactg gcaccactac tgggagaaca acccatccgc 
gggggctttt cgcaagacgg gggtgcacga tgcagacttt gagtctaacg 
tgacggccac cttggcctcc atcaataaaa tccggatctt caaggggaga 
tgacgcagtg aagggctgag gatggacgca ctgtcacacc tctgcatttc 
cagccccagc atcttgctgg agccgttcca tcccggagct tggaggggca 
gcctcaggtg tgtgcctggg c 
 
 
 
 
 
 
